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Summary  
There is accumulating evidence that genetic variations play an important role in 
osteoporosis by reducing bone mass and increasing the risk of fragility fractures. 
Many different genetic variants with mild effects contribute to the regulation of bone 
mineral density and fracture risk. Investigating the effect of genetic variants in 
osteoporosis may elucidate new mechanisms of bone homeostasis and possibly 
create new effective pharmaceutical targets for osteoporosis in the future.  
In the present study, data from genome-wide association studies, candidate gene 
association studies, and meta-analysis studies have been used to select stronger 
candidate genetic variants for further study. Iranian population samples were utilized 
in this project to investigate the effect of these selected genetic variants. Functional 
studies examined the association with genetic variants and the function of osteoclast 
cells and in the allelic expression imbalance (AEI) in target cells.  
The analysis of AEI was used to investigate the effect of cis-acting factors on the 
transcribed SNPs in the target cells via evaluation of cDNA from tissues expressing 
those transcribed SNPs in the heterozygous individual. The preliminary analysis of 
the Iranian population data showed features similar to other populations. There were 
also statistically significant associations between BMD and risk SNPs: VDR-
rs731236, P2RX7-rs3751143, RANK-rs884205, RANKL-rs9594738, RANKL-
rs9594759, LRP5-rs2306862, OPG-rs2073618, OPG-rs11995824, OPG-rs4355801, 
and ESR1-rs2077647. There were statistically significant associations between 
osteoclast number and risk allele of RANKL rs9594759 /rs1021188 SNPs. These 
associations are in the direction that would be expected from risk alleles of BMD. AIE 
analysis suggested evidence of cis acting effects in both osteoclast culture and blood 
samples for two risk SNPs, ESR1-rs2504063 and VDR-rs731236 which were each 
associated with BMD in the Iranian population. This study and other same studies 
helps to improve our knowledge about the role of genetic variation in osteoporosis 
with the goal of providing a genetic profile can be used for genetic screening tests for 
the identification of individual at risk of osteoporosis. A suitable genetic profiling test 
helps to find useful treatment. Novel pathways that contribute to control of BMD could 
be identified, improving our knowledge about the effect of genetic variation with the 
possibility of producing new therapeutic agents. 
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1.1 Bone 
 
Bone is a dynamic and living tissue with the structural and materialistic properties to enable 
limb mobility and protection of internal organs. Bone functions as a reservoir for minerals, 
and modulates calcium and phosphorus homeostasis. As an endocrine organ, the cells of the 
bone respond to hormonal signals and secrete factors that regulate various cellular functions 
including pancreatic beta cell insulin production and kidney phosphorus excretion (Guntur 
and Rosen 2012). Bone also has an important role in blood production via the bone marrow 
(Zappitelli and Aubin 2014).  
Bone is composed of cortical and trabecular bone, cartilage, hematopoietic tissue and 
connective tissue. The cortical bone is the hard compact outer layer of bones and accounts for 
approximately 80% of the total mass of bone in an adult skeleton. Trabecular bone accounts 
for the remaining 20% of bone mass and is a spongy or porous form of tissue filled with 
hematopoietic marrow, fatty marrow and blood vessels. The bones in vertebrates are either 
flat bones (hip, scapula and skull) or long bones (tibia, humerus and femur). Flat bones are 
made of trabecular tissue surrounded by layers of cortical bone. Long bones consist of the 
shaft or diaphysis, metaphysis and epiphysis regions. The diaphysis is composed mostly of 
cortical bone, while the metaphysis and epiphysis contain trabecular bone with a protective 
shell of cortical bone. The denser cortical bone is important for loading, whereas the 
trabecular bone has a larger surface area per unit volume for facilitating metabolic activity 
(Favus 2008).  
Bone is mainly composed of the bone matrix, which consists of organic and inorganic matter. 
The organic matter is 90-95% type I collagen, providing tensile ability and a non-collagenous 
portion consisting of serum proteins. The inorganic component of the bone matrix is made up 
of calcium and phosphate in the form of hydroxyapatite, which fills the “holes” between the 
collagen fibrils providing strength under compression (Favus 2008). The bone marrow 
consists of a hematopoietic component known as the parenchyma and a vascular component 
known as the stroma. Within the parenchyma, hematopoietic stem cells and hematopoietic 
progenitor cells exist close to the endosteum of the bone and around blood vessels (Zhao, Xu 
et al. 2012). Bone tissue consists of osteoclasts, osteoblasts, osteocytes and bone lining cells. 
1.1.1 Bone structure and function 
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These cells have fundamental roles in new bone tissue development, bone maintenance and 
mineral regulation (Morrison and Scadden 2014)  .  
 
 
Bone cells are responsible for the development of new bones, the maintenance of bones, and 
the regulation of minerals in the body. There are four main categories of bone cells which 
include: osteoclast, osteoblast, osteocyte, and lining cells (Zappitelli and Aubin 2014). 
1.1.2.1 Osteoclasts 
 
Osteoclasts are multinucleated cells that are responsible for the removal or resorption of 
bone. They are found in resorption pits also known as Howship's lacunae, within the bone 
surface. Osteoclasts are formed as a result of the fusion and subsequent differentiation of 
monocyte cells. The cytoplasm of osteoclast cells is homogeneous, “foamy” appearance, due 
to the large number of vesicles and vacuoles, which contain acid phosphatase. Osteoclasts are 
characterised by staining for high expression of tatrate resistant acid phosphatase (TRAP) and 
cathepsin K (Delaisse 2014). Monocytes differentiate to osteoclast and migrate to the 
resorption site, where the initial event in bone resorption occurs. The attachment between 
osteoclast and bone surface forms a special site, known as the “sealing” zone. In this area 
plasma membrane of osteoclast attaches firmly to the bone matrix and an isolated 
extracellular microenvironment is generated between the cell and bone matrix (Teitelbaum 
2000). At the bone resorption site, osteoclast cells form specialised ruffled border membranes 
using a high number of intracellular acidic vesicles in the plasma membrane of the 
osteoclasts. The extensively folded borders of the ruffled membrane are morphologically 
characteristic of actively resorbing osteoclasts and facilitate bone removal by increasing the 
cell surface for secretion. Vesicles release a large quantity of acid, mostly crystalline 
hydroxyapatite, which functions to dissolve the bone mineral (Vaananen and Laitala-
Leinonen 2008). Degradation of organic part and then removal of degradation products occur 
from the resorption site. At the end osteoclast returns to the non-resorbing stage or apoptosis 
occurs: these are the final events in the bone resorption by osteoclasts (Vaananen, Zhao et al. 
2000). 
1.1.2 Cells of the bone 
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The two important factors which drive osteoclastogenesis are macrophage colony stimulating 
factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL), a member of 
tumour necrosis factor (TNF) family (Boyle, Simonet et al. 2003). In 1997, Simonet et al. 
showed that over-expression or administration of a protein, osteoprotegerin (OPG) inhibits 
the osteoclast formation. Today it is known that OPG competes with RANKL for Receptor 
Activator of Nuclear Factor κB (RANK) (Vaananen, Zhao et al. 2000).  
One way to study the function of genes in osteoporosis is to focus on osteoclast activity. 
Osteoclasts can be generated in vitro from the blood of an individual identified as having 
specific alleles in the gene of interest. Osteoclast function can be measured by culturing 
peripheral blood mononuclear cells (PBMCs) on the dentine wafers (ivory wafers), and then 
by investigation of resorption lacunas, which are produced by differentiated osteoclasts 
(Chan, Gartland et al. 2007). The number of osteoclasts that are generated in vitro and the 
rates of resorption and apoptosis can be determined as osteoclast activity (Gartland, Buckley 
et al. 2003; Chan, Gartland et al. 2007).   
 
1.1.2.2 Osteoblasts 
 
Osteoblasts are mononuclear cells responsible for bone formation. Osteoblasts differentiate 
from mesenchymal precursor cells, which have the same origin as chondrocytes, tendon cells, 
myoblasts and adipocytes. Osteoblast cells have a large nucleus, extensive endoplasmic 
reticulum and enlarged Golgi. These cells have the ability to secrete type I collagen and 
specific proteins such as albumin, which form the organic matter of the bone matrix and 
regulate the bone matrix mineralisation (Harada and Rodan 2003). During the embryonic 
stage osteoblast differentiation occurs in two pathways: endochondral ossification and 
intramembranous ossification. During early embryogenesis, the collar bone surrounds the 
cartilage template. After invasion of vascular tissue, chondrocytes are replaced by osteoblasts 
and this process is called endochondral ossification. Endochondral ossification regulates the 
formation of all the skeletal bones with the exception of the skull, the mandibles and the 
clavicles. On the other hand, mesenchymal progenitor cells differentiate directly into 
osteoblasts, a process known as intramembranous ossification (Ducy, Schinke et al. 2000). 
 
19 | Chapter 1 
 
1.1.2.3 Osteocytes 
 
Osteocytes are mononuclear cells comprising a thin ring of cytoplasm and numerous cellular 
extensions. They support bone structure and metabolic functions. Osteocytes are the terminal 
differentiation stage of osteoblasts. When osteoblasts are trapped in the matrix they are 
differentiated to osteocytes. Osteocyte cells are localized in lacunae and their cellular 
extensions occupy tiny canals called canaliculi. Osteocytes in the mineralized matrix have 
direct communication with each other and bone surface lining cells. They can live for long 
periods but in ageing bone the intra-cellular connections between the osteocytes are 
disrupted, leading to apoptosis (Favus 2008). 
1.1.2.4 Bone lining cells 
 
Bone lining cells are a subpopulation of the osteoblast family and are characterised by their 
long, flattened and spindly appearance. They are associated with the bone surface at sites 
where a thin non-mineralized collagen layer is existed. Although they do not produce an 
osteoid layer like an osteoblast cell does, bone lining cells still belong to the same lineage as 
osteoblasts as they are associated with the surface of bone, express alkaline phosphatase and 
are responsive to PTH. Bone lining cells regulate bone remodelling by preventing interaction 
of osteoclast precursors with the bone surface. Signals that initiate osteoclast formation may 
also stimulate the bone lining cells to prepare for bone resorption mediated through 
collagenase activity, which breaks down un-mineralised bone, revealing the mineralised 
matrix underneath. The bone lining cells are then able to migrate to cover the re-modelling 
area, mainly at sites next to osteoclasts, creating a microenvironment (in phagocytosis of 
collagen at the bone surface) for the link required during bone remodeling. It has been 
suggested that the bone lining cells are responsible for the cell to cell interactions between 
RANKL and RANK receptor on osteoclast precursors (Everts, Delaissé et al. 2002). 
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Bone remodelling is an important and lifelong metabolic process where bone is renewed 
continuously in response to a variety of stimuli. The most important of these stimuli are 
functional demands, which depend on density, strength, and shape of the bone in response to 
load alterations. The important functions of bone remodelling are maintaining anatomical and 
structural integrity of the skeleton and regulating serum calcium by supplying calcium from 
the skeleton to the serum. Bone remodelling is a complex process involving interactions 
between different cell phenotypes and is regulated by a variety of biochemical factors 
(Delaisse 2014). 
Bone remodelling can be described as a 4-stage cyclic process involving osteoclasts, 
osteoblasts, osteocytes and bone lining cells: resting, resorption, reversal and formation 
(Figure 1.1). In the resorption phase, differentiated osteoclasts attach to the bone and digest it 
by acidification and proteolytic mechanisms. This phase is followed by the reversal stage. 
During reversal, osteoblasts are recruited to the site of resorption to start bone formation. 
Following this stage osteoblasts spread over the resorption areas and bone formation begins 
with the secretion of osteoid, which comprises matrix of collagen and other proteins. Finally, 
bone-lining cells cover the surface of the bone and osteocytes are entombed in the matrix 
(Delaisse 2014) 
 
 
 
 
 
 
 
 
 
1.1.3 Bone remodelling 
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Figure  1-1: bone remodeling 
 A: The basic molecular unit (BMU) moves along the trabecular surface. B: Complex BMU-
lining cells attach themselves to exposed collagen and attract pre-osteoclast cells. 
Multinucleated cells differentiate themselves from pre-osteoclast cells and resorb a cavity. C: 
Pre-osteoblasts are changed to osteoblasts. Osteoblasts produce osteoid. Previous osteoid 
starts to mineralize (horizontal lines). Osteoblasts begin to flatten. Osteoblasts change to 
lining cells covering the surface of the bone; bone remodelling is now complete, but BMU is 
still advancing (to the right). 
 
 
 
 
 
A 
B 
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Bone remodelling is tightly regulated by a number of factors including local cytokines such 
as RANKL, interlukin-1 (IL-1), interlukin-6 (IL-6), and systemic hormones such as 
calcitonin, parathyroid hormone (PTH), and 1,25–dihydroxy vitamin D3 (Vitamin D). 
RANKL is expressed on the cell surface of osteoblasts and attaches to the RANK. RANK is 
responsible for the differentiation and activation of osteoclasts from osteoclast precursors. As 
the decoy receptor to RANK, OPG produced by osteoblast and stromal cells, inhibits 
interaction of RANKL. Increased levels of RANK have an anabolic effect on bone (Figure 
1.2) (Sambrook and Cooper 2006). Twenty five percent of trabecular bone and only three 
percent of cortical bone are replaced by this mechanism within the skeleton each year. 
Trabecular bones have more surface contact with bone marrow in comparison with cortical 
bones and this difference shows the role of local factors (Manolagas 1995)  
 
 
23 | Chapter 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1-2: Hormonal control of bone resorption 
  A: Pro-resorptive and calcitropic factors. Expression of RANKL is induced in osteoblasts, 
activated T cells, synovial fibroblasts, and bone marrow stromal cells. It binds to membrane-
bound receptor RANK to induce osteoclast differentiation, activation, and survival.  B: 
Anabolic and anti-osteoclastic factors. OPG has anabolic effects. OPG binds to and 
neutralizes RANKL then induces block in osteoclastogenesis and decreases survival of pre-
existing osteoclasts.         
 
A 
B 
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1.1.3.1 Bone remodelling in disease  
 
As the process of bone remodelling maintains skeletal integrity throughout life, imbalances in 
the underlying mechanisms can result in bone disorders. Around the fourth or fifth decade of 
life the processes of resorption and formation are not matched, and resorption activity is 
increased compared to formation in both women and men (Fauci 2008). There is increasing 
evidence to suggest that the cells involved in the remodelling of the skeleton under 
physiological conditions are the same cells involved in pathologic conditions. Abnormalities 
in the bone remodelling process can result in various skeletal disorders reflecting changes in 
the organic matrix, mineral phase and cellular mechanisms of remodelling. These skeletal 
disorders are either hereditary, acquired or both. The most common bone metabolism 
disorders affecting the skeleton are osteoporosis, osteomalacia, hyperparathyroidism and 
chronic renal failure and Paget’s disease (Feng and McDonald 2011). 
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1.2 Osteoporosis bone disease 
 
Osteoporosis is a skeletal disorder characterised by a reduction in the strength of bone with a 
consequent increase in bone fragility and susceptibility to fracture. Low bone mass is 
associated with micro-architectural deterioration of bone tissue (Fauci 2008). The World 
Health Organization (WHO) operationally defined osteoporosis based on measurement of 
bone mineral density (BMD) which is associated with bone fracture. This definition of 
osteoporosis is a bone mineral density (BMD) that is more than 2.5 SD below the young adult 
mean for the population (Kanis 1994). However, this definition only determines a gradual 
decline in mineralization and does not give a particular aspect of decline in micro- 
architecture (Cole, Dennison et al. 2008).  
 
The loss of strength and bone mass in osteoporotic bone disease can be as a result of a 
multitude of factors including; the inability to reach optimal peak bone mass in early 
adulthood, increased resorption of bone having reached peak mass, or dysfunction of bone 
formation during bone remodelling. Osteoporosis is classified as primary or secondary, with 
the primary osteoporosis being the most common metabolic disorder of the skeleton. Primary 
osteoporosis is further categorised as type I and type II based on the etiology differences. 
Type I osteoporosis is also known as postmenopausal osteoporosis, and is seen commonly in 
postmenopausal women. Type I osteoporosis is thought to be caused by estrogen hormone 
deficiency associated with menopause. The type II osteoporosis also known as age-related 
osteoporosis is linked to ageing in males and female individuals. The less frequent secondary 
osteoporosis refers to disorders of the bone secondary to other medical conditions, alterations 
in the level and type of physical activity, or caused by therapeutic interventions (Sattui and 
Saag 2014).  
 
It is expected that by 2050, the world population will increase, as a result it is also thought 
that the population of elderly people will also grow (Kassim Javaid, Chana et al. 2013). In the 
UK, by the year 2020, the over 85 years old age group is estimated to rise to 2.1 million, 
whereas this population was 1.2 million in 2002 (Clark 2002). This increase in the ageing 
population in the UK is predicted to cause double the number of osteoporotic fractures over 
the next 50 years (Kanis and Johnell 2005). The incidence of osteoporosis varies between 
male and female individuals. In males, the prevalence of osteoporosis based on total hip 
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BMD, ranged from 1% (in the UK) to 4% (in Japan). The prevalence, when based on spine 
BMD ranged from 3% (in Canada) to 8% (in France, Italy, Spain and Germany). In the 
female population, the prevalence of osteoporosis ranged from 9% (in the UK) to 15% (in 
France and Germany) calculated from total hip BMD data. Prevalence calculated from spine 
BMD data ranged from 16% (USA) to 38% (Japan)(Wade, Strader et al. 2014) .  
 
The most prominent outcome of osteoporosis is the associated increase in hip fractures. In 
fact, it is estimated that by the year 2050, hip fracture incidences will increase from the 1.66 
million in 1990 to 6.26 million (Dhanwal, Dennison et al. 2011). In the UK, one in two 
women and one in five men that are aged over 50 years will have suffered from an 
osteoporotic fracture in their remaining lifetime. In the United States approximately 10 
million Americans have osteoporosis and an estimated 1.5 million fragility fractures occur 
each year (Kassim Javaid, Chana et al. 2013). In one study which was performed in the city of 
Shiraz in Iran, the incidence rate on hip fracture was higher for both genders compared with 
other Asian countries and this was similar to the rates reported in some European or American 
areas (Soveid, Serati et al. 2005). 
There are three important adverse effects after osteoporotic fracture: mortality, disability, and 
cost that are correlated with type of fracture. Hip fracture has the most adverse outcome: the 
risk of death is 10-20% more than normal population in the first year after fracture but 
decreases over time (Sambrook and Cooper 2006). Hip fractures are the most important 
complication associated with osteoporosis and are linked to morbidity and sometimes 
mortality. Patients with hip fracture are prone to pressure sores and bronchopneumonia after 
fracture. Another fracture that occurs in osteoporotic patients is vertebral fracture. Vertebral 
deformities have been seen three times as frequently as hip fracture in studies using 
radiographic screening of populations. Kyphosis can be induced by multiple fractures, and in 
the acute stages of fracture severe back pain is the major symptom in the patients (Cole, 
Dennison et al. 2008). Adults with any type of fracture are at substantially greater risk of 
other types of fracture, particularly in the first year. The risk of further vertebral fracture 
increases ten-fold after a fracture in vertebrae. Furthermore, after a distal forearm fracture 
risk of hip fracture is increased 1.4 times in women and 2.7 times in men (Sambrook and 
Cooper 2006). 
In the United States over 2 million osteoporotic fractures occurred in 2005 and hip fractures 
alone were responsible for 72% of the associated 20 billion dollar cost. In the United States, 
27 | Chapter 1 
 
annual fractures and costs will rise by approximately 50% by the year 2025 in comparison 
with 2005. European countries are also estimated to spend an estimated 30 billion euros for 
all osteoporotic fractures every year (Sambrook and Cooper 2006). In comparison to other 
chronic non-communicable diseases, osteoporotic fractures induce more disability-adjusted 
life years (DALYs) in Europe (Cole, Dennison et al. 2008). 
 
 
Bone mineral density is a quantity of bone mass per volume or area (amount of matter per 
cubic centimetre of bone) (Kanis, McCloskey et al. 2008). There are several techniques for 
measuring BMD but the gold standard method for diagnosis of osteoporosis is dual-energy x-
ray absorptiometry (DXA) (Koh 2004). In this technique, two x-ray beams with different 
energy levels are used to determine the mineral content of bone tissue. Alternate techniques 
including quantitative ultrasound and computed tomography for assessing the condition of 
the skeleton are not as validated as DXA. Results produced by the DXA are compared to 
normal values by T and Z scores. The T-score is defined as the number of standard deviations 
above or below the mean BMD of a healthy 20 years old adult with the same patient's race 
and sex. To avoid an overestimation of bone mineral deficits, the results are also compared to 
the mean of a healthy individual with race, sex and age matched. The Z-score is defined as 
the number of standard deviations above or below the mean BMD of a healthy individual 
with the same patient's race, sex and age. For instance, a 65-year-old woman with a T-score 
of -2.5 (2.5 SD below mean for a young control group) has a Z- score of -1(1 SD below mean 
for age) (Figure 1.3-A)  (Fauci 2008). DXA has the ability to measure bone mineral density 
at different sites, but usually is used at a specific site that has more validation for predicting 
risk of fracture. For example DXA of hip has the most validation for determining risk of 
fracture at the hip or even at other sites (Koh 2004). The reference measurement site and 
range which is recommended for a young population group is the femoral neck measurements 
in Caucasian women aged 20–29 years from NHANES III reference database (Third National 
Health and Nutrition Examination Survey). 
A systematic review and meta-analysis of observational population-based studies using 
“absorptiometry” suggest that fracture risks increase approximately two-fold for every 
1.2.1 Clinical diagnosis 
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standard deviation decrease in BMD (Kanis, Burlet et al. 2008). The predictive value of 
BMD for hip fracture is at least as good as that of blood pressure for stroke (Kanis 2002). The 
data from observational studies suggest that the absolute risk of fracture for any given BMD 
and age is similar in both genders. Thus, the same diagnostic cut-off values for BMD are now 
applied to in women and men (Kanis, Bianchi et al. 2011). There are four categories which 
describe diagnostic criteria for osteoporosis; normal, osteopenia, osteoporosis and severe 
osteoporosis ( figure 1.3-B) (Kanis, McCloskey et al. 2008). 
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Diagnostic criteria for osteoporosis 
 
Normal 
 
Bone density is within 1 SD of the young 
adult  reference mean ( T-score=> -1 SD) 
Osteopenia 
 
Bone density is within 1 to 2.5 
SD below the adult reference 
mean ( -2.5<T-score< -1) 
Osteoporosis 
 
Bone density is 2.5 SD or more below the 
adult reference mean (T-score=<-2.5) 
Severe (established) 
osteoporosis 
 
Bone density is more than 2.5 SD 
below the adult reference mean 
and there have been one or more 
osteoporotic fractures. 
 
Figure  1-3: Criteria for osteoporosis 
A: Relationship between Z-scores and T-scores in a 65-year-old woman. A value of -1 SD of 
Z-score in 65 years old is equal to -2.5 SD of T-score in 20 years old and less than this is 
defined as osteoporosis. B: Diagnostic criteria for osteoporosis. (Graph adapted from Fausi 
et al, Harrison's Principal of Internal Medicine, 17th edition).  
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The oestrogen-endocrine pathway is associated with the onset of osteoporosis in both women 
and men. Oestrogen is an essential component required for epiphyseal closure in puberty in 
women and men, and regulates bone turnover in both genders (Raisz 2005). Oestrogen is 
associated with increased osteoclast bone resorption activity and increased osteoclast 
numbers (Figure 1.4) (Manolagas 2000). Oestrogen deficiency is specifically a key player in 
the loss of bone in women, particularly those aged 70 years and older. The role of oestrogen 
in the regulation of bone metabolism is highlighted by findings that showed treatment rapidly 
reduced bone breakdown in older women (Raisz 2005). Oestrogen deficiency results in the 
release of cytokines by circulating monocytes, namely cytokines interlukin 1 (IL-1) and 
TNFα. These cytokines target mesenchymal cells, promoting the release of the lymphokine 
IL-7. IL-7 supresses both osteoblasts and T cells function via stimulation of pro-
osteoclastogenic cytokines macrophage colony stimulating factor (M-CSF) and activated 
nuclear factor κ B ligand (RANKL) production. Interlukin 7 (IL-7) also acts to decrease 
osteoprotegerin (OPG) expression, the decoy receptor for RANKL. As a consequence of the 
latter changes, net osteoclastic activity is increased. Monocyte-derived IL-1 and tumour 
necrosis factor α (TNFα) synergize with RANKL to increase the loss of bone (Ross 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 Molecular mechanisms involved in osteoporosis  
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Figure  1-4: Estrogen-mediated bone loss in vivo 
 Oestrogen deficiency results in the release of IL-1 and TNFα by circulating monocytes. 
These cytokines stimulate mesenchymal cells to release IL-7, which induce bone loss by two 
pathways, suppression of bone formation and activation of bone resorption. 
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Understanding of the RANKL/RANK/OPG pathway has contributed to determining the 
mechanisms underlying the regulation of bone formation and resorption. RANKL and OPG 
are members of the TNF family and TNF receptor (TNFr) superfamilies, respectively, and 
binding to RANK regulates osteoclast formation, activation and survival in both normal bone 
modelling and remodelling processes. The RANK/RANKL/OPG axis is now also thought to 
be pivotal in several other pathologic conditions characterised by increased bone turnover 
(Ross 2003).  
The canonical Wnt signalling pathway is also involved in the regulation of osteoblast 
differentiation and osteoclast suppression (Figure 1.5) (Canalis 2013). The Wnt proteins are 
a family of secreted glycoproteins that are involved in a multitude of cellular events including 
cell growth, differentiation, function, and apoptosis. Wnt signalling in an osteoblast is 
activated by binding of the Wnt proteins to their co-receptors; low-density lipoprotein 
receptor–related protein 5 (LRP5) and frizzled (Fz). Upon activation of Wnt signalling, a 
‘destructive’ protein complex comprising: Adenomatosis polyposis coli (APC), Casein kinase 
1α (CK1α), and Axin molecules become blocked downstream of the Wnt-receptor complex. 
The inhibition of the ‘destructive protein complex’ is regulated by the binding and 
subsequent phosphorylation of the dishevelled (dsh) protein to the Wnt-receptor complex.  
An important mediator of canonical Wnt signalling, B-catenin, is stabilised and accumulates 
in the cytoplasm of the cell, where it is phosphorylated and then translocates into the nucleus. 
Nuclear B-catenin binds to transcription factors belong to the T-cell factor/lymphoid 
enhancing factor (TCF/LEF) to induce the transcription of osteoblast-specific genes including 
Runt-related transcription factor 2 (Runx2), collagen, osteocalcin and osteonectin. In the 
absence of a Wnt protein, where Wnt signalling is not activated, dsh binds to the Axin 
component of the ‘destructive protein complex’ and this complex is then free to bind to B-
catenin. B-catenin is degraded in the proteasome, resulting in low nuclear B-catenin levels 
and subsequently gene transcription is supressed. Antagonists of the Wnt pathway, such as 
Dickkopf-related protein, Secreted frizzled-related protein (SFRP) and sclerostin block Wnt 
signalling by interacting with Wnt proteins or transmembrane LRP/Frz receptors (Canalis 
2013).  
 
Our understanding of the molecular links between Wnt signalling and bone development 
have improved greatly since the first findings linking LRP5 mutations to alterations in human 
bone mass. It is now clear that Wnt/β-catenin signalling is responsible for increasing bone 
mass via numerous mechanisms involving osteoblastogenesis and suppression of osteoblast 
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and osteocyte apoptosis. Wnt/β-catenin is also known to increase the ratio of OPG to 
RANKL, repressing osteoclastogenesis (Krishnan, Bryant et al. 2006).  
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Figure  1-5: Canonical Wnt signaling and bone remodeling 
 Wnt/b-catenin induces osteoblastogenesis and increases bone formation. Canonical Wnt 
signaling suppresses osteoclastogenesis is suppressed by Wnt-induced OPG. Wnt signalling 
also suppresses osteoclast precursor’s function/resorption by an OPG-independent 
mechanism. This co-regulatory effect of Wnt on osteoblast and osteoclast cells causes an 
overall increase in bone mass. Wnt antagonists sclerostin and Dkk-1 bind to Wnt co-receptor, 
thereby preventing Wnt-receptor interaction and signaling. 
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1.3 Effect of genetic variation in osteoporosis  
 
Osteoporosis is one of the most widespread and costly diseases worldwide and the incidence 
of this disease is increasing due to the gradual ageing of the global population. Genetic 
factors are important in the pathogenesis of osteoporosis, with links to a reduction in BMD 
and an increased susceptibility to osteoporotic fractures (Cheung, Xiao et al. 2010). Family 
and twin studies indicate that more than 50% of the variance in peak bone mass is defined by 
genetic factors (Krall and Dawson-Hughes 1993; Gueguen, Jouanny et al. 1995). Although 
the role of genetic factors in the pathogenesis of bone loss remains unclear, heritability 
studies have determined that genetics does have a strong associations on a variety of 
osteoporotic fracture risk elements, which include quantitative ultrasound properties of bone, 
BMI and bone turnover markers (Kaprio, Rimpela et al. 1995; Arden, Baker et al. 1996; 
Hunter, De Lange et al. 2001). There is approximately a fourfold greater risk of having low 
whole body BMD in a son from a father with low BMD compared to a father with normal 
BMD and a five times higher risk in a daughter from a mother with low BMD compared to a 
mother with normal BMD (Zmuda, Sheu et al. 2006). Genetic effects on BMD are mediated 
by several genetic factors with mild influences (Uitterlinden, Ralston et al. 2006). More 
studies are needed for determining the relation between genetic factors and bone loss 
(Uitterlinden, Ralston et al. 2006). This information prompts us to identify the genetic factors 
that are associated with osteoporosis for therapeutic intervention. 
It should be noted that sometimes patients have severe osteoporosis and fragility fractures or 
unusually high bone mass (HBM) that can be a characteristic of rare diseases which are 
genetic in nature and inherited in a classical monogenic mendelian manner such as: 
osteogenesis imperfecta, osteopetrosis, aromatase deficiency, oestrogen receptor deficiency, 
sclerosteosis, and high bone mass syndrome (Table 1.1) (Ralston 2010). In these diseases the 
effect of genes is severe. Despite the fact that these diseases are rare studies show that 
polymorphic variations in genes, which are mutated in this rare bone disease also exert 
influence on BMD in the general population (Uitterlinden, Ralston et al. 2006). 
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Disease Phenotype Genes 
Osteogenesis Imperfect Low BMD, fractures COL1A1, COL1A2, 
CRTAP, LEPRE1 
Osteopetrosis High bone mass Fractures, bone 
marrow failure, blindness, 
osteoarthritis 
TCIRG1, CATK, 
OSTM1, RANKL, 
RANK 
Aromatase deficiency Osteoporosis CYP17 
Oestrogen receptor 
deficiency 
Osteoporosis, tall stature  ESR1 
Sclerosteosis High bone mass, bone overgrowth, 
nerve compression syndromes 
SOST 
High bone mass syndrome High bone mass, torus palatines LRP5 
 
Table  1-1: Genes for monogenic bone diseases associated with abnormal bone 
mass 
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Genetic association studies investigate correlation between genetic variation and disease risk 
to identify genome regions or candidate genes that contribute to a specific disease. A higher 
frequency of a SNP allele or genotype in a series of individuals affected with a disease is 
evidence that the tested variant increases the risk of a specific disease. Due to recent technical 
advances SNPs are the most commonly used in association studies. Association studies are 
used for identifying genes linked to the susceptibility to complex disorders. The term 
‘complex’ is applied to traits and diseases which both multi genetic variants and 
environmental factors contribute to the risk of susceptibility. Role of different genetic 
variants has been studied in various illnesses like diabetes, heart disease, autoimmune 
diseases and psychiatric traits with each variant having only a subtle effect (Lewis and Knight 
2012). 
 
There are two different types of association study commonly used for the investigation of 
genetic variants in osteoporosis: genome-wide association study and candidate gene 
association study (Zmuda, Sheu et al. 2005; Richards, Zheng et al. 2012). In many different 
diseases associations with polymorphisms in candidate genes have been confirmed 
(Lohmueller et al. 2003). Many novel associations are being identified by GWAS in genes 
that had not been a priori strong candidate genes for the disease (Wellcome Trust Case 
Control Consortium 2007). The development of the GWAS over the last few years, has 
introduced a powerful tool for the investigation of the genetic architecture of human disease 
(Bush and Moore 2012). GWAS approach the analysis of complex traits by genotyping  a 
very large number of markers across the genomic  DNA  of many people and relate these 
variants with observable traits such as: BMI, or blood pressure, or common diseases (Pearson 
2008). . GWAS are particularly useful in complex disorders such as osteoporosis, asthma, 
cancer, diabetes, heart disease and mental illnesses because most genetic variants associated 
with these diseases in humans are believed to have mild effect on them (Stranger, Stahl et al. 
2011). 
The completion of the Human Genome Project in 2003 and the International Hap Map 
Project in 2005 provide facilities for studying the genetic contributions to common diseases. 
Human genome sequences and human genetic variation are available via computerized 
1.3.1  Osteoporosis Genome-wide association and candidate gene studies 
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databases. Whole-genome samples for genetic variations can be analysed quickly and 
accurately by current high-throughput sequencing technologies. 
In the candidate gene approach genetic variants are tested based on a prior hypothesis 
regarding the role of that gene or gene product in the pathophysiology of the disease, but in 
the GWAS the whole genome can be investigated without a prior hypothesis of which genes 
or genetic variants have effect on the disease (Wilkening, Chen et al. 2009). Rather the 
hypothesis is that we believe there are risk genes to be found. The GWAS approach can be 
problematic because during this method very many statistics tests are performed that can be 
an unprecedented potential for false-positive results, so it has become common practice to 
follow GWAS positive signals with replication studies (Bush and Moore 2012). 
 
The first influential GWAS was published in 2006 (Dewan, Liu et al. 2006); it determined the 
association between a gene and age-related macular degeneration (ARMD), the leading cause 
of acquired blindness in adults. Following this study, there has been a considerable increase 
in genomic discoveries involving complex diseases. Osteoporosis is a complex disorder 
influenced by multiple genes mostly with mild effect.  
Candidate gene association studies aim to establish or characterise association between the 
polymorphic variants occurring within a specific gene or locus and a quantitative trait or 
disease of interest (Teare 2011). Candidate gene association studies have been used many 
times in the field of osteoporosis. Several polymorphisms associated with BMD, bone loss or 
osteoporotic fractures have been identified by performance of many candidate gene 
association studies but few findings have been replicated in independent studies (Ralston 
2007). Meta-analysis is a statistical tool for combining results across genetic studies and is 
fast becoming the gold standard technique for resolving discrepancies in genetic association 
studies. The difficulties in producing robust, replicable results in genetic association studies 
are due to the small genetic effects and highlight the need for studies with many thousands of 
subjects (Munafo and Flint 2004). In one meta-analysis study by Richards et al, 150 human 
candidate genes were analysed for their associations with BMD or fractures. Results showed 
only 9 of 150 candidate genes were linked with the regulation of BMD (Richards, Kavvoura 
et al. 2009). As a result, candidate genes for this study were identified through a systemic 
review (explained in the method section 2.2.1) which was subsequently reported by candidate 
gene association study (CGAS), meta-analysis of candidate gene association study (MA-C), 
genome-wide association study (GWAS) and meta-analysis of genome-wide association 
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study (MA-G). Two extra candidate genes: VDR and P2RX7 were added to the list of 
selected candidate genes as explained in the method section 2.2.1. 
 
 
1.3.2.1 RANKL 
 
As mentioned previously, RANKL had an essential regulatory role in osteoclastogenesis. 
Interaction between RANKL and its receptor RANK on osteoclast precursors, induces 
osteoclast differentiation and promotes bone resorption (Lau and Guo 2011). RANKL was 
initially analysed as a candidate gene associated with osteoporosis in 2006 (Li, Hou et al. 
2010). Hsu et al assessed RANKL association with OPG and RANK in 1,120 Chinese with 
extremely low hip BMD or high hip BMD. This study found that the rs9594782 T>C 
polymorphism located in the 5-UTR of the gene, was associated with BMD in men. This 
association was not reflected in the female subjects. Hsu et al reported that men with the 
TC/CC genotypes were twice as likely to have extremely low hip BMD and also had lower 
whole body BMD (Hsu, Niu et al. 2006). The Deng group evaluated the association of 
RANKL with 19 candidate genes in a total of 1,873 individuals from 405 Caucasian nuclear 
families. Their data correlated with the Hsu et al, in that it supported the evidence that 
RANKL was strongly associated with hip BMD (Xiong, Shen et al. 2006). 
According to the GWASs, RANKL SNPs rs9594759, rs9594738 and rs1021188 were 
selected (Paternoster, Lorentzon et al. 2013; Welter, MacArthur et al. 2014). The SNP 
rs9594759 located 113 kb upstream of RANKL, is known to be highly associated with spine 
BMD (Styrkarsdottir, Halldorsson et al. 2008). This association was replicated across the 
meta-analysis of five GWASs (Rivadeneira, Kavvoura et al. 2008). SNP rs9594738 was 
significantly associated with BMD in two GWASs (Styrkarsdottir, Halldorsson et al. 2008; 
Duncan, Danoy et al. 2011). 
1.3.2.2 RANK 
 
As the receptor for RANKL, RANK is an integral part of the RANK/RANKL/OPG axis and 
is involved in osteoclast differentiation and activation. The first RANK/BMD genetic 
1.3.2 Selected candidate genes from systemic review in addition two extra 
candidate genes  
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association studies by Choi et al reported no association between RANK SNP rs1805034 and 
BMD (Choi, Shin et al. 2006). However, in a Chinese study using a cohort of 1120 subjects, 
there was evidence of an association between SNP rs1805034 and hip BMD in men only 
(Hsu, Niu et al. 2006). The GWASs reported two RANK SNPs Rs3018362 and Rs884205 
associated with BMD (Welter, MacArthur et al. 2014). In their initial GWAS, Styrkarsdottir 
and colleagues found that SNP rs3018362 located on 27 kb downstream of the TNFRSF11A 
gene, was consistently associated with hip BMD. However, this association did not reach 
genome-wide significance (Styrkarsdottir, Halldorsson et al. 2008). In their subsequent 
GWAS this association became significant genome-wide as a result of increased replication 
samples (P = 5.4 × 10
8
) and this study was the first to demonstrate that link between RANK 
and osteoporosis (Styrkarsdottir, Halldorsson et al. 2009). Two meta-analytic studies of 
GWAS data supported previous findings indicating RANK as an osteoporosis gene 
(Richards, Kavvoura et al. 2009; Rivadeneira, Styrkarsdottir et al. 2009). Furthermore, the 
results from two Genome wide meta-analysis studies supported evidence of the link between 
rs884205 and BMD (Rivadeneira, Styrkarsdottir et al. 2009; Estrada, Styrkarsdottir et al. 
2012).  
 
1.3.2.3 Osteoprotegerin 
 
OPG as a member of the TNF receptor superfamily, is the soluble decoy receptor to RANKL 
which inhibits interaction between RANKL and RANK (Krakauer 2008). OPG has been 
considered an important gene candidate in osteoporosis due to findings that report 
polymorphisms in OPG are thought to genetically influence BMD (Pocock, Eisman et al. 
1987; Hofbauer and Schoppet 2002; Langdahl, Carstens et al. 2002; Yamada, Ando et al. 
2003; Arko, Prezelj et al. 2005; Vidal, Formosa et al. 2011). Lee et al collated the data from 8 
studies and using an extensive literature search, evaluated the association between OPG 
polymorphisms and BMD (Garcia-Unzueta et al. 2008; Kim et al. 2007; Langdahl et al. 2002; 
MoVett et al. 2008; Ueland et al. 2007; Yamada et al. 2003; Zhao et al. 2005). The three 
OPG polymorphisms rs2073618, rs2073617, and rs3102735 were shortlisted as potential 
links to BMD. From these, SNP rs2073618 was shown to be associated with lumbar BMD in 
European and Asian populations. SNP rs2073618 was shown to be associated with femoral 
neck and total hip BMD only in the European population only (Lee, Woo et al. 2010). A 
41 | Chapter 1 
 
meta-analysis performed by Luo et al on the associations between OPG rs3102735 and 
rs2073618 polymorphisms and osteoporosis suggested that the G allele of the OPG 
rs3102735 could increase the risk of developing osteoporosis, whereas the C allele of 
rs2073618 was protective against osteoporosis (Luo, Hu et al. 2014). 
GWASs reported two SNPs, rs64469804 and rs6993813 associated with both spine and hip 
bone BMD and they are in LD with the rs2073618 and rs3102735 polymorphisms in the OPG 
gene (Styrkarsdottir, Halldorsson et al. 2008). Another SNP, rs4355801, located in the 3
`
UTR 
of the OPG gene was found to be significantly associated with lumbar spine BMD (P = 7.6 × 
10
-10
) and femoral neck BMD (P = 3.3 × 10
-8
) (Richards, Rivadeneira et al. 2008). Meta-
analysis of five GWASs confirmed these findings (Rivadeneira, Styrkarsdottir et al. 2009). 
The significant association between OPG SNP rs2062377 and BMD was reported by three 
GWASs (Rivadeneira, Styrkarsdottir et al. 2009; Estrada, Styrkarsdottir et al. 2012; 
Paternoster, Lorentzon et al. 2013). In a study by Rivadeneira et al, findings suggested SNP 
rs11995824 association with total hip BMD (Rivadeneira, Styrkarsdottir et al. 2009). In 
addition, Hsu, Zillikens et al showed there are significant associations between rs2062375 
and total hip BMD (Hsu, Zillikens et al. 2010). 
1.3.2.4 ESR1 
 
Estrogen plays an important role in the regulation of human bone mass and bone geometry 
(Gennari, Merlotti et al. 2005). Therefore, estrogen receptors are considered important 
therapeutic targets in osteoporosis bone disease (Ohta 2014). The impact of the gene 
encoding the estrogen receptor (ESR1) on bone growth was first demonstrated in a male 
subject who was homozygous for a loss-of-function mutation in ESR1. Sequencing of exon 2 
showed that a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a 
premature stop codon, showed a lack of ossification of the growth plate and low bone mass 
(Smith, Boyd et al. 1994). 
The genetic link between BMD/fracture and ERS1 polymorphisms has been reported in 
numerous genetic studies. The ESR1 polymorphic sites reported are namely the XbaI 
(dbSNP: rs9340799), PvuII (dbSNP: rs2234693), and microsatellite thymine–adenine 
dinucleotide (TA) repeat polymorphisms. However, there are inconsistencies between the 
results reported in these studies (Ioannidis, Stavrou et al. 2002; Ioannidis, Ralston et al. 2004; 
Wang, Tang et al. 2007). The GWAS by Styrkarsdottir et al detected an association of the 
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ESR1 SNP rs1999805 with spine BMD (P = 2×10
-8
) and an association between SNPs 
rs1038304 and rs4870044 with both spine BMD (rs1038304, P = 4×10
-11
) (rs4870044, P = 
2×10
-11
) and hip BMD (rs1038304, P = 5×10
-9
) (rs4870044, P = 2×10
-7
) in a European 
population (Styrkarsdottir, Halldorsson et al. 2008). In another study by this group an 
association of the SNP rs6929137 and spine BMD was detected (P = 2×10
-10
) (Styrkarsdottir, 
Halldorsson et al. 2009). The meta-analysis of five GWASs confirmed association between 
rs2941740 with Hip BMD (P = 2×10
-10
) and SNP rs2504063 with spine BMD (P = 6×10
-11
) 
(Rivadeneira, Styrkarsdottir et al. 2009).  
1.3.2.5 LRP5 
 
The LRP5 and LRP6 receptor proteins in the osteoblast cells are an important component of 
the Wnt signalling pathway involved in the regulation of bone mass and metabolism (Sassi, 
Sahli et al. 2014). LRP5 has a central role in the normal morphology, development and 
formation of bone (Cheung, Xiao et al. 2010). LRP5 protein transduces canonical signals 
downstream to stimulate the stem cell renewal, osteoblastogenesis and increases the ratio of 
OPG to RANKL (Urano and Inoue 2014). The key role of the LRP5 gene in bone mass 
regulation was initially identified from the study of rare human monogenic skeletal diseases.  
Inactivating mutations in the human LRP5 gene result in autosomal recessive osteoporosis-
pseudoglioma syndrome characterised by a reduction in bone mass (Gong, Slee et al. 2001). 
Activating mutations in the LRP5 gene cause autosomal-dominant bone disease characterised 
by an abnormal increase in bone mass (Van Wesenbeeck, Cleiren et al. 2003).  
The most commonly studied non-synonymous LRP SNPs rs4988321 and rs3736228 were 
genotyped by GENOMOS investigators in 37,534 individuals across Europe and North 
America (van Meurs, Trikalinos et al. 2008). Results of these studies showed that both SNPs 
rs4988321 and rs3736228 were associated with reduced lumbar spine BMD, reduced femoral 
neck BMD and increased risk to vertebral fracture (van Meurs, Trikalinos et al. 2008). A 
Bayesian meta-analysis of ten studies constituting 16,705 subjects showed a modest effect of 
the SNPs rs4988321 on BMD (Tran, Nguyen et al. 2008). Although the molecular 
mechanism remains unclear, the Ala1330Val (rs4988321) mutants had significantly lower 
level of Wnt-signalling capacity when compared with the wild type molecule in two 
independent TCF-LEF reporter assays (Kiel et al. 2007; Urano et al. 2009).  
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The link between LRP5 SNP rs3736228 and BMD was highlighted by the GWAS (Richards, 
Rivadeneira et al. 2008) and the Genome-wide meta-analysis study (Estrada, Styrkarsdottir et 
al. 2012). GWASs also demonstrated an association between rs599083 and spine BMD 
(P=5×10
-8
) (Rivadeneira, Styrkarsdottir et al. 2009). A recent Genome-wide meta-analysis 
study by Zhang L et al showed a genetic link between LRP5 SNP rs525592 and spine BMD 
(P = 3×10
-11
) (Zhang, Choi et al. 2014). 
 
1.3.2.6 Vitamin D receptor  
 
The first candidate gene-linked to BMD was the vitamin D receptor (VDR) (Morrison, Qi et 
al. 1994). VDR is expressed in various tissues including the intestine, thyroid and kidney and 
has a pivotal role in calcium homeostasis. It is clear that the vitamin D endocrine system has 
an important regulatory role in the metabolism of bone. The specific interaction between 
VDR and 1, 25-dihydroxy vitamin D3 (1,25(OH)2D3) influences skeletal development, 
skeletal architecture, hormonal secretion and immune function (Singh, Singh et al. 2013). 
VDR represses the expression of the proximal activator of 1,25(OH)2D3, hydroxylase, and 
also stimulates the expression of the 1,25(OH)2D3 inactivating enzyme CYP24 (Christakos, 
Hewison et al. 2013). 
Findings from recent studies have identified numerous polymorphisms in the VDR gene. 
Until now, research has primarily focused on the polymorphisms located on the limited area 
in the 3′ end of the VDR gene, namely; BsmI, ApaI, and TaqI (Marini and Brandi 2010). The 
Cdx-2 polymorphism was identified as another VDR polymorphism in the promoter region of 
the VDR gene, and has since been associated with BMD in Japanese women (Arai, 
Miyamoto et al. 2001). The cdx-2 polymorphism correlates with fracture in other populations 
but not specifically with BMD (Fang, van Meurs et al. 2003). Alleles that were identified in 
the promoter region and the 3' un-translated region were associated with an increased risk of 
fracture. It was revealed that the promoter haplotypes that increase fracture risk correlated 
with reduced VDR expression, whereas the 3' UTR risk haplotype was associated with 
increased degradation of VDR mRNA (Fang, van Meurs et al. 2005). Grunberg et al 
reconstructed three major haplotypes in the VDR 3'- un-translated region (UTR) baT, BAt, 
and bAT haplotypes that they named Hap1, Hap2, and Hap3, respectively. Their study aimed 
at determining any associations of Hap1, Hap2 and Hap3 with BMD and risk of fracture. 
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Their data showed that the Hap1 haplotype was associated with increased risk of vertebral 
fractures (OR, 1.655; 95% CI, 1.146–2.391; p < 0.01) (Grundberg, Lau et al. 2007). 
In meta-analysis studies in which statistical procedures combine the results of several 
independent studies with a set of related research hypotheses, BsmI, ApaI, TaqI 
polymorphism were not found to be associated with BMD or fracture (Fang, Rivadeneira et 
al. 2006; Uitterlinden, Ralston et al. 2006; Qin, Dong et al. 2013; Ma, Zhou et al. 2014). 
Although some show an association between FOK1 and BMD (Wang, Liu et al. 2013) and 
BSMI and BMD (Jia, Sun et al. 2013) (Thakkinstian, D'Este et al. 2004). 
1.3.2.7 P2RX7  
 
Purinergic receptors are plasma membrane proteins involved in several cellular actions that 
have adenosine triphosphate (ATP) or other nucleotides as their natural ligands. To date three 
classes of purinergic receptors have been identified including P1 receptors, P2Y receptors, 
and P2X receptors. The P1 and P2Y molecules are G-protein-coupled receptors and P2X is a 
ligand-gated ion channel (Gartland 2012). Various P2Y and P2X receptor subtypes have been 
identified on bone cells. Eight recognised subtypes of P2Y and seven recognized subtypes of 
P2X are shown to be functionally expressed by bone cells (Wesselius, Bours et al. 2011). 
Activation of the P2-receptor subtypes by extracellular nucleotides can regulate several 
cellular actions such as bone formation, mineral deposition, cytokine release, bone resorption, 
and apoptosis. Thus bone formation and resorption in the bone microenvironment are 
modulated by these receptors(Rumney, Wang et al. 2012). 
The P2RX7 gene is located in close proximity to the tip of the long arm of chromosome 12 
(12q24), spans over 53kb and consists of 13 exons. P2RX7 seems to exert opposite effects on 
osteoblast and osteoclast function depending on extracellular ATP concentrations. Low 
extracellular concentrations of ATP are defined 0.2-2 µM and high extracellular 
concentrations of ATP are 200-2000 µM (Wesselius, Bours et al. 2011).Human osteoclasts, 
both in vitro and in vivo express P2X7 protein. Prolonged or repeated activation of the 
P2RX7 induces osteoclast death (Agrawal, Buckley et al. 2010). A study by Korcok et al 
showed that P2RX7 activation in osteoclasts that had low extracellular concentrations of 
ATP, enhanced multinucleated and mature osteoclast formation by increasing nuclear 
localisation of the transcription factor NF-κB, independently of RANKL. NF-κB is an 
important regulator of osteoclast formation and activity (Korcok, Raimundo et al. 2004). 
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Gartland et al showed for the first time that activation of P2RX7 in a sub-population of 
human osteoblasts that express functional P2RX7, leads to apoptosis in these cells (Gartland, 
Hipskind et al. 2001). In contrast P2RX7 activation stimulates osteogenesis via activation of 
alkaline phosphatase, which promotes mineralization by hydrolysing inorganic 
pyrophosphate (Zappitelli and Aubin) (Panupinthu, Rogers et al. 2008)  
In other studies, it was shown that a 10-year fracture incidence in a cohort of approximately 
1800 Danish postmenopausal women was significantly associated with both the rs3751143 
and the rs1653624 polymorphism of P2RX7 (Ohlendorff, Tofteng et al. 2007). This study 
also showed that the rs3751143 polymorphism was closely related to ATP-induced osteoclast 
apoptosis in vitro as osteoclasts from individuals homozygous for risk allele were 
significantly less susceptible to apoptosis than osteoclasts from individuals carrying the wild 
type allele. Thus increased fracture incidence could be due to an increased number of 
osteoclasts. Gartland et al reported that post-menopausal women with the Gln
307
 mutation of 
rs28360457 polymorphism had a significantly lower lumbar spine BMD than women without 
this mutation. Also they showed that a combined group of heterozygous subjects who had 
any loss of function of 6 SNPs (rs35933842, rs208294, rs28360457, rs2230911, rs3751143, 
and rs1653624) had nearly nine-fold greater annualized percent change in LS-BMD than 
subjects who were wild-type at the SNP positions (Gartland, Skarratt et al. 2012). In addition, 
Wesselius et al further reported findings that suggested associations between BMD and four 
non-synonymous polymorphism (rs3751143, rs28360447, rs1262536, and rs2230912) of 
P2RX7 (Wesselius, Bours et al. 2013).  
1.4 Allelic expression imbalance 
 
Genome-wide association studies using SNP maps have revealed dozens of disease-
associated loci and have revolutionised the mapping of common genetic loci determining 
susceptibility to a wide range of multifactorial disorders (Wellcome Trust Case Control 
2007). Current evidence shows that only a small fraction of the causal loci consists of 
variants (non-synonymous SNPs) directly affect the protein amino-acid sequence. Therefore 
a large fraction of the loci is expected to have a regulatory role on gene expression via effects 
on transcription, splicing, and message stability and sometimes induces Allelic-specific gene 
expression (ASGE) (Heap, Yang et al. 2010). 
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ASGE or Allelic expression imbalance (AEI) is an important factor for phenotypic variability 
in humans and consequently for the development of common diseases (Schadt, Monks et al. 
2003). The association between AEI and X-chromosome inactivation phenomena and 
genomic imprinting has been extensively studied (Constancia, Pickard et al. 1998) But new 
studies have demonstrated the variability of gene expression that exists within and between 
populations (Enard, Khaitovich et al. 2002; Cheung, Conlin et al. 2003) and now we 
understand that AEI is commonly present among non-imprinted genes (Cowles, Hirschhorn 
et al. 2002; Yan, Yuan et al. 2002). Allelic variation in gene expression and its relation with 
some human illnesses has been shown in association with certain genes (Yan, Dobbie et al. 
2002; Yan, Yuan et al. 2002). Variation from gene expression may be caused by changes in 
the sequence of regulatory elements such as SNPs. Recent studies have demonstrated how 
this phenomenon is common through genome and tissues (Dixon, Liang et al. 2007; Stranger, 
Nica et al. 2007). 25-35% of differences seen between individuals in terms of allelic gene 
expression may be explained by these changes. 
Therefore, in order to understand the extent of regulatory variation that is functionally 
important, we need AEI identification and characterization.  Additionally, this will draw our 
attention to allelic differences in candidate genes that may guide us to relation between 
genetic variation and complex traits and common diseases (Palacios, Gazave et al. 2009).  
On a basic level, gene expression is the process in which functional gene products are 
synthesised by using the information of genes. These products are proteins or non-protein 
coding genes, such as transfer RNA (tRNA) genes or ribosomal RNA (rRNA) genes. Any 
step of gene expression has the potential to be modulated from the DNA-RNA transcription 
step to post-translational modification of a protein. Recently several studies have shown that 
genetic variation at the sequence level can regulate the gene expression in a cell and this 
regulation is very important (Gaur, Li et al. 2013).  
Most variation contributing to disease susceptibility, especially in complex disease, will alter 
expression rather than function of proteins (Williams, Chan et al. 2007). Such changes in 
gene expression may occur in two ways: by acting on genes at a distance through an 
expressed transcription factor (or non-coding RNA) on both the maternal and paternal 
chromosome (trans-acting factor), or by acting to regulate a gene on the same allele which 
resides on the same chromosome (cis-acting factor) (Monks, Leonardson et al. 2004; Cheung, 
Spielman et al. 2005). An inherited cis-acting variant, or less often, silencing of allele 
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expression from one parent (gene imprinting) induces allelic imbalance expression. Trans-
acting factors and environmental backgrounds influence expression of both alleles: thus they 
are not responsible for allelic imbalance expression (Tung, Fedrigo et al. 2009).Cis-acting 
mutations may alter regulation for just one allele through a change to promoter, intron 
regions or enhancer elements that affect transcription factor-binding sites. The allele-specific 
expression is investigated by evaluation of cDNA from tissues expressing the genes of 
interest in the heterozygous individual because it is not possible to measure the relative allele 
expression in the homozygous person. This is instead of using traditional methods to identify 
SNPs in vitro which are time-consuming and challenging (Marsh 2007). A major advantage 
of this approach is that the two SNP alleles are measured in the context of the same trans-
acting and environmental factors with likely cis-acting regulatory variants or parent of origin 
(imprinting) effects (Farh, Grimson et al. 2005). 
Vidal et al demonstrated that at least 25 % of the human genes display Allelic Specific 
Expression (ASE) (Vidal, de Souza et al. 2011). The result of Heap et al showed that 4.6 % of 
heterozygous single-nucleotide polymorphism (SNP)–sample pairs have evidence of ASE 
(P<0.001). Using the Illumina Allele-Specific Expression platform, Serre et al investigate 
reported 2,968 SNPs located in 1,380 genes of more than 80 individuals and confirmed that 
differential allelic expression is a widespread phenomenon affecting the expression of 20 % 
of human genes. Although the complex regulatory mechanism remains unknown, it has been 
demonstrated that cis-regulation of some genes is shared across cell types (Emilsson et al. 
2008; Myers et al. 2007; Schadt et al. 2008; Dimas et al. 2009). Consequently genetics have a 
significant role in variation on gene expression between individuals. GWAS show allelic 
imbalance expression in about 10–20% of expressed genes (if imbalance that sporadically 
occurs in one or only a few individuals is not considered) (Milani, Gupta et al. 2007; Serre, 
Gurd et al. 2008). These differences can correlate with phenotypic differences or even with 
risk of diseases (Teare, Heighway et al. 2006). Hence allelic imbalance expression analysis 
could be an interesting strategy for functional analysis of genetic factors. Grundberg et al. 
2007 investigated the function of the VDR 3` haplotypes by studying allelic imbalance 
analysis of VDR transcripts in the normal chromosomal context of 70 unrelated human 
trabecular bone samples. This was performed by the quantitative genotyping of coding 
polymorphisms in RNA samples and in corresponding DNA samples. Both were sequenced 
in parallel from the trabecular bone samples. Finally they showed that over-expression of 
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VDR baT haplotype could be considered as a risk allele for osteoporosis (Grundberg, Lau et 
al. 2007). 
 
49 | Chapter 1 
 
1.5 Aims 
 
The aims of the present study are as follows: 
Aim 1: Investigate the genetic loci associated with BMD variation and osteoporosis in the 
Iranian population by bone mineral density, blood sampling, and genotyping on the recruited 
people. The extent of association between BMD and these candidates will be evaluated in the 
Iranian population sample.  
Aim 2: Determine the effect of genetic variants in the function of osteoclast cells  
Aim 3: Determine whether cis-acting factors of the genetic variations identified in aim 1 lead 
to allelic imbalance in different cellular populations, namely whole blood and differentiated 
osteoclasts. 
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Chapter 2 –  Materials and Methods 
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2.1  Study participants and phenotypes 
 
 
The Iranian Multi-centre Osteoporosis Study (IMOS) is a continuing study to determine 
reference values for bone densitometry in the female and male Iranian population from 2005. 
Five centres in southern, northern and central Iran (Tehran, Shiraz, Mashad, Booshehr, and 
Tabriz) take part in this project. Randomized clustered sampling was used to select healthy 
women and men aged 20 to 75 years of all areas of the corresponding cities. Data of the 
registered birth deliveries from all public and private hospitals of each city in a three 
consecutive day were gathered to define clusters.  The distribution of the first deliveries has 
been shown to be highly comparable to the total population distributions concerning several 
factors such as, health status and socioeconomic (Larijani, Moayyeri et al. 2006). Fifty 
addresses of the first child deliveries were chosen as a basis for the selection of fifty clusters 
in each centre. First, the home address of the selected mother was found, and then twenty 
four neighbour houses were searched with a defined arrangement by proceeding round in a 
clockwise direction. Only one person from a randomly defined age range was selected for the 
study from each house. Hence in all of the five cities the number of invited subjects was 6000 
persons, of whom 5339 persons accepted invitation from IMOS (response rate 88%) 
(Larijani, Moayyeri et al. 2006). 
 
Subjects with the following conditions or diseases were excepted to confirm all participant 
are healthy subjects for this study: known history or evidence of hepatic or renal failure, 
rheumatoid arthritis, parathyroid or adrenal disease, thyroid disease,  metabolic bone disease, 
sterility, diabetes mellitus, oligo-menorrhea, alcoholism, malignancy, mal-absorption, 
lactation, pregnancy, immobility for more than one week, medications influencing bone 
metabolism, and smoking more than 10 cigarettes per day. In sum 437 persons were omitted 
from the study. The study protocol was permitted by the research ethics committee of the 
Iranian Ministry of Health and Medical Education. Written informed consent got from all 
contributors.  
  
Subjects for this PhD study were selected from the Shiraz centre. In the Shiraz centre 540 
subjects were selected randomly from 1080 subjects who were registered in the IMOS cohort. 
2.1.1  Iranian Multi-centre Osteoporosis Study cohort study 
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Invitations were sent to them to attend the Nemazi hospital for this study and study 
participant visited the hospital between May 2009 and February 2010. All participants 
provided written informed consent after being fully informed of the nature of the study. 
Height was read from a free-standing height with the nearest 0.5cm. Subjects were weighed 
in light street clothes without shoes using Soehnle® digital scale with the nearest 100 gr. 
Body mass index (BMI) was calculated as weight (kg) divided by the square of height (m). 
Bone mineral density and blood samples were taken. Definitive data of bone mineral density 
measurements of the total proximal femur and lumbar vertebrae (L2–L4) in the antero-
posterior position are available. Blood sampling was taken from 512 persons for DNA 
extraction. Bone mineral densitometry was done for 501 persons. Finally there were 501 
persons who blood samples and BMD were available, as a major part of the work of this 
project. Each participant spent around two hours in Nemazi hospital for all the above work 
up. 
 
  
The most precise method available for bone densitometry in clinical practice is dual-energy 
X-ray absorptiometry (DEXA). It is used to measure appendicular and axial sites and can be 
used to measure total body bone mass. Minimal radiation exposure was performed as 
produced in the method by Black et al (Blake and Fogelman 1997). In DEXA two discrete 
low energies are generated by an X-ray tube. Low energy beams are attenuated more in bone 
than in soft tissues. For calculating the attenuation caused by the bone and to neutralize the 
effect of soft tissue, two simultaneous absorption curves are generated, after measuring the 
absorption of each of the two X-ray beams. In this technology an area of bone density 
(gm/cm²) is calculated from linear measurement of bone mineral content (gm or gm/cm) by 
dividing the bone mineral content by the area that was scanned (Blake and Fogelman 1997). 
In this study the recruited subjects were referred for BMD measurement using a GE Lunar 
DPX-IQ Bone densitometer (GE Healthcare, Madison, WI USA) at the endocrine research 
centre of Nemazi hospital. Definitive data of bone mineral density measurements of the total 
proximal femur and lumbar vertebrae (L2–L4) in the anterior-posterior position are available. 
The QC of BMD measurement is essential to be sure about the consistency of BMD 
measurement. For this purpose, Error ranges from measuring device, radio-technologist’s 
experience, and patient’s condition should be considered and minimized (Kim and Yang 
2.1.2  Bone mineral density (BMD) measurement 
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2014). Daily QC is necessary for checking device condition. The tendency of BMD change is 
assessed by evaluating results of repeated scans of same subject which the average value, 
standard deviation and coefficient of variation can be found for each set of repeated 
measurements (Nagy and Clair 2000). For instance, if the accuracy of a Dual X-ray 
absorptiometry of total hip bone density measurement have a %CV of 2-5%, this indicated 
that the measurement of BMD tend to vary by 2-5% of the real BMD. In fact the %CV is 
describing the variability of the measurement about the true value. Therefore, the smaller the 
%CV means the more accurate device.  
  
 
2.2  Genotyping 
 
 
Systematic reviews typically involve a detailed and comprehensive search strategy with the 
objective of reducing bias by identifying and extracting specific data sets from relevant 
studies (Uman 2011). This study required the systematic review of publications that were 
relevant to bone mineral density, which involved genetic association in human populations.  
As was discussed in the introduction section bone mineral density is considered an important 
risk factor to predict the likelihood of  fragility fracture and is widely used in clinical practice 
to identify those at increased risk for fracture (Johnell, Kanis et al. 2005). Other risk factors 
that should be considered in assessment of fracture risk are such as: age, sex, race, country of 
residence, history of fragility fracture, corticosteroid use, and current smoking (Tremollieres, 
Pouilles et al. 2010). According to diagnostic criteria for osteoporosis was discussed in the 
introduction section, it is sensible to study association with BMD in osteoporosis study. 
The method of systematic review was performed as previously outlined (Xu, Dong et al. 
2010). The systemic review of the literature involved developing search strategies and 
locating the studies, selecting relevant studies and extracting data. 
 
1. In the search strategy stage for the selection of genes and their SNPs associated with 
osteoporosis, the literature from 2000 to December 2010 was scanned through the 
2.2.1 Systemic review of the literature for selection of candidate genes and 
SNPs of osteoporosis  
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Web of Knowledge and NIH database for genes using the searching key words 
“BMD” “osteoporosis” in combination with “association” “polymorphisms” and 
“gene”.  
2. This search retrieved article studies reported by: candidate gene association study 
(CGAS), meta-analysis of candidate gene association study (MA-C), genome-wide 
association study (GWAS) and meta-analysis of genome-wide association study (MA-
G).  
 
In this review, due to space limitations, only the most representative results that have had an 
immediate influence on understanding and research of genetic mechanisms underlying 
osteoporosis are discussed. Based on this search LRP5, RANK, RANKL, OPG and ESR1 were 
selected as genes that were associated with BMD in the literature reported by all CGAS, MA-
C, GWAS and MA-G studies. These genes are also involved in three biological pathways, the 
Wnt/-catenin signalling pathway, the estrogen endocrine pathway, and the 
RANKL/RANK/OPG pathway.  
 
GWAS review was used for the strategic selection of single nucleotide polymorphisms 
(SNPs) that were the most important in BMD. The catalogue of published GWAS in national 
human genome research institute (NHGRI) was used for searching risk SNPs of selected 
candidate genes (Table 2-1) (Hindorff, Sethupathy et al. 2009). There are some specific 
criteria for the selection of association studies in the national human genome research 
institute. Studies that searched at least 100,000 SNPs in the initial stages were chosen and the 
SNP-trait associations listed were limited to those with p-values of < 1.0 x10
-5
. By the end of 
2010, the database summarising the information comprising fourteen GWAS related to 
osteoporosis and BMD were gathered in the national human genome research institute of 
which one is was meta-analysis study of five GWAS.  
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Reported 
gene 
Trait Strongest 
SNP risk 
allele 
Articles P-
value 
Beta-
coefficient 
and [95% CI] 
OPG 
 (The 
RANKL/RANK
/OPG 
pathway) 
Established 
gene (CGAS+ 
MA-C +GWAS 
+MA-G) 
BMD 
(hip) 
rs11995824-G (Rivaden
eira, 
Styrkársd
ottir et al. 
2009) 
4×
10−9 
.07 [0.05-0.09]  
BMD 
(spine) 
rs2062377-T 4×
10−16 
.09 [0.07-0.11]  
BMD rs4355801-A (Richards
, 
Rivadene
ira et al. 
2008) 
8×
10−10 
.09 [NR]  
BMD 
(spine) 
rs2062375-G (Hsu, 
Demissie
-Banjaw 
et al. 
2008) 
3 x 
10−11 
.14 [NR] 
BMD 
(spine) 
rs6469804-A Styrkarsd
ottir, 
Halldorss
on et al. 
2008) 
7 x  
10−15 
.12 [0.09-0.15] 
ESR1 
(The estrogen 
endocrine 
pathway) 
Established 
gene (CGAS+ 
MA-C +GWAS 
+MA-G) 
BMD 
(hip) 
rs2941740-G (Rivaden
eira, 
Styrkársd
ottir et al. 
2009) 
2 x  
10−10 
.07 [0.05-0.09]  
rs1038304-G (Styrkars
dottir, 
Halldorss
on et al. 
2009) 
  
4 
x
10−10 
.08 [0.06-0.11]  
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Reported 
gene 
Trait Strongest 
SNP risk 
allele 
Articles P-
value 
Beta-
coefficient 
and [95% CI] 
rs1038304-G (Styrkars
dottir, 
Halldorss
on et al. 
2008) 
5 x 
10-9 
.08 [0.06-0.11] 
BMD 
(spine) 
rs4870044-T 2 x 
10−11 
.11 [0.08-0.14]  
BMD 
(spine) 
rs6929137-A (Styrkars
dottir, 
Halldorss
on et al. 
2009) 
2 x  
10−10 
.1 [0.07-0.13] 
BMD 
(spine) 
rs2504063-A (Rivaden
eira, 
Styrkársd
ottir et al. 
2009) 
6 x 
10−11 
.08 [0.06-0.10] 
BMD 
(spine) 
rs1999805-C (Styrkars
dottir, 
Halldorss
on et al. 
2008) 
2 x 
10−8 
.09 [0.06-0.12] 
LRP5 
(The Wnt/β-
catenin 
signalling 
pathway) 
Established 
gene (CGAS+ 
MA-C +GWAS 
+MA-G) 
BMD 
(spine) 
rs599083-G (Rivaden
eira, 
Styrkársd
ottir et al. 
2009) 
5 x 
10−8 
.07 [0.05-0.09]  
BMD rs3736228-T (Richards
, 
Rivadene
ira et al. 
2008) 
6 x 
10−12 
.13 [NR]  
RANKL BMD 
(hip) 
rs9594738-T (Styrkars
dottir, 
2 x 
10−8 
.1 [0.06-0.13] 
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Reported 
gene 
Trait Strongest 
SNP risk 
allele 
Articles P-
value 
Beta-
coefficient 
and [95% CI] 
(TNFRSF11) 
(The 
RANKL/RANK
/OPG 
pathway) 
 
Established 
gene 
(CGAS+GWA
S+MA-G) 
BMD 
(spine) 
rs9594759-T Halldorss
on et al. 
2008) 
2 x 
10−21 
.17 [0.14-0.21]  
BMD  rs1021188-C (Paternos
ter, 
Lorentzo
n et al. 
2010) 
2 x 
10−14 
3.89 [1.91-
5.87] 
RANK  
(TNFRSF11) 
(The 
RANKL/RANK
/OPG 
pathway) 
 
Established 
gene 
(CGAS+GWA
S+MA-G) 
 
BMD rs884205-A (Rivaden
eira, 
Styrkársd
ottir et al. 
2009) 
6 x 
10−9 
.09 [0.06-0.12]  
BMD 
(hip) 
Rs3018362-A (Styrkars
dottir, 
Halldorss
on et al. 
2008) 
1 x 
10−6  
.07[0.04-0.10] 
 
Table  2-1: List of candidates arising from CGAS, MA-C, GWAS, and MA-G 
studies with their risk SNPs (Hindorff LA ; Li, Hou et al. 2010) 
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The VDR gene was the first candidate gene studies with respect to osteoporosis identifies in 
several CGAS and MA-C studies within the literature (Li, Hou et al. 2010). In Particular the 
VDR genes, as the most studied candidate gene related to osteoporosis in Iranian population 
(Hossein-nezhad, Varzaneh et al. 2011; Pouresmaeili, Jamshidi et al. 2013) were also added 
to the panel of BMD associated genes for genotyping. Additionally, Gartland et al. 2012 has 
data to show that P2RX7 is a novel candidate gene associated with BMD and also Ohlendorff 
et al. 2007 showed association between P2RX7 gene and osteoporotic fracture risk   
(Ohlendorff, Tofteng et al. 2007; Gartland, Skarratt et al. 2012). As a result this gene was also 
added to the panel of BMD associated genes for genotyping (Table 2.2) 
 
 
Gene Trait Risk Articles P-value beta-
coefficient 
and (95% CI) 
VDR 
(CGAS+ MA-
C) 
 
BMD (Spine) Rs2228570-T (Wang, Liu et 
al. 2013) 
0.001 -0.87  
(-1.38,0.35) 
BMD 
(Femoral 
neck) 
0.001 -0.43 
(-0.93, 0.06) 
P2RX7 
(CGAS) 
BMD 
(Spine) 
rs28360457-A (Gartland, 
Skarratt et al. 
2012) 
0.004 -0.12 (NR) 
BMD rs3751143 (Wesselius, 
Bours et al. 
2013) 
0.018 2.47(1.15, 
5.32) 
 
Table  2-2: List of candidates arising from CGAS and MA-C or just CGAS 
studies with their risk SNPs 
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To perform Allelic Expression Imbalance (AEI) analysis, individuals heterozygous for 
transcribed SNP were chosen where the contribution of each of the two alleles assessed by 
quantifying the relative amount of transcripts from each. Unequal expression was then 
defined as AEI. Therefore, the transcribed SNPs with the highest heterozygosity for the 
candidate osteoporosis genes identified in section 2.2.1 (LRP5, RANK, RANKL, P2RX7, 
ESR1, OPG and VDR) were determined using the NCBI reference assembly 
(http://www.ncbi.nlm.nih.gov/projects/SNP). The osteoporosis-gene candidate transcribed 
SNPs were selected using the NCBI database software as follows: 
1. The search to identify a candidate transcribed SNP was initiated at the NCBI 
homepage by entering the gene name in ‘SNP’ search bar. 
2. The SNP was selected from the retrieved results i.e reported and annotated SNP for 
the query gene was retrieved (Figure 2.1 A). 
3. Under the ‘Gene View’ section cSNP was selected from the gene variation options 
and the resulting transcribed SNPs were displayed in a table. A range of information 
associated with the transcribed SNPs for the candidate gene was available including 
chromosome position, clinical association/significance and importantly, 
heterozygosity (Figure 2.1 B).  
4. Following the transcribed SNP selection process, the SNP with the highest 
heterozygosity was selected from the complete transcribed SNP list retrieved by 
NCBI for future AEI study analysis. The criteria for deeming a transcribed SNP as 
‘highly heterozygous’ was directly related to the associated heterozygosity value. For 
example a SNP that had a heterozygosity value of 0.237 was more heterozygous 
compared to a SNP with a heterozygosity value of 0.001 (Figure 2.1 B). The minor 
allele frequency (MAF) refers to the frequency at which the least common allele 
occurs in a given population. Where heterozygosity could not be defined for 
transcribed SNPs, the MAF could be a more useful clue to identifying transcribed 
SNPs with more chance to be heterozygous in the population table (table 2.3). 
 
 
 
 
2.2.2  Selection of transcribed SNPs using NCBI reference assembly database 
60 | Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2-1: Transcribed SNPs with the highest heterozygosity were selected 
from the retrieved results for the query gene 
 The SNPs associated with LRP5 are used as an example.  
A 
B 
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Table  2-3 : Transcribed SNPs of selected candidate genes with the highest 
MAF in the NCBI 
 
 
 
 
 
 
Transcribed SNP MAF 
 
ESR1  
2077647 0.4665  
OPG  
2073618 0.3333 
1804854 0.0881 
LRP5  
556442 0.4207 
2306862 0.1102 
545382 0.1585 
RANKL  
9562415 0.0415 
RANK  
1805034 0.4058 
35211496 0.0573 
P2RX7  
2230911 0.1649 
2230912 0.0693 
208294 0.47 
7958311 0.2558 
1718119 0.3225 
1621388 0.3203 
VDR  
731236 0.2766 
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2.3  DNA Extraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
The QIAamp 96 DNA Blood Kit was used for the isolation of DNA from peripheral blood 
and using a fast 96-well-plate procedure. In principle, DNA binds specifically to the QIAamp 
silica-gel membrane while the contaminants pass through and are removed. Inhibitors of 
polymerase chain reaction including divalent cations and proteins are completely removed in 
wash steps. As a result pure nucleic acid is eluted in water or buffer ready to use in gene 
expression procedures. The purified DNA is up to 50 Kb in size and DNA of this length 
denatures completely. Typically a yield of 6 µg per 200 µl can be obtained from healthy 
whole blood.  
Briefly, the protease stock solution at a volume of 20µl was pipetted into the bottom of the 
collection micro-tubes. 200µl of human peripheral blood was collected by brachial vein 
puncture method (Galena 1992; Okeson and Wulbrecht 1998). Blood was collected into 
micro-tubes by touching the insides of the tubes without wetting the rims. Buffer AL in the 
amount of 200 µL was added to each blood sample, without wetting the rims of the collection 
Material   
ITEM SUPPLIER 
QIAamp 96 Plates 4 12 
 
S-Blocks 
Collection Microtubes (racked)  
Elution Microtubes CL (racked)  
Caps for Collection Microtubes  
Caps for Elution Microtubes  
AirPore Tape  
QIAGEN® Protease  
Protease Solvent 
Buffer AL 
Buffer AW1 (concentrate 
Buffer AW2 (concentrate) 
Buffer AE 
96-Well Plate Register  
Selection Guide 
Qiagen 
Molecular-grade Ethanol   Sigma-Aldrich 
Heratherm Incubator Thermo Scientific 
63 | Chapter 2 
 
micro-tubes for cell lysis. Collection micro-tubes were sealed by using the caps. The rack of 
micro-tubes was covered with the plastic cover provided and mixed thoroughly by shaking 
vigorously for 15 seconds. The rack was centrifuged briefly at 6000 x g to collect any solution 
from the caps and then incubated at 70°C for at least 10 min. The rack was centrifuged 
briefly at 6000 x g rpm to collect any lysate from the caps. Caps were removed and 200 μL of 
100% ethanol added to each tube. The tubes were sealed by using new caps for collection 
micro-tubes and shaken vigorously for 15 seconds. The rack was centrifuged briefly at 6000 x 
g to collect any solution from the caps.  
The QIAamp 96 plate was placed on top of an S-Block. The plate was marked for later 
identification. The mixture of 620 μL per collection micro-tube was applied carefully to the 
QIAamp 96 plate. The QIAamp 96 plate was sealed with an AirPore Tape sheet. The S-Block 
(96-well blocks with 2.2 ml wells), and QIAamp 96 plate were loaded onto the carrier, placed 
in the rotor bucket, and centrifuged at 6000 x g for 4 minutes. The tape was removed and 500 
μl Buffer AW1 (wash buffer for removing all residual contaminants without affecting DNA 
binding) was added to each well. The QIAamp 96 plate was sealed with a new AirPore Tape 
sheet and centrifuged at 6000 x g for 2 minutes. The tape was removed and 500 μL Buffer 
AW2 was added carefully to each well for removing all residual contaminants without 
affecting DNA binding. Each well was centrifuged at full speed 20000 x g for 3 minutes.  
The QIAamp 96 plate was placed on top of a rack of elution micro-tubes. For elution of 
DNA, 200 μL Buffer AE, equilibrated to room temperature, was added to each well using a 
multichannel pipette. The QIAamp 96 plate was sealed with a new AirPore tape sheet, 
incubated for 1 minute at room temperature and centrifuged at 6000 x g for 4 minutes. The 
wells of the micro-tubes were sealed with the caps and stored at -20°C. 
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2.4  Genotyping using Competitive Allele-Specific Polymerase chain reaction 
(KASPar) assay 
 
Single nucleotide polymorphisms (SNPs) genotyping was performed by Competitive Allele-
Specific Polymerase chain reaction (KASPar) assay by KBioscience services. SNP 
genotyping is the measurement of genetic variations of SNPs between members of a species 
using a SNP-based genotyping platform. KASPar assay SNP genotyping system from 
KBioscience is based on Fluorescent Resonance Energy Transfer (FRET) technology. In this 
SNP-genotyping platform, FRET is coupled with the power of competitive allele specific 
PCR, allowing for determination of SNP or insertion/deletion genotypes. Following 
completion of the reaction, the data reported were evaluated using the KlusterCaller 1.1 
software (KBioscience).  
Distribution of genotype frequencies was tested for consistency to Hardy–Weinberg 
equilibrium. Three SNPs showed a deviation from HWE (at the p=0.05 level) which were 
excluded. For quality control missing data for each SNP and in each sample were calculated. 
If missing data for each SNP were more than 25% of data that SNP was excluded which 
missing data for all SNPs were less than 25% of data in this genotyping. If missing data in 
each sample were more than 5% of data, that sample was excluded which ten samples were 
excluded. 
2.5  Sample selection procedure for Allelic Imbalance Expression and 
osteoclast function study  
In the first part of this study, 540 individuals were selected randomly and both blood 
sampling and BMD were done for 501 individuals as described in the section 2.1.1. 
Genotyping of the peripheral blood samples donated from these 501 volunteers were 
performed as described in the section 2.4. Due to the time and cost limitations of our core 
genomic facility in Shiraz, it was not possible to include all 501 samples within the AEI 
study. Thus, the minimum numbers of volunteer peripheral blood and osteoclast culture 
samples that were necessary to produce statistically viable results within the AEI study were 
calculated by “sample size tables for clinical studies software”. 
It was feasible and affordable to use 16 osteoclast cultures and perform AEI analysis on 52 
blood samples. By using the above software, assuming a two-sided 0.05 significance level, 16 
samples would provide 80% power to detect a true difference in the mean ratios of 0.8 of 
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standard deviation. Assuming 0.05 significant level, 52 samples would provide 80% power to 
detect a true difference in the mean ratios of 0.4 of a standard deviation 
The above calculations showed that with these relatively modest sample sizes it was possible 
to detect medium effect sizes within the AEI study. There was a minimum requirement of 52 
peripheral blood samples and 16 osteoclast culture samples. The total numbers of 52 subjects 
were selected to maximise the number of heterozygosity at each of the transcribed SNPs. 
This would ensure that the sample of 52 (16) would be maximally informative for the AEI for 
all selected genes. This was performed by sorting the samples according to the number of 
heterozygous SNPs of the six transcribed SNPs: rs556442, rs2073618, rs208294, rs2077647, 
rs1805034, rs731236. Each SNP was coded as heterozygous or homozygous according to 
genotyping result. First sixteen samples were selected for osteoclast culture (Table 2.4).  
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Table  2-4: Sample sorting according to the number of heterozygous SNPs of 
the six transcribed SNPs: rs556442, rs2073618, rs208294, rs2077647, 
rs1805034, rs731236. 
The 52 subjects were given identification codes outlined in the first column. The ticks 
represent a heterozygous SNP for a particular subject. The total number of subjects out of the 
possible 52 subjects, heterozygous for each of the 6 SNPs could be determined.  
 
 
Sample 
ID 
All rs556442 rs2073618 rs208294 rs2077647 rs1805034 rs731236 
A498AL 6 √ √ √ √ √ √ 
R255NA 6 √ √ √ √ √ √ 
K90HA 6 √ √ √ √ √ √ 
S539SI 6 √ √ √ √ √ √ 
T513MO 5 √ √ √ √ √ - 
A266FA 5 √ √ √ √ √ - 
R438AG 5 √ √ √ √ √ - 
E335RA 5 - √ √ √ √ √ 
S189ZO 5 √ √ √ √ √ - 
S116KH 5 - √ √ √ √ √ 
S200ZE 5 √ √ - √ √ √ 
A2AT 5 √ - √ √ √ √ 
G179AL 5 - √ √ √ √ √ 
K455HO 5 √ - √ √ √ √ 
M272MA 5 √ - √ √ √ √ 
G472GO 5 √ √ - √ √ √ 
G204OM 5 - √ √ √ √ √ 
S137AF 5 √ - √ √ √ √ 
E388FA 5 - √ √ √ √ √ 
M345SH 5 - √ √ √ √ √ 
S203ME 5 √ - √ √ √ √ 
S475YA 5 √ - √ √ √ √ 
S343ZE 5 - √ √ √ √ - 
M288PE 5 - √ √ √ √ √ 
S206KH 5 √ - √ √ √ √ 
E228NA 5 √ √ √ - √ √ 
N479RE 5 √ √ √ - √ √ 
M320AB 5 √ √ √ - √ √ 
A555SH 5 √ √ √ - √ √ 
A329AK 5 √ √ √ √ - √ 
G383KE 5 √ √ √ √ - √ 
S446HA 5 √ √ √ √ - √ 
P571HA 5 √ √ √ √ - √ 
R177KO 5 √ √ √ √ - √ 
M450SA 5 √ √ √ √ - √ 
G298LE 5 √ √ √ √ - √ 
K339MO 5 √ √ √ √ - √ 
G461BE 5 √ √ - √ - - 
R119ES 5 √ √ √ √ - √ 
G257SH 5 √ √ √ √ - √ 
K551EB 5 √ √ √ - √ √ 
P414GO 4 √ √ - - √ √ 
A360ZE 4 - √ √ - √ √ 
M426NO 4 √ - √ - √ √ 
A469AM 4 √ - √ - √ √ 
S181AL 4 √ √ - - √ √ 
S460MO 4 √ √ - - √ √ 
S378SO 4 - √ √ - √ √ 
G299HA 4 - √ √ - √ √ 
K282MO 4 √ - √ - √ √ 
N408MO 4 - √ √ - √ √ 
N575BE 4 √ √ √ - √ - 
Total - 40 42 46 36 41 45 
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2.6 Assessing genotype group counts between transcribed and risk SNPs 
using cross tabulate function 
AEI is achieved in heterozygous transcribed samples and therefore should be defined taking 
into consideration the potential link between the heterozygous risk SNPs and heterozygous 
transcribed SNPs. A pivot table was used to cross tabulate the genotyping data of transcribed 
and risk SNPs within the 52 selected subject samples. For each of the six candidate genes, all 
genotyping data of transcribed and risk SNPs were transferred into excel worksheets to form 
the pivot table. Data collected from the transcribed SNPs were inserted into excel rows and 
the risk SNPs were inputted into excel columns of the pivot tables as described in the 
example illustrated in Table 2.5. Subsequently, the relationship between each of the 
transcribed SNPs and risk SNPs were assessed to determine a genetic association.  
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 Risk SNP rs3018362 
  
   
A:A G:A G:G 
Grand 
Total 
 
Transcribed 
SNP 
rs1805034 
C:C 
 
0 3 3 6 
T:C   3 18 23 44 
T:T   0 0 2 2 
Grand Total 
 
3 21 28 52 
 
Table  2-5: An example of a pivot table to assess genotype group links of a 
transcribed SNP and risk SNP 
 The transcribed rs1805034 SNP with its three genotypes (C: C, C: T, and T: T) were 
inserted in the pivot table columns and the risk rs3018362 SNP inserted in the row columns. 
This pivot table analysis showed that in the 52 samples there were 44 samples which were 
heterozygous for rs1805034 with the T: C genotype and 18 out of these 44 samples were also 
heterozygous for rs3018362 with G: A genotype.  
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2.7  Cell culture 
 
Material 
IITEM SUPPLIER 
Haemocytometer - Depth 0.1mm, 1/400mm
2
 Hawksley 
Cell culture flat bottom 96-well plates  Corning® Costar®  (New York, USA)   
BD Falcon™ Centrifuge tube – 15ml, 50ml Fisher Scientific 
Eppendorph Tubes (0.05 abd 1.5ml) Starstedt 
GPR Centrifuge Beckman Coulter 
Microcentrifuge IEC Micromase 
Water-cooled Labcut 1010 low-speed 
diamond saw 
Agar Scientific Ltd (Stansted, UK) 
Water Bath  Fisher Scientific 
Vortex Mixer VLP® Scientifica 
Z2 Counter Bechman Coulter Inc. 
MS columns for magnetic selection of 
CD14+ monocyte/macrophage population 
Miltenyi Biotec Ltd. (Bisley, UK) 
Glass coverslips of 6mm diameter Richardson’s of Leicester (Leicester, 
UK) 
Minimum Essential Media (MEM) -Alpha+ 
GlutaMAX 
Gilbco
TM
, Invitrogen (Paisley, UK) 
Human recombinant RANKL                                                             Insight Biotechnology Ltd. (Wembley, 
UK) 
Macrophage Colony Stimulating Factor (M-
CFS) 
R&D (Minneapolis, USA) 
Fetal calf serum (FCS) Gilbco
TM
, Invitrogen (Paisley, UK) 
Penicillin: Streptomycin Solution (PenStrep) Gilbco
TM
, Invitrogen (Paisley, UK) 
CD14 Microbeads Miltenyi Biotec Ltd. (Bisley, UK) 
Phosphate Buffered Saline (PBS) 
(pH-7.4 Ca2+ and Mg2+ free) 
Sigma-Aldrich ( Poole, UK)                                                                     
UltraPure™ 0.5M, 
Ethylenediaminetetraacetic acid (EDTA) 
Gilbco
TM
, Invitrogen (Paisley, UK) 
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(pH 8.0) 
Trypan blue Sigma-Aldrich ( Poole, UK)                                                                     
Lithium-Heparin and BD SST™ 
vacutainers               
BD Biosciences (Oxford, UK) 
 Histopaque®-1077                                                                              Sigma-Aldrich ( Poole, UK)                                                                     
 
 
 
To study the effect of genetic variation on osteoclast and function in vitro, peripheral blood 
(up to 100mL) was collected in lithium-heparin vacutainers from healthy volunteers. Human 
peripheral blood was collected by brachial vein puncture method (Galena 1992, Okeson and 
Wulbrecht 1998). Subjects were recruited from Shiraz Medical University approved by the 
University of Shiraz Research Ethics Committee. Informed Ethical consent was obtained 
from the volunteers prior to sample collection. The collected blood was diluted 1:1 ice-cold 
PBS supplemented with 2mM EDTA (Buffer 1) and 8 mL of this mixture was layered over 5 
mL of Histopaque®-1077 in 15 mL Falcon tubes. Blood was centrifuged at 400g for 30 
minutes at room temperature without break. Following centrifugation, the upper layer of the 
blood mixture was removed and the opaque interface containing the monocytes and 
lymphocytes fraction of blood was collected by using fine pipettes (Figure 2.2). 
Subsequently, the PBMCs fraction was washed with Buffer 1 at 300g and washed again at 
200g for 10 minutes.  
 
 
 
 
 
 
 
 
 
2.7.1 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
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Figure  2-2: Isolation of Peripheral Blood Mononuclear Cells 
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For cell counting, an aliquot of cell suspension was mixed 1:1 with 1% acetic acid in order to 
lyse any contaminating red cells. This mixture was applied carefully into a haemocytometer 
ensuring each chamber was properly filled. The number of cells was counted in 2×4 fields of 
counting surfaces. An average number of these fields were multiplied by 2 as dilution factor 
with acetic acid and by 104 because the volume under one square is equivalent to 10-4 mL 
(Figure 2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2-3: Cell count by haemocytometer 
Cells were counted from each corner square of the haemocytometer (A, B, C and D) and the 
average cell number calculated (cells/ml). 
 
 
 
 
2.7.2 Cell count using Haemocytometer  
A B 
C D 
The average cell number 
from A, B, C and D was 
multiplied by a dilution 
factor of 2 and by 10,000 
(104) to determine the 
number of cells per ml  
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2.7.3.1 Isolation of CD14+ monocytes from PBMCs 
 
CD14-positive (CD14
+
) monocytes were isolated from PBMCs using anti-CD14-coated 
beads (Miltenyi Biotec Ltd). The CD14 antigen belongs to the LPS receptor complex and is 
strongly expressed on most monocytes and macrophages. Osteoclast precursors derive from 
CD14
+
 monocytes (Massey and Flanagan 1999; Nicholson, Malakellis et al. 2000). Following 
purification and count of PBMC as outlined in sections 2.7.1 and 2.7.2 respectively, the 
PBMCs were washed with ice-cold PBS supplemented with 2mM EDTA (Buffer 1). Cells 
were centrifuged at 300g for 10min and the cell pellet resuspended in ice-cold PBS 
supplemented with 2mM EDTA + 0.5% BSA (Buffer 2) containing the magnetic microbeads 
conjugated with anti-human monoclonal CD14 antibody. PBMCs were resuspended at a cell 
density of 10
7
 cells in 80μL of Buffer 2, supplemented with microbeads at ratio of 4:1. To 
allow antibody binding, the cell suspension was then incubated for 15 minutes at 4°C. The 
CD14
+
 cell population was isolated from the unlabelled CD14
- 
cells using a MS-column 
mounted on a magnetic separator. 
2.7.3.2 Differentiation of CD14+ monocytes into mature osteoclasts  
 
Following isolation, the CD14
+
 monocytes were differentiated into mature osteoclasts by 
stimulation with macrophage colony-stimulating factor (M-CSF) and receptor activator of 
nuclear factor κB ligand (RANKL). Monocytes were cultured on sterile dentine disks or glass 
cover slips. Prior to the osteoclast cultures, the dentine disks were punched using a water-
cooled Labcut 1010 low-speed diamond saw (Agar Scientific Ltd., Stansted, UK). The cut 
disks were 5mm in diameter and up 60μm in thickness. Dentine disks were sterilised by 
sonication for 10 minutes in distilled water repeated twice, Disks were then stored in 70% 
ethanol for a minimum of 24 hours until required for cell culture. Prior to cell culture 
procedure, the dentine disks were washed once in PBS and pre-wetted in α-MEM for one 
hour at 37°C. Glass coverslips with a diameter of 6mm (Richardson’s of Leicester, Leicester, 
UK) were sterilized by dry heating at 175°C for 2 hours. The separated CD14
+
 cells were 
counted according to section 2.7.2 and seeded at a density of 4 × 10
4
 per well on sterile 
2.7.3 Osteoclast cultures 
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dentine disks or glass coverslips in the of a 96-well plate. CD14+ monocytes cells were 
cultured at 37˚C and 7% CO2 for approximately 2-3 weeks, in α-MEM supplemented with 
100 IU/mL penicillin, 100μg/mL streptomycin, 10% FCS,  30ng/mL RANKL and 25ng/mL 
M-CSF ; referred to as osteoclastogenic media unless otherwise specified. The 
osteoclastogenic media was replaced every 2–3 days.  
 
 
Material 
IITEM SUPPLIER 
sodium nitrite Sigma (Poole, UK) 
Pararosaniline Sigma (Poole, UK) 
sodium acetate trihydrate Sigma (Poole, UK) 
Gill's haematoxylin Sigma (Poole, UK) 
sodium tartrate dihydrate Sigma (Poole, UK) 
Naphthol AS-BI phosphate Sigma (Poole, UK) 
Hydrochloric acid (10125 4H) VWR (Lutterworth, UK) 
Dimethylformamide Fisher, (Loughborough, UK) 
DPX mounting reagent BDH Laboratory (Poole, UK) 
Acetic acid (10001 CU) VWR (Lutterworth, UK) 
 
 
Osteoclast cells which were cultured on disks or coverslips were fixed in 10% formalin and 
then stained for tartrate resistant acid phosphatase (TRAP). The isoenzyme TRAP stimulates 
the hydrolysis of phosphoproteins and nucleotides (Hayman, et al 2000) and is characterised 
as a cytochemical and functional marker of osteoclasts (Baron, et al 1986, Cole and Walters 
1987) (Minkin 1982). The TRAP staining assay involves hydrolysation of naphthol AS-BI 
phosphate by TRAP, which couples with the hexazotized dye, pararosaniline, to produce a 
coloured complex that precipitates at the site of osteoclast activity.  
  
2.7.4 Osteoclast Tartrate resistant acid phosphatase staining 
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Fixed osteoclast cultures were treated with 0.1M Sodium tartrate in 0.2M sodium acetate 
buffer (pH 5.2) for 5 minutes at 37°C. The acetate buffer was removed and the osteoclast 
cultures incubated in 20mg/mL Naphthol AS-BI phosphate/dimethylformamide acetate-
tartrate buffer for 30 minutes at 37°C. Cultures were further treated with acetate-tartrate 
buffer containing hexazotized pararosaniline solution for 15 minutes at 37°C. Osteoclast 
cultures were counterstained with Gill’s haematoxylin for 30-40 seconds. Excess stain was 
removed by washing several times with tap water. Coverslips were transferred from the wells 
in the culture plates and air-dried. Finally, cultures were mounted in DPX reagent and 
visualised under a light microscope. The dentine disks were also air-dried and stored at room 
temperature in preparation for quantification using a light microscope.  
 
 
Osteoclast cultures were assessed for total osteoclast number, number of resorbing osteoclasts 
and percentage resorption using point counting. When osteoclasts are placed on dentine slices 
they form resorption pits. The presence of functional osteoclast cells can be determined by 
measuring the amount of resorption on the dentine surface. Osteoclasts were characterised by 
TRAP positive stained cells with three or more nuclei. Resorbing osteoclasts were 
characterised as cells on or in close proximity to resorption pits. The dentine disks are TRAP 
stained and counterstained by Gill’s haemotoxylin. A 10x10 point grid was fit into an eye-
piece of the microscope. Using 10X magnification, 9 fields could be obtained for each 
dentine disk. In each field the points of intersection that fall over a resorption pit were 
counted (2 points for the first pits and 6 points for the second pit, Figure 2.4). All the points 
for all 9 fields were summed to give the measure for resorption for a disk. Other parameters 
that were counted included the total osteoclast number and the number of resorbing 
osteoclasts for the entire dentine disk. 
 
 
 
 
 
 
 
2.7.5 Osteoclasts quantification  
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Figure  2-4: Counting the points for quantification resorption area 
 The points of intersection that fall over a resorption pit were counted 
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2.8 Osteoclast and Blood RNA Extraction 
 
Material   
ITEM SUPPLIER 
ReliaPrep™ RNA Cell Miniprep 
 
ReliaPrep™ Minicolumns (50/pack) 
Column Wash Solution (CWE) 
Elution tubes (50/pack) 
Collection tubes (50/pack) 
BL buffer 
1-Thioglycerol (TG) 
Nuclease-Free Water 
DNase I (lyophilized) 
Yellow Core Buffer 
RNA Wash Solution (RWA) 
MnCl2, 0.09M 
 
Progema  
Microseal® 'B' Adhesive Seals Bio Rad 
Individual PCR Tubes, 0.5 ml and 
1.5ml  
Thermo-Scientific 
384-Well standard PCR Plates Thermo-Scientific 
95% Molecular-grade Ethanol Sigma-Aldrich 
Molecular-grade Isopropanol  Sigma-Aldrich 
 
 
RNA was extracted from cells cultured on dentine disks or coverslips using the column-based 
ReliaPrep RNA cell Miniprep kit (Promega). Dentine disks were placed into eppendorf tube 
containing 100µL of BL-TG buffer. To prepare the BL-TG buffer, 325μL of 1-Thioglycerol 
(TG) was added to 32.5ml of BL Buffer. RNA was sheared by repeat-pipetting of BL-TG 
buffer over the surface of the dentine disk. Lysates were pipetted into PCR-grade 
microcentrifuge eppendorfs and isopropanol was added in 1:3 ratios i.e. 35µL added to the 
100µL of BL-TG buffer, followed by thorough mixing by vortex to assist RNA shearing.  
Each cell lysate was transferred to a ReliaPrep™ Minicolumn inserted into a fresh collection 
tube. Lysates were centrifuged at 12,000 × g for 30 seconds at room temperature and the 
supernatant discarded. Next, 500μL of RNA wash solution containing 95% ethanol was 
added to the Minicolumn and again centrifuged at 12,000 × g for 30 seconds. To remove any 
genomic DNA contamination, RNA samples were treated with DNase enzyme. For each 
sample, 30µL of DNase I solution was prepared by mixing 24μL of Yellow Core buffer, 3μL 
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0.09M MnCl2 and 3μL of DNase I enzyme. Samples on the Minicolumn were treated with 
30ul of the DNase I solution for 15 minutes at room temperature.  
 
Minicolumns were washed with 200μL of column wash solution by centrifugation at 12,000 
× g for 15 seconds. Minicolumns were then washed with 500μL of RNA wash solution was 
by centrifugation at 12,000 RPM for 30 seconds. The Minicolumn membrane was washed 
again with 300μL of RNA wash solution by centrifugation at 13,000 × g for 2 minutes. 
Minicolumns were transferred to fresh Elution tubes and 30 µL of nuclease-free water added 
to each membrane and centrifuged at 13,000 g for 1 minute.  
 
The purity and nucleic acid concentration of RNA was determined using the NanoDrop-1000 
spectrophotometer (Thermo scientific) at an absorbance of 260nM (A260) and 280nM (A280). 
The concentration of 1µL of nucleic acid was determined using the Beer-Lambert law A = 
εƖc which calculates the difference between light absorbance (A), sample concentration (c) 
specific extinction coefficient (ε) and length of the light pathway which travels through the 
absorber (Ɩ). An A260/A280 ratio of 1.8-2.2 was considered an indicator of uncontaminated 
RNA.  
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2.9 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 
 
 
The reverse transcription (RT) procedure is based the catalyzing activity of reverse 
transcriptase enzyme which converts RNA template to complementary DNA (cDNA). The 
cDNA is required for the polymerase chain reaction (PCR) process to evaluate gene 
expression. cDNA synthesis is performed using an oligo(dT), a short piece of single-stranded 
DNA, which anneals to the 3' end poly-A tail of mRNA molecules. In all of the study 
experiments, RNA samples were converted to cDNA using the RevertAid H Minus First 
Strand cDNA Synthesis Kit (Thermo Scientific) following manufacturer’s instruction. The kit 
also includes RevertAid H Minus Reverse Transcriptase that has the ability to eliminate 
RNase H activity. 
Material   
REAGENTS  SUPPLIER 
RNAase-free eppendorfs Alpha Laboratories 
Full range100 BP DNA Ladder Norgen 
100mM DNTP mix  Thermo-scientific 
RevertAid H Minus First Strand cDNA 
Synthesis Kit 
Thermo-scientific 
DEPC-treated Water Ambion® Life Technologies 
Quantity One Software BioRad 
Gel Doc XR+ System BioRad 
Taqman Gene expression Assays Applied Biosystem 
2X Taqman Universal Master Mix Applied Biosystem 
ABI 7900HT Platform Applied Biosystem 
Ethidium Bromide BioRad 
Agarose Sigma-Aldrich 
Tris/Borate/EDTA (TBE) buffer  Applichem 
X5 DNA Loading buffer Kappa Biosystems 
2.9.1 Complementary DNA (cDNA) synthesis  
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Briefly, first strand cDNA synthesis was performed by initially mixing and centrifuging all 
components of the kit and placing on ice. Prior RT reaction, RNA samples were placed on 
ice. To reduce risk of RNA contamination, all working environment was sterilised using 
RNaseZap® RNase decontamination solution and tubes and pipettes irradiated in a UV hood 
for 20 minutes prior to use. The following reagents were added into a sterile PCR grade 
eppendorf and maintained on ice: Template RNA poly(A) mRNA 1 μg 0.5-1 μg, primer oligo 
(dT) primer 1 μL, nuclease free water to make a total of 12 μL. RNA samples were then 
returned to be chilled on ice. Next, 4 μL of 5X reaction buffer, 1 μL of RiboLock RNase 
Inhibitor (20 u/μL), 2 μL of 10 mM dNTP Mix and 1 μL of RevertAid H Minus M-MuLV 
Reverse Transcriptase (200 u/μL) were added to the RNA mixture to give a total volume of 
20 μL. The mixture was incubated for 60 min at 42°C. The reaction was terminated by 
heating at 70°C for 5 minutes. To detect any DNA contamination, for each RNA sample a 
corresponding no-RT sample was also prepared which did not contain RT.  
 
 
Polymerase chain reaction (PCR) is the enzymatic amplification of specific DNA sequences. 
PCR involves multiple cycles of template denaturation, primer annealing, and primer 
elongation. During denaturation the two cDNA strands are cleaved, requiring a temperature 
of 94ºC to denature the DNA. In the annealing stage, the primers anneal with their specific 
target sequences on each of the single stranded DNA templates. Annealing temperatures 
dependent on the length and guanine/cytosine (G/C) ratio of the primer and can range 
between 53ºC and 65ºC.   
 
End-point PCR was performed using Promega GoTaq® DNA polymerase. For each 50 μL 
reaction, the reaction mixture was prepared as below (Table 2.3). Product with no cDNA 
templates were also used for detection contamination in samples. The baseline PCR 
amplification reactions were pre-incubated at 94°C for 2 minutes, followed by 34 cycles of 
denaturation at 94°C for 60 seconds, anneal at 55°C for 30 seconds and extension at 72°C for 
30 seconds. End-point PCR products were visualized on an ethidium bromide-stained agarose 
gel. 2g of agarose (Sigma Aldrich) was dissolved by heating in 100ml of 1X 
2.9.2 End-point Polymerase Chain Reaction 
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Tris/Borate/EDTA (TBE) buffer to produce a 2% gel. Ethidium bromide (10µL) was mixed 
into agarose solution and the agarose allowed setting for at least 1 hour at room temperature. 
The agarose gel was transferred to an electrophoresis tank containing TBE buffer and loaded 
with 10µl of DNA ladder (full range100 BP Norgen) and 25µL of PCR product containing 
X5 DNA loading buffer. Electrophoresis was performed for 30 minutes at 100V. DNA 
fragments were detected by UV light using the Gel Doc XR+ System and the Quantity one 
software. 
 
 
 
 
 
 
 
 
 
 
 
Table  2-6: The PCR settings for each 25μL reaction 
 
  
Component  Amount per reaction 
5X Green GoTaq® Reaction 
Buffer (1.5mM MgCl2) 
       10μL  
Forward primer (0.2μM)         1μL  
Reverse primer (0.2μM)         1μL  
dNTP mix (0.2mM)         1μL  
GoTaq® DNA Polymerase 
(5u/μl)  
       0.25μL  
Nuclease free water.         35.75μL  
template DNA         1μL 
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Quantitative reverse tanscription PCR (qRT-PCR) exponentially measures products produced 
during PCR cycles using TaqMan oligonucleotide probes. In principle, the sequence-specific 
TaqMan probe has a fluorescent probe also known as a Reporter bound to the 5' end, and a 
‘quencher’ molecule attached to the 3' end of the sequence. The probes hybridize to the target 
sequences in the amplicon during PCR amplification. The close proximity of the reporter and 
quencher molecules prevents detection of fluorescence by Fluorescence resonance energy 
transfer (FRET). Uncoupling of the reporter and quencher as a result of polymerase activity 
results in increases in fluorescence intensity that correlates to the number of the probe 
cleavage cycles. 
Human TaqMan® assays were used to determine GAPDH expression. A 7µl reaction mix 
was prepared per sample by mixing 5µl of TaqMan® gene expression mastermix, 0.5µl 
TaqMan® GAPDH assay and 1.5µl nuclease-free water. To this reaction, 3µl of cDNA 
template was added and loaded into a 384 well PCR plate. As a negative control for PCR 
reaction mix contamination, reaction mix was loaded with 3µl of nuclease-free water instead 
of cDNA. Optical adhesive covers plates were used to seal PCR plates and PCR performed 
using the Applied Biosystems 7900HT Real-Time PCR system. Data were analysed using the 
SDS 2.2.1 software and the measured cycle threshold (CT) values were representative of the 
number of cycles at which each specific reaction crossed a selected threshold. The baseline of 
a PCR reaction was set to remove any background fluorescence. High CT values correlated 
with less cDNA template and an increased number of amplification cycles to reach the 
fluorescence intensity threshold.  
 
  
2.9.3 Real Time quantitative Reverse Transcription-PCR (qRT-PCR) 
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As each candidate gene was known to have a different transcript variant, the Ensemble 
genome browser software (http://www.ensembl.org) was used to identify all of the existing 
variants. The Cluster omega software (http://www.ebi.ac.uk/Tools/msa/clustalo/) was further 
used to identify specific sequential regions of an exon shared by all of the transcript variants. 
The sequences which spanned the exons were preferential for primer design and the Primer 3 
software (http://primer3.ut.ee/) was used to design primers. In-Silico PCR 
(http://genome.ucsc.edu/cgi-bin/hgPcr?command=start) was used to determine whether the 
designed primers were able to polymerase the specific regions of the cDNA. Primers were 
designed for determining the expression of candidate genes: ESR1, TNFRSR11B, LRP5, VDR 
and P2RX7, with the common part of the transcribed variant of each candidate genes. The 
lyophilised primers were dissolved in DEPC-treated water when was arrived to the lab to 
reach a concentration of 10µM suitable for working (Table 2.7). 
 
 
 
 
 
 
 
 
 
 
 
  
2.9.4 Primer design 
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Candidate 
Gene/SNP 
(Rs) 
Sequence ( 5’ -> 3’) Melting 
Temperature  
°C 
RANK   
F1 ATCCCCTGGGTGGTTTTATC 59.88    
R1 CCAGTGATCCACAGTCATGC 60.12 
P2RX7   
F1 GCAGCTGCAGTGATGTTTTC 58.31 
R1 CTGCTATCCCCTTCACCTTG 57.66 
LRP5   
F1 CCTGGATTTGAACTCGGACT 59.14 
R1 TTACAGGGGCACAGAGAAGC 60.40 
VDR   
F1 GCCCACCATAAGACCTACGA 59.96 
R1 AGATTGGAGAAGCTGGACGA 59.95 
ESR1   
F1 ATGATCAACTGGGCGAAGAG 60.22 
R1 GATCTCCACCATGCCCTCTA 60.03 
OPG   
F1 GGGGACCACAATGAACAACT 59.68 
R1 ACACGGTCTTCCACTTTGCT 59.77 
 
Table  2-7: The sequences and the melting temperature for the forward and 
reverse primers specific to ESR1, TNFRSR11B, LRP5, VDR and P2RX7 
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2.10 Sequenom 
 
Allele specific expression analysis was performed by MassARRAY 
TM
 platform by 
Wellcome Trust Centre for Human Genetics service of the Oxford University. The procedure 
for investigating allele-specific expression was similar to that used when performing gene 
screens/disease-association SNP, with pooled DNA populations (Herbon, Werner et al. 2003; 
Tang, Oeth et al. 2004), with the exception that cDNA was used as a template for PCR as 
opposed to genomic DNA. In fact the ratio of alleles from one group is compared to another 
to define if any statistically significant difference in allele frequency exists between them. 
The cDNA of interest was amplified by PCR. MassARRAY Typer version 3.1 software was 
used for the MassARRAYsystem to achieve quantitative processing for Allele-Specific 
Expression Analysis. 
2.11 Statistical analysis 
 
Graph Pad Prism 6 was used to analyse data. For sample sizes below 50 data was inspected 
for being consistent with normality and non-parametric statistical hypothesis tests were used 
if this was not a fair assumption.   For comparing the means of two groups, a student’s t-test 
was used. For small samples (below 50) where data were suspected of being non-normal and 
the student’s t-test resulted in a p-value below 0.05 the Mann Whitney  test was then used to 
check that a significant difference remained. If the result then become non-significant this 
suggested that the conclusions are sensitive to the normality assumption and the evidence is 
weakened but here, in subsequent chapters when the student’s t-test resulted in a p-value 
below 0.05 in non-parametric data, the Mann Whitney test was also in a p-value below 0.05 . 
For comparing more than two groups, One- way ANOVA was used. For analysing 
correlation between two continues variables where at least one was not consistent with the 
normal distribution, Pearson correlation coefficient was computed. For checking association 
between SNPs and BMD linear regression analysis by using IBM® SPSS® statistics was 
performed. Genotype specific effects on BMD was analysed by univariate analysis of 
variance. Dr Santibanez-Koref kindly adapted his specific software to analyse data of AEI 
study which is named as MSK-test in this thesis. This software enables to do the analysis 
(compare the mean allelic expression ratio in the two phases) when haplotypes are unknown. 
Outliers in the data were removed using the Grubb’s outlier test 
(http://graphpad.com/quickcalcs/Grubbs1.cfm). 
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Chapter 3 –  Genetic SNP association with Bone Mineral 
Density in an Iranian population  
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3.1 Hypothesis and Objectives 
 
There are associations between specific transcribed and risk SNPs and bone mineral density 
(BMD) within the Iranian population.  
To test this hypothesis the following objectives were determined: 
 
 Determine the BMD of a random selection of subjects from an Iranian population. 
 
 Evaluate the genetic associations between the selected SNPs and BMD. 
 
  Determine whether the genetic associations observed in this Iranian population study 
are consistent with results from other populations.  
3.1.1 Hypothesis 
3.1.2 Specific objectives 
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3.2 Introduction 
 
Having recently identified 62 genome-wide-significant loci, the genome-wide association 
studies have now provided clearer insights into the allelic architecture osteoporosis (Richards, 
Zheng et al. 2012). However, genetic factors linked to BMD are also dependent on sex and 
age (Karasik and Ferrari 2008). There are limited studies investigating the effect of genetic 
factors on bone mineral density (BMD) in the Iranian population. The articles which have 
studied the association between genetic factor and BMD in the Iranian population were 
searched using PubMed software using the systematic article review, as performed earlier in 
the thesis as outlined in the method section 2.2.1. The search terms were as follows: 
1) Genetic association study 
2) Iranian 
3) bone mineral density 
 
Results of the systemic article review process on NOV 2012 showed in first step five article. 
Of these, after deleting unrelated articles there were only three that studied the genetic 
associations of osteoporosis and BMD in the Iranian population (Golbahar, Hamidi et al. 
2004; Hossein-nezhad, Varzaneh et al. 2011; Pouresmaeili, Jamshidi et al. 2013). In order to 
determine whether the genetic factors involved in the pathogenesis of osteoporosis and 
alterations in BMD within the Iranian population are comparable to that of western 
populations, genetic studies of the Iranian population must first be performed.  
The approaches to identify and characterise genes involved in the pathogenesis of 
osteoporosis usually involve establishing links between phenotypic characteristics and 
polymorphic genetic markers in the same way as candidate gene association studies (Stewart 
and Ralston 2000). The phenotypic characteristic could be a continuous variable such as 
BMD and the genetic marker could be such as single nucleotide polymorphisms (SNPs).  
This chapter consider, the polymorphic variants occurring within seven candidate genes; 
ESR, LRP5, RANK, RANKL, OPG, P2RX2 and VDR known to be associated with BMD, 
which is measured using dual energy X-ray absorptiometry as outlined in the method section 
2.1.2. The selection of these genes and SNPs selection was performed using the systematic 
review processes outlined in section 2.2.1 and transcribed SNPs selection outlined in the 
method section 2.2.2. Phenotypic and genetic analysis of the Iranian population sample was 
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performed using bone densitometry, blood sampling, and genotyping. Per allele and per 
genotype specific analysis have been used to evaluate association between the candidate 
SNPs (risk and transcribed) and the BMD of our population.  
The IMOS-AD study population consisted of a total of 501 healthy men and women subjects 
aged between 20 and 75 years of age recruited from the south of Iran. This sample size 
allowed the statistical evaluation of any genetic association between BMD and these 
candidates in the Iranian sample. Assuming 0.5 significant level, 500 samples would provide 
%80 power to detect theory difference in the mean ratio of 0.25 of standard deviation. The 
main aim of this chapter was to describe the features of the Iranian population and determine 
whether the genetic associations observed with BMD within this Iranian population study 
were comparable with other populations (figure 3.1). BMD was selected in preference to 
fractures in this study because there were not a clear past history in sample population to 
distinguish osteoporotic fracture from other types of bone fractures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-1: Flow chart to illustrate the processes involved in assessing gene 
associations with BMD 
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3.3 Results 
 
Descriptive statistics and sample quality control of 501 randomly selected Iranians were 
determined in the first part of this study. Each subject was supplied with a questionnaire from 
which descriptive analysis factors for this study including age, height, weight and BMI were 
determined. Data were collected from each subject as specified in the method section 2.1 and 
split into male and female. The data were analysed separately by gender as BMI is known to 
be compatibly higher in females than in males in the Iranian population (Bahrami, 
Sadatsafavi et al. 2006). Statistical differences between genders were formally compared 
using a student t-test.  
Statistical analysis showed that there were no significant differences in age between the male 
and female subjects of our sample group (Figure 3.2 A). Data showed that the male subjects 
within our sample population had significantly higher weight and height metrics compared to 
the female subjects (***P<0.001, Figure 3.2 B, C). The calculated BMI was higher for 
females than for the male subjects within the selected Iranian population sample 
(***P<0.001, Figure 3.2 D). 
 
 
 
 
 
 
 
 
  
3.3.1 The BMI of the males and females within a random selection of subjects 
from an Iranian population 
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Figure  3-2: Physical characteristics of both male and female study subjects 
The age, height, weight and BMI of female and males were determined. (A) There were no 
gender differences in age.  (B, C,) The weight and height of the males within the subject 
population were higher than that of the female subjects. (D) The male subjects had lower 
BMI values compared to female subjects. N=501, Student’s unpaired t-test. ***P<0.001. 
 ( box-and-whisker plot: the marked line shows the median, and the bottom and top of the box show 
the lower and upper quartiles.) 
Statistical evaluation of the demographic characteristics of female and male 
subjects 
Variable Total Female Male  
 Mean±SD Mean±SD Mean±SD p-value 
AGE 
 
47.48±16 46.7±15.7 48.3±16.3 0.19 
HEIGHT 
 
161.2±9.6 154.5±5.8 168.4±7.4 <.001 
WEIGHT 
 
64.5±11.8 62.2±11.8 66.9±11.4 <.001 
BMI 
 
24.8±4.4 26.05±4.6 23.6±3.67 <.001 
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Statistical evaluation of the demographic characteristics of female and male 
subjects 
Variable Total Female Male  
 Mean±SD Mean±SD Mean±SD p-value 
AGE 
 
47.48±16 46.7±15.7 48.3±16.3 0.19 
HEIGHT 
 
161.2±9.6 154.5±5.8 168.4±7.4 <.001 
WEIGHT 
 
64.5±11.8 62.2±11.8 66.9±11.4 <.001 
BMI 
 
24.8±4.4 26.05±4.6 23.6±3.67 <.001 
 
E 
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The L2-L4 (L2-L4_BMD), neck of femur (Neck_BMD), femur trochanter (Troch_BMD) and 
total hip BMD (Total_BMD) of IMOS-AD sample consisting of 501 individuals was assessed 
using the bone Scanner according to the method section 2.1.2. Data from the whole sample 
population were separated into male and female groups to determine any gender associations 
with BMD and any statistical relationships determined using a student’s t-test.  
Analysis of the Iranian sample population showed that the male subjects had significantly 
higher BMD means associated with L2-L4_BMD, neck_BMD, troch_BMD and total_BMD 
compared to that of the female population (***P<0.001, Figure 3.3, A-D). The data 
consisting of the BMD values of all participants were also summarised in Figure 3.3 E.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 The BMD of IMOS-AD subjects  
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BMD of  participants 
Variable Total Female Male  
 Mean±SD Mean±SD Mean±SD p-value 
L2_L4_BMD 1.031±0.17 1±0.17 1.06±0.15 <.001 
NECK_BMD 0.870±0.15 0.827±0.14 0.918±0.14 <.001 
TROCH_BMD 0.741±0.14 0.689±0.13 0.798±0.13 <.001 
TOTAL HIP_BMD 0.906±0.15 0.864±0.15 0.952±0.13 <.001 
 
Figure  3-3: The total hip BMD was higher in male subjects 
The L2-L4, Neck, Troch and total hip BMD of female and males were determined. (A, B, C, 
D) There were gender differences in L2-L4, troch, neck, and total hip BMD (E) the female 
subjects had lower BMD values compared to male subjects. N=501, Student’s unpaired t-test. 
**P<0.01,****P<0.001. ( box-and-whisker plot: the marked line shows the median, and the 
bottom and top of the box show the lower and upper quartiles.) 
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To determine any correlations between BMD and BMI factors which included age, height and 
weight, statistical analysis was performed using a Pearson’s correlation coefficient test. BMD 
and BMI data collected from sections 3.3.1 and 3.3.2 were exported into the Graphpad 
software and analysed for statistical correlations. 
There were statistically significantly negative correlations between age with L2-L4_BMD, 
age with neck BMD, and age with total hip BMD. In addition analysis showed that there were 
positive correlations between both height and weight with L2-L4 BMD, neck BMD, and total 
hip BMD (Figure 3.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.3 Correlation between BMD and BMI of a random selection of subjects from 
an Iranian population  
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Statistical analysis of the correlations between BMD and age, height and weight 
within the Iranian population study subjects 
Variable  L2_L4 
BMD 
NECK 
BMD 
TOTAL HIP 
BMD 
AGE *Correlation  Coefficient 
P-value 
-0.455 
 
< 0.0001 
 
-0.388 
 
< 0.0001 
-0.492 
 
< 0.0001 
HEIGHT *Correlation Coefficient 
 P-value 
0.332 
 
< 0.0001 
0.464 
 
< 0.0001 
0.161 
 
< 0.0001 
WEIGHT *Correlation Coefficient  
 P-value 
0.085 
 
< 0.0001 
0.187 
 
< 0.0001 
0.185 
 
< 0.0001 
 
Figure  3-4: Correlations were determined between the BMD and age, height 
and weight of the study subjects 
 (A, B, C) There were negative correlations between age and L2-L4 BMD, neck BMD, and 
total hip BMD.  (D, E, F) There were positive correlations between height and L2-L4 BMD, 
neck BMD, and total hip BMD. (G, H, I) There were positive correlations between weight 
and L2-L4 BMD, neck BMD, and total hip BMD.  (J) There were statistically significantly 
negative correlations between age and L2-L4 BMD, neck BMD, and total hip BMD. The 
correlations of both height and weight with L2-L4 BMD, neck BMD, and total hip BMD were 
significantly positive as would be expected. *Pearson's r   
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G 
H 
 
H 
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I 
J 
 
J 
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 LRP5, RANK, RANKL, ESR1, VDR, P2XR7 and OPG were selected as genes according to 
the method outlined in the method section 2.2.1.  In this section the risk SNPs associated 
with BMD were determined using the catalogue of GWAS, as outlined in the method section 
2.2.1. The transcribed SNPs with highest heterozygosity for the LRP5, RANK, RANKL, 
P2RX7, ESR1, OPG and VDR genes were determined using NCBI reference assembly as 
outlined in the method section 2.2.2. Data of genotyping, were performed for each SNP as 
outlined in section 2.4., were first qualified as outlined in section 2.4 and then except data of 
ten samples and two SNPs which were excluded, other data were used for genotyping 
specific analysis and per allele specific analysis.  
 
3.3.4.1 Analysis of genotyping data of ESR candidate gene and BMD in the IMOS-AD 
study  
 
Within the ESR gene, a total of 7 SNPs was identified for this study: Rs2077647, Rs2504063, 
Rs1999805, Rs4870044, Rs1038304, Rs2941740 and Rs6929137. Genotyping specific 
analysis determined an existing association between Rs2077647 and total hip BMD (P-
value<0.000, Table 3.1). Analysis of per allele specific analysis data also showed a 
significant association between Rs2077647 and L2-L4 BMD (P-value<0.036, Table 3.1). No 
other associations were statistically significant between any of the BMD factors and 
Rs2504063, Rs1999805, Rs4870044, Rs1038304, Rs2941740 and Rs6929137 SNPs. 
 
 
 
 
 
 
 
 
3.3.4 Analysis of genotyping data of seven selected candidate genes and BMD 
in the Iranian subjects 
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ESR1 
 
SNPs/genotyping L2-L4 BMD 
Coefficient (CI) 
NECK BMD 
Coefficient (CI) 
Total Hip BMD 
Coefficient (CI) 
Rs 2504063 
Baseline genotyping: GG 
Risk Allele: A 
Risk allele frequency: 45.62% 
AG/GG .014(-.019_.046) 0.013(-0.013-0.04) .014(-.011_.040) 
AA/GG .004(-.035_.042) -0.04(-0.03-0.03) -.014(-.044_.017) 
P-value .67 0.403 .128 
Per risk allele 
effect 
.003(-.017_.022) -0.001(-0.02-0.014) -.006(-.021_.010) 
P-value .795 0.86 .465 
Rs 1999805 
Baseline genotyping: GG 
Risk Allele: A 
Risk allele frequency:46.61% 
AG/GG -.001(-.033_.031) .004(-.021_.029) .010(-.015_.035) 
AA/GG -.010(-.047_.028) -.004(-.033_.025) .008(-.022_.037) 
P-value .860 .851 .722 
Per risk allele 
effect -.005(-.023_.014) 
-.002(-.016_.013) .004(-.010_.019) 
P-vaue .628 .819 .567 
Rs 4870044 
Baseline genotyping:C:C 
Risk Allele:T 
Risk allele frequency:32.26% 
T:C/C:C .002(-.028_.031) .003(-.020_.026) .000(-.023_.023) 
T:T/C:C -.004(-.049_.041) .000(-.035_.036) -.001(-.036_.035) 
P-value .970 .967 .999 
Per risk allele 
effect 
-.001(-.020_.021) .001(-.015_.017) -.000(-.016_.016) 
P-vaue .935 .897 .967 
Rs 1038304 
Baseline genotyping:A:A 
Risk Allele:G        
Risk allele frequency: 57.95% 
G:A/A:A .023(-.016_.063) .016(-.016_.047) .028(-.004_.060) 
G:G/A:A .033(-.009_.075) .025(-.008_.059) .035(.001_.069) 
P-value .309 .327 .118 
Per risk allele 
effect 
.015(-.005_.036) .012(-.004_.028) .016(-.001_.032) 
P-vaue .144 .141 .062 
Rs 2941740 
Baseline genotyping:A:A 
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Risk Allele:G 
Risk allele frequency: 26.31% 
G:A/A:A .014(-.016_.044) .006(-.018_.030) .015(-.009_.038) 
G:G/A:A .027(-.021_.075) .002(-.036_.039) .003(-.035_.041) 
P-value .445 .881 .476 
Per risk allele 
effect 
.013(-.007_.034) .003(-.014_.019) .006(-.010_.023) 
P-vaue .203 .747 .448 
Rs 6929137 
Baseline genotyping:G:G 
Risk Allele:A 
Risk allele frequency: 38.4% 
A:G/G:G .028(-.002_.058) .019(-.005_.043) .027(.003_.051) 
A:A/G:G .035(-.008_.079) .008(-.026_.042) .022(-.013_.056) 
P-value .122 .282 .079 
Per risk allele 
effect 
.020(-.000_.041) .007(-.009_.024) .015(-.002_.031) 
P-vaue .054 .363 .077 
Rs 2077647 
Baseline genotyping:T:T 
Risk Allele:C 
Risk allele frequency:48.67% 
C:T/T:T .018(-.015_.051) .013(-.012_.039) .027(.001_.053) 
C:C/T:T .041(.003_.079) .017(-.013_.047) .024(-.006_.054) 
P-value .109 .478 .000 
Per risk allele 
effect 
.020 (.001_.039) .009 (-.006_.023) .012 (-.003_.027) 
P-value .036 .258 .108 
 
Table  3-1: SNP genotyping for the ESR1 gene 
Genotype specific analysis and per allele specific analysis were performed for each SNP, 
adjusting for age and sex. Genotype specific analysis showed that Rs2077647 is associated 
with total hip BMD, P-value=0.000. Per allele specific analysis shows an association 
between risk allele of Rs2077647 and L2-L4 BMD. N=501, linear regression. 
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3.3.4.2 Analysis of genotyping data of OPG candidate gene and BMD in the IMOS-AD 
study 
 
For the OPG gene, a total of 7 SNPs were identified for this study; Rs2073618, Rs1804854, 
Rs6469804, Rs2062375, Rs4355801, Rs2062377, and Rs11995824. Genotyping specific 
analysis showed a significant association between Rs4355801 and L2-L4 BMD (P-
value<0.010, Table 3.2). Per allele specific analysis also showed an association between 
Rs4355801 and L2-L4 BMD (P-value<0.029, Table 3.2). 
 
Both genotype specific analysis and per allele specific analysis also showed an association 
between Rs11995824 and L2-L4 BMD (P-value<0.032 and P-value<0.044, Table 3.2). 
Additionally data produced from per allele specific analysis showed an association between 
Rs2073618 and L2-L4 BMD (P-value<0.022, Table 3.2). Using genotype specific analysis 
and per allele specific analysis, no other associations were determined between any of the 
BMD factors and Rs1804854, Rs6469804, Rs2062375, Rs4355801 and Rs2062377 SNPs.  
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OPG 
 
SNPs/genotyping L2-L4 BMD 
Coefficient (CI) 
NECK BMD 
Coefficient (CI) 
Total hip BMD 
Coefficient (CI) 
Rs: 6469804 
Baseline genotyping:G:G 
Risk Allele:A 
Risk allele frequency:69.87% 
G:A/G:G -.064(-.110_-.018) -.040(-.076_-.003) -.038(-.075_-.001) 
A:A/G:G -.066(-.112_-.021) -.036(-.072_.000) -.038(-.074_-.002) 
P-value .013 .099 .099 
Per risk allele 
effect 
-.023(.043_-.003) -.011(-.027_.005) -.012(.029_.004) 
P-vaue .026 .195 .129 
Rs: 4355801 
Baseline genotyping:G:G 
Risk Allele:A 
Risk allele frequency:70.99% 
G:A/G:G -.071(-.120_-.022) -.018(-.057_.021) -.026(-.065_.013) 
A:A/G:G -.073(-.121_-.025) -.024(-.063_.014) -.033(-.072_.005) 
P-value .010 .450 .233 
Per risk allele 
effect 
-.023 (-.044_-.002) -.010 (-.026_.007) -.013 (-.029_.003) 
P-vaue .029 .240 .119 
Rs: 2062375 
Baseline genotyping:C:C 
Risk Allele:G 
Risk allele frequency:33.62% 
G:C/C:C .009(-.021_.039) .001(-.023_.025) .000(-.024_.023) 
G:G/C:C .027(-.017_.070) .009(-.025_.044) .007(-.027_.041) 
P-value .473 .857 .908 
Per risk allele 
effect 
.012(.008_.032) .004(-.012-.020) .002(-.013_.018) 
P-vaue .235 .638 .761 
Rs: 2062377 
Baseline genotyping:A:A 
Risk Allele:T 
Risk allele frequency:28.68% 
A:T/A:A .006(-.023_.035) -.004(-.027_.018) -.001(-.024_.022) 
T:T/A:A .046(-.002_.094) .026(-.012_.064) .030(-.009_.068) 
P-value .172 .308 .274 
Per risk allele 
effect 
.017(-.004_.037) .006(-.010_.023) .009(-.008_.025) 
P-vaue .118 .452 .301 
Rs :11995824 
Baseline genotyping:C:C 
Risk Allele:G 
Risk allele frequency:46.62% 
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Table  3-2: SNP genotyping for the OPG gene 
 Genotype specific analysis and per allele specific analysis were performed for each SNP, 
adjusting for age and sex. Both genotype specific analysis and per allele specific analysis 
show Rs4355801is associated with L2-L4 BMD P-value=0.010, P-value=.029. There is also 
an association between Rs11995824 and L2-L4 BMD, P-value=.032 and P-value= .044. 
There is evidence of per allele specific analysis to show an association between Rs2073618 
and L2-L4 BMD, P-value=.022.  N=501, linear regression.  
 
 
 
 
 
 
 
 
 
 
 
G:C/C:C -.058(-.105_-.010) -.042(-.079_-.004) -.042(-.080_-.005) 
G:G/C:C -.061(-.107_-.014) -.037(-.074_.000) -.041(-.078_-.004) 
P-value .032 .086 .071 
Per risk allele 
effect 
-.021 (-.042_-.001) -.011 (-.027_.006) -.013 (-.029_.005) 
P-vaue .044 .199 .125 
Rs: 2073618 
Baseline genotyping:C:C 
Risk Allele:G 
Risk allele frequency:35.83% 
C:G/C:C .003(-.027_.032) .004(-.019_.028) .000(-.023_.023) 
G:G/C:C .057(.016_.098) .031(-.002_.063) .032(-.001_.064) 
P-value .016 .165 .122 
Per risk allele 
effect 
.023 (.003_.042) .013 (-.002_.028) .012 (-.003_.027) 
P-vaue .022 .099 .120 
Rs: 1804854 
Baseline genotyping:A:A 
Risk Allele:G 
Risk allele frequency:16.23% 
G:A/A:A .043(-.070_.157) .009(-.081_.099) .013(-.078_.104) 
P-value .452 .844 .776 
Per risk allele 
effect 
.043(-.070_.157) .009(-.081_.099) .013(-.078_.104) 
P-vaue .452 .844 .776 
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3.3.4.3 Analysis of genotyping data of LRP5 candidate gene and BMD in the Iranian 
population  
 
For the LRP5 gene, a total of 5 SNPs was identified for this study: Rs545382, Rs2306862, 
Rs556442, Rs599083, and Rs3736228. Per allele specific analysis just showed an association 
between Rs2306862 and L2-L4 BMD (P-value<0.042, Table 3.3). No other associations 
were determined between any of the BMD factors and Rs545382, Rs556442, Rs599083, and 
Rs3736228 SNPs. 
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LRP5 
 
SNPs/genotyping L2-L4 BMD 
Coefficient (CI) 
NECK BMD 
Coefficient (CI) 
Total Hip BMD 
Coefficient (CI) 
Rs: 599083 
Baseline genotyping:T:T 
Risk Allele:G 
Risk allele frequency:32% 
G:T/T:T -.012(-.042_.018) .003(-.020_.027) .003(-.021_.026) 
G:G/T:T -.027(-.066_.013) .001(-.030_.033) .005(-.026_.037) 
P-value .400 .961 .943 
Per risk allele 
effect 
-.013(-.032_.006) .001(-.014_.016) .003(-.012_.018) 
P-vaue .177 .868 .732 
Rs: 3736228 
Baseline genotyping:C:C 
Risk Allele:T 
Risk allele frequency:11% 
T:C/C:C -.024(-.058_.010) .016(-.011_.043) -.046(-.153_.061) 
T:T/C:C -.066(-.199_.068) -.049(-.155_.057) .023(-.004_.050) 
P-value .258 .311 .167 
Per risk allele 
effect 
-.026(-.057_.005) .008(-.016_.033) .014(-.011_.039) 
P-vaue .103 .503 .269 
Rs: 545382 
Baseline genotyping:T:T 
Risk Allele:C 
Risk allele frequency:59.92% 
T:C/C:C -.030(-.137_.078) -.077(-.162_.007) -.074(-.159_.010) 
T:T/C:C -.027(-.132_.078) -.074(-.156_.008) -.066(-.149_.016) 
P-value .864 .193 .222 
Per risk allele 
effect 
-.002(-.030_.027) -.007(-.030_.015) -.003(-.025_.020) 
P-vaue .914 .523 .810 
Rs:2306862 
Baseline genotyping:C:C 
Risk Allele:T 
Risk allele frequency:54.92% 
T:C/C:C -.025(-.060_.010) .004(-.024_.032) .009(-.019_.037) 
C:C/C:C -.086(-.186_.014) -.021(-.100_.059) -.031(-.111_.049) 
P-value .107 .830 .587 
Per risk allele 
effect 
-.031(-.060_-.001) -.001(-.024_.023) .001(-.022_.025) 
P-vaue .042 .966 .902 
Rs: 556442 
Baseline genotyping:G:G 
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Risk Allele:A 
Risk allele frequency:11.93% 
A:G/G:G .007(-.032_.047) -.002(-.033_.029) -.009(-.040_.022) 
A:A/G:G .023(-.017_.064) -.007(-.038_.024) -.013(-.044_.019) 
P-value .428 .873 .727 
Per risk allele 
effect 
.013(-.007_.032) -.004(-.019_.011) -.006(-.021_.009) 
P-value .204 .618 .446 
 
Table  3-3: SNP genotyping for the LRP5 gene 
Genotype specific analysis and per allele specific analysis were performed for each SNP, 
adjusting for age and sex. Genotyping analysis showed that for the LRP5gene the risk 
SNP2306862 (highlighted in red) was associated with L2-L4 BMD. N=501, linear 
regression.  
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3.3.4.4 Analysis of genotyping data of RANKL candidate gene and BMD in the IMOS-
AD study  
 
For the RANKL gene, a total of 4 SNPs was identified for this study: Rs9562415, 
Rs9594738, Rs9594759, and Rs1021188. Per allele specific analysis as an allele specific 
analysis showed a significant association between Rs9594738 and L2-L4 BMD (P-
value<0.019, Table 3.4). Per allele specific analysis also showed an association between 
Rs9594759 and L2-L4 BMD (P-value<0.032, Table 3.4), no other associations were 
determined between any of the BMD factors and Rs9562415 and Rs1021188 SNPs.   
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RANKL 
 
SNPs/genotyping L2-L4 BMD 
Coefficient (CI) 
NECK BMD 
Coefficient (CI) 
Total Hip BMD 
Coefficient (CI) 
Rs : 9594738 
Baseline genotyping: C:C 
Risk Allele: T        Risk allele frequency:25.37% 
T:C/C:C .029(.000_.058) -.003(-.026_.020) -.006(-.029_.017) 
T:T/C:C .046(-.006_.097) .039(-.001_.079) .044(.004_.085) 
P-value .061 .133 .063 
Per risk allele 
effect 
.025 (.004_.047) .010 (-.007_.027) .010 (-.006_.027) 
P-vaue .019 .236 .225 
Rs : 9594759 
Baseline genotyping: C:C 
Risk Allele: T        Risk allele frequency:39.71 
T:C/C:C .017(-.014_.048) .006(-.018_.031) -.001(-.025_.024) 
T:T/C:C .042(.004_.079) .012(-.017_.042) .008(-.022_.038) 
P-value .097 .704 .187 
Per risk allele 
effect 
.020(.002_.039) .006(-.008_.021) .003(-.011_.018) 
P-vaue .032 .402 .645 
Rs : 1021188 
Baseline genotyping: T:T 
Risk Allele: C          Risk allele frequency:14.05% 
T:C/T:T -.020(-.052_.013) -.001(-.027_.025) -.010(-.036_.016) 
C:C/T:T -.038(-.125_.049) -.068(-.137_.001) -.070(-.140_-.001) 
P-value .982 .154 .120 
Per risk allele 
effect 
-.019(-.046_.008) -.012(-.034_.009) -.018(-.040_.003) 
P-vaue .161 .261 .095 
Rs :9562415 
Baseline genotyping: T:T 
Risk Allele:C         Risk allele frequency:2% 
T:C/T:T -.009(-.122_.104) .000(-.088_.089) -.010(-.100_.080) 
C:C/T:T -.217(-.515_.081) -.129(-.363_.106) -.189(-.426_.048) 
P-value .357 .559 .286 
Per risk allele 
effect 
-.045(-.135_.045) -.023(-.094_.048) -.041(-.113_.031) 
P-vaue .325 .521 .264 
Table  3-4: SNP genotyping for the RANKL gene 
Genotype specific analysis and per allele specific analysis were performed for each SNP, 
adjusting for age and sex.  Genotyping analysis showed that for the RANKL gene the risk 
SNP 9594736 and Rs9594759 (highlighted in red) are associated with L2-L4 BMD. N=501, 
linear regression. 
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3.3.4.5 Analysis of genotyping data of RANK candidate gene and BMD in the IMOS-
AD study 
 
For the RANK gene, a total of 4 SNPs was identified for this study: Rs1805034, 
Rs35211496, Rs884205, and Rs3018362. Both genotype specific analysis and per allele 
specific analysis showed an association between Rs884205 and total hip BMD (P-
value<0.042, Table 3.5). No other associations were determined between any of the BMD 
factors and Rs1805034, Rs35211496, and Rs3018362 SNPs.   
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RANK 
SNPs/genotyping L2-L4 BMD 
Coefficient (CI) 
NECK BMD 
Coefficient (CI) 
Total Hip BMD 
Coefficient (CI) 
Rs : 884205 
Baseline genotyping: C:C 
Risk Allele: A          Risk allele frequency:42.62% 
A:C/C:C -.020(-.049_.010) -.009(-.032_.015) -.015(-.038_.009) 
A:A/C:C .019(-.057_.096) -.060(-.121_.000) -.061(-.122_.000) 
P-value .342 .129 .088 
Per risk allele 
effect 
-.009(-.034_.015) -.016(-.036_.003) -.020(-.040_-.001) 
P-vaue .464 .101 .042 
Rs : 3018362 
Baseline genotyping: G:G 
Risk Allele: A          Risk allele frequency:31.36% 
A:G/G:G -.013(-.042_.016) -.006(-.029_.016) -.003(-.026_.020) 
A:A/G:G .025(-.025_.076) .022(-.018_.061) .022(-.018_.062) 
P-value 1.216 .381 .476 
Per risk allele 
effect 
-.002(-.024_.019) -.004(-.021_.013) -.005(-.022_.012) 
P-vaue .846 .655 .555 
Rs:1805034 
Baseline genotyping:C:C 
Risk Allele: T           Risk allele frequency:33.11% 
T:C/C:C .010(-.019_.040) -.016(-.039_.007) -.007(-.030_.016) 
T:T/C:C .026(-.021_.072) .002(-.034_.039) .003(-.034_.040) 
P-value .523 .319 .786 
Per risk allele 
effect 
.012(-.009_.033) -.005(-.021_.012) -.001(-.018_.015) 
P-vaue .259 .582 .888 
Rs : 35211496 
Baseline genotyping: C:C 
Risk Allele: T           Risk allele frequency:9.27% 
T:C/C:C -.014(-.050_.021) -.031(-.059_-.004) -.031(-.059_-.002) 
T:T/C:C -.006(-.178_.167) .020(-.114_.153) .032(-.103_.168) 
P-value .731 .079 .089 
Per risk allele 
effect 
-.013(.046_-.021) -.026(-.052_-.000) -.024(-.050_.002) 
P-vaue .452 .052 .073 
 
Table  3-5: SNP genotyping for the RANK gene 
Genotype specific analysis and per allele specific analysis were performed for each SNP, 
adjusting for age and sex. Genotyping analysis showed that for the RANK gene the risk SNP 
884205 (highlighted in red) is associated with total hip BMD. N=501, linear regression. 
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3.3.4.6 Analysis of genotyping data of P2RX7 candidate gene and BMD in the Iranian 
population  
 
For the P2RX7 gene a total of 8 SNPs was identified for this study: Rs28360457, Rs2230911, 
Rs2230912, Rs208294, Rs7958311, Rs1718119, Rs1621388, and Rs3751143. Per allele 
specific analysis as an allele specific analysis showed a significant association between 
Rs3751143 and NECK BMD (P-value<0.024, Table 3.6). Both genotype specific analysis 
and per allele specific analysis showed an association between Rs3751143 and total hip BMD 
(P-value<0.020 and P-value<0.045, Table 3.6), no other associations were determined 
between any of the BMD factors and Rs28360457, Rs2230911, Rs2230912, Rs208294, 
Rs7958311, Rs1718119, and Rs1621388 SNPs.  
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P2RX7 
 
SNPs/genotyping L2-L4 BMD 
Coefficient (CI) 
NECK BMD 
Coefficient (CI) 
Total Hip BMD 
Coefficient (CI) 
Rs: 3751143 
Baseline genotyping: T:T 
Risk Allele: G         Risk allele frequency:23.74% 
T:G/G:G -.023(-.053_.006) -.026(-.049_-.003) -.023(-.046_.000) 
T:T/G:G -.037(-.093_.020) -.029(-.073_.014) -.027(-.071_.018) 
P-value .186 .060 .020 
Per risk allele 
effect 
-.021 (-.043_.002) -.020 (-.037_-.003) -.018 (-.035_.000) 
P-vaue .069 .024 .045 
Rs: 28360457 
Baseline genotyping: G:G 
Risk Allele: A         Risk allele frequency:5% 
A:G/G:G .088(-.209_.386) .078(-.156_.312) .073(-.164_.310) 
P-value .559 .511 .547 
Per risk allele 
effect 
.088(-.209_.386) .078(-.156_.312) .073(-.164_.310) 
P-vaue .559 .511 .547 
Rs: 2230911 
Baseline genotyping: G:G 
Risk Allele: C          Risk allele frequency:5.23% 
C:G/G:G .041(-.004_.087) .020(-.015_.056) .024(-.012_.060) 
C:C/G:G -.211(-.508_.085) .024(-.209_.258) .047(-.188_.282) 
P-value .074 .527 .400 
Per risk allele 
effect 
.029(-.015_.073) .020(-.015_.054) .024(-.011_.059) 
P-vaue .191 .261 .176 
Rs: 2230912 
Baseline genotyping: A:A 
Risk Allele: G          Risk allele frequency:14.88% 
A:G/A:A -.002(-.033_.030) .007(-.018_.032) .004(-.021_.029) 
G:G/A:A -.049(-.136_.037) -.012(-.081_.056) -.018(-.087_.052) 
P-value .534 .783 .830 
Per risk allele 
effect 
-.009(-.036_.017) .003(-.018_.024) -.000(-.022_.021) 
P-vaue .487 .797 .977 
Rs: 208294 
Baseline genotyping: G:G 
Risk Allele: A        Risk allele frequency:53.07% 
G:A/G:G .007(-.028_.041) .002(-.025_.028) .002(-.025_.029) 
A:A/G:G -.023(-.060_.015) -.017(-.046_.012) -.020(-.049_.010) 
P-value .200 .306 .209 
Per risk allele -.012(-.031_.007) -.009(-.024_.005) -.010(-.025_.004) 
112 | Chapter 3 
 
effect 
P-value .203 .219 .163 
Rs: 7958311 
Baseline genotyping: G:G 
Risk Allele: A        Risk allele frequency:21.83% 
G:A/G:G -.004(-.033_.024) .012(-.010_.034) .017(-.006_.039) 
A:A/G:G .037(-.032_.106) .035(-.019_.088) .028(-.027_.082) 
P-value .511 .308 .260 
Per risk allele 
effect 
.005(-.019_.028) .014(-.004_.033) .016(-.003_.034) 
P-value .695 .133 .102 
Rs: 1718119 
Baseline genotyping: C:C 
Risk Allele: T        Risk allele frequency:36.78% 
C:T/C:C -.001(-.030_.029) -.007(-.031_.017) -.012(-.036_.012) 
T:T/C:C .013(-.029_.055) -.006(-.040_.027) -.014(-.048_.020) 
P-value .804 .835 .540 
Per risk allele 
effect 
.005(-.015_.024) -.004(-.020_.012) -.008(-.024_.008) 
P-value .643 .618 .305 
Rs: 1621388 
Baseline genotyping: G:G 
Risk Allele: A       Risk allele frequency:37.86% 
G:A/G:G .004(-.027_.034) -.004(-.027_.020) -.009(-.033_.014) 
A:A/G:G .021(-.021_.063) .007(-.025_.040) -.001(-.034_.032) 
P-value .620 .789 .725 
Per risk allele 
effect 
.009(-.011_.029) .002(-.014_.017) -.003(-.018_.013) 
P-value .387 .803 .747 
 
Table  3-6: SNP genotyping for the P2RX7 gene 
Genotype specific analysis and per allele specific analysis were performed for each SNP, 
adjusting for age and sex. Genotyping analysis showed that for the P2RX7 gene the risk SNP 
Rs3751143 is associated with both neck and total hip BMD. N=501, linear regression. 
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3.3.4.7 Analysis of genotyping data of VDR candidate gene and BMD in the IMOS-AD 
study  
 
For the VDR gene two SNPs were identified for this study: Rs731236 (Taq1) and Rs2228570 
(Fok1). Per allele specific analysis as an allele specific analysis showed a significant 
association between Rs731236 and L2-L4 BMD (P-value<0.038, Table 3.7). Both genotype 
specific analysis and per allele specific analysis also showed an association between 
Rs731236 and NECK BMD (P-value<0.002 and P-value<0.001, Table 3.7). Both genotype 
specific analysis and per allele specific analysis also showed an association between 
Rs731236 and total hip BMD (P-value<0.000 and P-value<0.002, Table 3.7). No other 
associations were determined between any of the BMD factors and Rs2228570 SNP.  
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VDR 
 
SNPs/genotyping L2-L4 BMD 
Coefficient (CI) 
NECK BMD 
Coefficient (CI) 
Total Hip BMD 
Coefficient (CI) 
Rs :731236 
Baseline genotyping: T:T 
Risk Allele: C          Risk allele frequency:32.67% 
T:C/T:T .022(-.007_.050) .050 .050-.007 .050 .037(.015_.059) .037(.014_.060) 
C:C/T:T .045(-.003_.092) .044(.007_.081) .050(.012_.087) 
P-value .116 .002 .001 
Per risk allele 
effect 
.022 (.001_.043) .027(.011_.044) .029(.013_.046) 
P-vaue .038 .001 .000 
Rs 2228570 
Baseline genotyping: T:T 
Risk Allele: C          Risk allele frequency:73.44% 
T:C/T:T .017(-.038_.072) .013(-.030_.056) -.028(-.071_.015) 
C:C/T:T .031(-.023_.084) .022(-.020_.064) -.016(-.058_.027) 
P-value .430 .507 .362 
Per risk allele 
effect 
.014(-.007_.036) .010(-.007_.027) .001(-.016_.018) 
P-vaue .195 .248 .918 
 
Table  3-7: SNP genotyping for the VDR gene 
Genotype specific analysis and per allele specific analysis were performed for each SNP, 
adjusting for age and sex. Genotyping analysis showed that for the VDR gene, the risk SNP 
731236 (highlighted in red) is associated with L2-L4, neck, and total hip BMD. N=501, 
linear regression. 
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3.3.4.8 A summary of significant associations determined between BMD and selected 
SNPs in this study 
List of SNPs with significant P-value in genotype specific analysis and per allele  analysis  
 
  Genotype specific analysis P-value Per Allele analysis P-value 
SNPs L2-L4 NECK Total L2-L4 NECK 
 
Total 
VDR 
Rs:731236 .116 .002 .001 .038 .001 .000 
T:C/T:T .022(-.007_.050) .037(.015_.059) .037(.014_.060) .022 
(.001_.043) 
.027(.011_.044) .029(.013_.046) 
C:C/T:T .045(-.003_.092) .044(.007_.081) .050(.012_.087) 
P2RX7 
Rs:3751143 .186 .060 .020 .069 .024 .045 
T:G/G:G -.023(-.053_.006) -.026(-.049_-
.003) 
-.023(-
.046_.000) 
-.021 (-
.043_.002) 
-.020 (-.037_-
.003) 
-.018 (-
.035_.000) 
T:T/G:G -.037(-.093_.020) -.029(-
.073_.014) 
-.027(-
.071_.018) 
RANK 
Rs:884205 .342 .129 .088 .464 .101 .042 
A:C/C:C -.020(-.049_.010) -.009(-
.032_.015) 
-.015(-
.038_.009) 
-.009(-
.034_.015) 
-.016(-
.036_.003) 
-.020(-.040_-
.001) 
A:A/C:C .019(-.057_.096) -.060(-
.121_.000) 
-.061(-
.122_.000) 
RANKL 
Rs:9594738 .061 .133 .063 .019 .236 .225 
T:C/C:C .029(.000_.058) -.003(-
.026_.020) 
-.006(-
.029_.017) 
.025 
(.004_.047) 
.010 (-
.007_.027) 
.010 (-
.006_.027) 
T:T/C:C .046(-.006_.097) .039(-
.001_.079) 
.044(.004_.085) 
Rs:9594759 .097 .704 .187 .032 .402 .645 
T:C/C:C .017(-
.014_.048) 
.006(-
.018_.031) 
-.001(-
.025_.024) 
   
T:T/C:C .042(.004_.079) .012(-
.017_.042) 
.008(-
.022_.038) 
   
OPG 
Rs:2073618 .016 .165 .122 .022 .099 .120 
C:G/C:C .003(-.027_.032) .004(-
.019_.028) 
.000(-
.023_.023) 
.023 
(.003_.042) 
.013 (-
.002_.028) 
.012 (-
.003_.027) 
G:G/C:C .057(.016_.098) .031(-
.002_.063) 
.032(-
.001_.064) 
Rs:11995824 .032 .086 .071 .044 .199 .125 
G:C/C:C -.058(-.105_-.010) -.042(-.079_-
.004) 
-.042(-.080_-
.005) 
-.021 (-
.042_-.001) 
-.011 (-
.027_.006) 
-.013 (-.029_) 
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Table  3-8: Summary of associations between BMD and SNPs 
 
 
 
 
 
 
 
 
 
 
 
 
G:G/C:C -.061(-.107_-.014) -.037(-
.074_.000) 
-.041(-.078_-
.004) 
Rs:4355801 .010 .450 .233 .029 .240 .119 
G:A/G:G -.071(-.120_-.022) -.018(-
.057_.021) 
-.026(-
.065_.013) 
-.023 (-
.044_-.002) 
-.010 (-
.026_.007) 
-.013 (-
.029_.003) 
A:A/G:G -.073(-.121_-.025) -.024(-
.063_.014) 
-.033(-
.072_.005) 
ESR1 
Rs:2077647 .109 .478 .000 .036 .258 .108 
C:T/T:T .018(-.015_.051) .013(-
.012_.039) 
.027(.001_.053) .020 
(.001_.039) 
.009 (-
.006_.023) 
.012 (-
.003_.027) 
C:C/T:T .041(.003_.079) .017(-
.013_.047) 
.024(-
.006_.054) 
LRP5 
RS:2306862 .107 .830 .587 .042 .966 .902 
T:C/C:C -.025(-
.060_.010) 
.004(-
.024_.032) 
.009(-
.019_.037) 
-.031(-
.060_-
.001) 
-.001(-
.024_.023) 
.001(-
.022_.025) 
T:T/C:C -.086(-
.186_.014) 
-.021(-
.100_.059) 
-.031(-
.111_.049) 
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3.3.4.9 A summary of genetic BMD associations study in the Iranian population and 
current study 
 
Hossein-Nezhad et al 2009 showed there is a significant association between different 
genotypes of rs2228570 and spine BMD in premenopausal women CC (1.20± 0.17), CT 
(1.14± 0.05), and TT (1.03± 0.13) with P-value=0.001and also postmenopausal women CC 
(1.20± 0.17), CT (1.14± 0.05), and TT (1.03± 0.13) with P-value=0.001.  Hossein-Nezhad et 
al 2009 also showed there is a significant association between different genotypes of 
rs2228570 and total hip BMD in premenopausal women CC (1± 0.1), CT (0.96± 0.05), and 
TT (0.90±0.12) with P-value=0.001 but there is no association in postmenopausal women. 
The present study showed that there is no association between rs2228570 and BMD and 
revealed there is an association between rs731236 of VDR and spine 0.022 (95%CI 0.001, 
0.43; p = 0.038), neck BMD 0.027(95%CI 0.011, 0.44; p = 0.001), and total hip BMD 
0.029(95%CI 0.013, 0.46; p = 0.000). Golbahar et.al 2004 showed there is no association 
between rs1801133 and both spine and femoral neck BMD in post-menopausal women 
(Table 3.9). 
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Table  3-9: Summary of associations between BMD and SNPs in the Iranian 
population 
Data of the all genetic association studies between BMD and SNPs in the Iranian population 
(according to the systematic review explained in the introduction part) were summarized and 
compared with data of available same candidate gene in the current study. It is showed that 
the result of association study between rs2228570 and BMD in one of those papers was not 
the same as in the current study.
*
methylene tetra hydro folate reductase 
Genetic BMD associations study in the Iranian population  
Author Sample 
size 
Sex Candidate gene/ 
polymorphism 
Phenotypes P-
value 
 
(Hossein-
nezhad, 
Varzaneh 
et al. 2011) 
312 Female 
Pre-
menopausal 
VDR
  
gene 
Rs2228570 
CT/CC vs. TT 
Spine BMD 0.001 
 
Total hip 
BMD 
0.001 
Female 
Post-
menopausal 
Spine BMD 0.001 
Total hip 
BMD 
0.50 
(Golbahar, 
Hamidi et 
al. 2004) 
271 Female 
Post-
menopausal 
MTHFR
* 
gene 
Rs1801133 
TC/TT vs. CC 
 
Spine BMD 0.806 
Femoral 
neck BMD 
0.802 
Current 
study 
501 Male &Female VDR  gene 
Rs2228570 
CT/CC vs T:T 
 
Spine BMD 0.195 
 
Neck 
BMD 
0.248 
Total hip 
BMD 
0.918 
VDR  gene 
Rs731236 
CT/CC vs T:T 
 
Spine BMD 0.116 
Neck 
BMD 
0.002 
Total hip 
BMD 
0.001 
119 | Chapter 3 
 
3.4 Discussion 
 
There is a multitude of factors that can influence the risk of developing osteoporosis, 
including age, gender, physical activity levels, diet and medication. However, it has been 
established that one of the key clinical risk factors of osteoporosis is a positive family history, 
highlighting the significance of genetics in the aetiology of osteoporosis (Li, Hou et al. 2010). 
Currently, BMD is the most commonly used predictor of osteoporotic fractures, and as a 
result is often used as a marker phenotype for osteoporosis (Li, Hou et al. 2010). This chapter 
looked at whether the BMD of a random selection of subjects from an Iranian population was 
genetically associated with a selection of candidate genes known to be associated with BMD. 
Next, the most associated SNPs for the LRP5, RANK, RANKL, P2RX7, ESR1, OPG and VDR 
genes were selected for genotyping, and any genetic associations between the specific SNPs 
and BMD were evaluated. The final objective of this part of the study was to determine 
whether the genetic associations observed in our Iranian population study were consistent 
with other demographic populations. Therefore we hypothesise that there are genomic 
associations between specific SNPs and BMD within the Iranian population. 
 
Differences in sex, age and BMI are all possible causes of slight differences in findings 
between studies (Johnson et al. 2009; Shen et al. 2005), which also give rise to variations in 
genetic association studies. Producing a descriptive analysis of a sample group prior to 
genetic studies is therefore important for determining genetic associations. In this study the 
descriptive analysis of our random selection of subjects from the Iranian population showed 
that there were no significant differences between the mean ages of the males and females 
within the group.  Additionally the weight and height of the males were higher than that of 
the females, as observed in similar subject groups of other similar Iranian studies (Bahrami, 
Sadatsafavi et al. 2006). These data are an indication that as the descriptive characteristics of 
the randomly selected sample group was comparable to samples within other studies; further 
genetic studies would also be comparable to the literature. Interestingly data showed that our 
male subjects had a lower BMI range compared to the female subjects and these data were 
consistent with findings from Bahrami et al (Bahrami, Sadatsafavi et al. 2006).  
Data collected from the BMD analysis of our Iranian population samples showed that the 
total hip BMD of the male subjects was higher than the female subjects. The average BMD of 
our male sample group was 0.95 mg/cm
2
 and the females had an average BMD value of 0.86 
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mg/cm2. These data were consistent with BMD data obtained from other Iranian groups 
(Larijani, Moayyeri et al. 2006),(Omrani 2006) European groups (Styrkarsdottir, Halldorsson 
et al. 2010) and American groups (Mazess and Barden 1999).These data suggest that the 
BMD pattern observed within our sample group was comparable to that of others used in 
similar genetic association studies (Kiel, Ferrari et al. 2007) (Shang, Lin et al. 2013). As a 
result this increases the viability of data obtained from future genetic association studies.  
 
As mentioned previously, a low BMD is associated with the risk of developing osteoporosis 
(Cummings, Nevitt et al. 1995). The relationship between BMD and BMI, including its 
weight and height constituents is widely reported (Felson, Zhang et al. 1993; Ravn, Cizza et 
al. 1999; Nguyen, Center et al. 2000). In the literature BMD is reported to be lower in lean 
postmenopausal women in the majority of studies. However, some studies have also reported 
increased BMD in lean postmenopausal women (Salamat, Salamat et al. 2013). Analysis to 
determine the existence of any correlation between BMD and BMI constituents in our random 
selection of Iranian subjects showed that correlations of height and weight with L2-L4 BMD, 
neck BMD, and total hip BMD were significantly positive. This was not unexpected, and it 
was shown by other researchers (Munasinghe, Botea et al. 2002; Mascarenhas, Negreiro et al. 
2003; Lei, Deng et al. 2004; Yeh, Chen et al. 2004). There were also significant negative 
correlations between age and BMD, which were consistent with other reports (Nguyen, 
Center et al. 2000).  
 
It is expected that many different genetic variants contribute to the regulation of BMD. Most 
of the variants are associated with small effect size, but there is evidence that rare variants of 
large effect size also contribute in some individuals (Ralston 2010). In the past 10 years there 
have been advances in the identification and validation of osteoporosis susceptibility loci via 
large-scale association studies, meta-analyses and GWAS of SNPs. A thorough review of 
latter developments has revealed that  more than 15 genes can be assigned as confirmed 
BMD genes linked to osteoporosis (Li, Hou et al. 2010). The LRP5, RANK, RANKL, P2RX7, 
ESR1, OPG and VDR genes selected for this study are known to have important roles in four 
well defined biological pathways; the oestrogen endocrine pathway, the Wnt/β-catenin 
signalling pathway, the RANKL/RANK/OPG pathway and the vitamin D synthesis pathway 
(Li, Hou et al. 2010). There are limited data related to effective genetic variants in 
osteoporosis, particularly in respect to the mentioned genes, in the Iranian population. 
Genotyping specific analysis and allele specific analysis were performed to determine 
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significant associations between BMD and our 37 selected SNPs (section 3.3.4). Associations 
were calculated between each of the 37 SNPs and L2-L4 BMD, NECK_BMD and Total_ 
BMD. For this association analysis, a total of 37 x 6 (222) hypothesis tests were performed. 
Therefore, due to repeated testing we would expect to find 11 of the tests to be significant 
under the null by chance (P<0.05). Genotype specific analysis and per allele specific analysis 
of the BMDs of our Iranian population sample and selected SNPs showed that 19 associations 
were P<0.05 (Table 3.10). Hence we do see some evidence of associations with this set of 
genetic loci in the Iranian sample. However, the SNPs selected for analysis in this cohort are 
already established as risk SNPs so in this evaluation we are mainly interested to know if the 
overall pattern of association is similar to other populations or may be different. Such 
differences may be due to different population, alleles, or the impact of a distinct 
environment; hence it is more the estimate and 95%CI that is of interest.   
 
Number of significant P-value for association between SNPs and BMD in both 
genotype and per allele specific analysis  models 
 
Analysis L2-L4 BMD Neck BMD Total Hip BMD 
 
Total number of 
associations 
Univariate  
Analysis 
2/37 1/37 4/37  
Per allele 
specific 
analysis 
7/37 2/37 3/37  
Total  9/74 3/74 7/74 19/229 
 
Table  3-10: BMD and SNP association analysis 
Genotype specific analysis and per allele specific analysis were performed to determine 
significant genetic associations between each of the 37 selected SNPs and BMD parameters. 
Genotyping data showed a total of 19 significant associations between selected SNPs and the 
BMD of our Iranian population sample. N=501, linear regression, P<0.05.  
 
Out of the 37 selected SNPs our genotyping data identified associations between BMD and 8 
of these SNPs: Rs731236, Rs3751143, Rs884205, Rs9594738, Rs2073618, Rs4355801, and 
Rs2077647 (Table 3.11). Genotyping analysis of SNPs belonging to the ESR gene showed a 
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significant association between BMD (L2-L4 and Total) and RS 2077647 in our Iranian 
population sample. To date associations between SNP RS 2077647 and BMD have not been 
demonstrated in any Iranian population prior to this study. Interestingly findings from Sonoda 
et al were consistent with our data, in that they showed a significant increase in BMD with 
minor alleles of rs2077647 located in the first exon of ESR1 (Sonoda, Takada et al. 2012). 
On the other hand in 2009 Rivadeneira et al group performed meta-analysis study of five 
genome-wide association studies of lumbar spine and femoral neck BMD. This group 
identified 20 BMD loci that reached genome-wide significance level (GWS; P<10
8
), where 
ESR1 was one of the known BMD loci. In comparison to the genotyping data obtained from 
our select Iranian sample, Rivadeneira et al showed rs2504063 (P-value=6.1E
-11
) and 
rs2941740 (P-value=2.0E
-09
) were associated with lumbar and femoral BMD (Rivadeneira, 
Styrkarsdottir et al. 2009). In contrast, Holliday et al findings showed associations of 
rs1999805 not only with femoral BMD and spinal BMD but also with calcaneus BMD 0.10 
(95%CI 0.05, 0.16; p = 0.0001) and trabecular BMD at the distal radius 0.18 (95%CI 0.06, 
0.29; p = 0.003) (Holliday, Pye et al. 2011).  
 
In another large GWAS analysis between SNPs most implicated in the discovery set and 
BMD of the lumbar spine and hip was performed in Icelandic (4169), Danish (2269), and 
Australian (1491) subjects as replication sets (Styrkarsdottir, Halldorsson et al. 2008). In this 
study sequence variants in five genomic regions were significantly associated with BMD in 
the discovery set and in the replication sets. The ESR1 gene was one of the five genomic 
regions which: rs1999805: −0.11 (95%CI −0.15, −0.06), rs6929137: −0.10 (95%CI −0.15, 
−0.05), rs1038304: −0.10 (95%CI −0.14, −0.06), and rs4870044: −0.11 (95%CI −0.16, 
−0.07) of this locus were associated with BMD (Styrkarsdottir, Halldorsson et al. 2008).    
 
For the RANK gene, the present study showed that SNP rs884205 was associated with total 
hip BMD, and the same association was observed in studies by Styrkarsdottir et al within a 
European and East Asian population (Estrada, Styrkarsdottir et al 2012; Rivadenier, 
Styrkarsdottir et al 2009). The present study further showed that RANKL SNPs rs9594738 
and rs9594759 were also linked closely to spine BMD, similar to studies by Duncan et al and 
Styrkarsdottir et al in the European population (Duncan, Danoy et al 2001; Styrkarsdottir, 
Halldorsson et al 2008). The OPG SNP rs2073618, rs1995824 and rs4355801 associations 
with spine BMD determined in the present were also observed in other studies specific to 
spine and hip BMD in post/pre-menopausal women and the European population respectively 
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(Mencej-Bedrač, Preželj et al. 2011; (Shang, Lin et al. 2013). The ESR1 SNP 2077647 
associated with spine BMD in the present study was also associated with post-menopausal 
osteoporosis in Japanese women in a recent study (Sonoda, Takada et al 2012). LRP5 SNP 
rs2306862 was associated with BMD in men and women in the present study as well as in a 
larger study carried out by Kiel et al. Interestingly, where we observed an association with 
spine BMD, the Kiel study shown an association of rs2306862 with femoral neck BMD in 
men only. Although there are few data on P2RX7, one study did correlate with ours in that 
SNP rs3751143 was associated with BMD in a similar number of subjects (Wesselius, Bours 
et al. 2013). From our data we infer that BMD is genetically dependent and these findings 
correlated with the literature (Arden, Baker et al. 1996). 
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Genetic BMD associations worldwide compared to the present Iranian study 
Author Sample size sex Gene/ 
Polymorphism 
Phenotypes P-value 
Coefficient 
(CI) 
RANK 
Dastgheib et al 501 Male & 
Female 
Rs884205 
A-allele 
 
Total hip 
BMD 
0.042 
-.020(-.040_-
.001) 
(Estrada, 
Styrkarsdottir 
et al. 2012) 
Initial: up to 
32,961 
European and 
East Asian 
ancestry 
individuals 
Replication: Up 
to 50,933 
European and 
East Asian 
ancestry 
individuals 
Male & 
Female 
Rs884205 
A-allele 
 
Total hip 
BMD 
2 x 10
-17
* 
 
.05 (NA)  
(Rivadeneira, 
Styrkarsdottir 
et al. 2009) 
19,195 
European 
ancestry 
individuals 
Male & 
Female 
Rs884205 
A-allele 
 
Spine BMD 9 x 10
-9
* 
 
.08 (0.05-
0.11) 
RANKL 
Dastgheib et al 501 Male & 
Female 
Rs:9594738 
T-Allele 
Spine BMD 0.019 
 
.025 
(.004_.047) 
(Duncan, 
Danoy et al. 
2011) 
Initial: European 
ancestry 900 
cases with low 
hip BMD, 1,055 
cases with high 
hip BMD 
Replication: 
20,898 
European 
ancestry 
 
Female Rs:9594738 
T-Allele 
Spine BMD 4 x 10
-6* 
 
0.15 (NA)  
(Styrkarsdottir, 
Halldorsson et 
al. 2008) 
Initial:5,861 
European 
ancestry 
individuals 
Replication: 
7,925 European 
ancestry 
individuals 
Male & 
Female 
Rs:9594738 
T-Allele 
Spine BMD 2 x10
-8* 
 
0.1 (0.06-
0.13) 
 
Dastgheib et al 501 Male & 
Female 
Rs:9594759 
T-Allele 
Spine BMD .032 
 
.020(0.002_.0
39) 
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(Styrkarsdottir, 
Halldorsson et 
al. 2009) 
Initial:6,865 
European 
ancestry 
individuals 
Replication: 
8,510 European 
ancestry 
individuals 
Male & 
Female 
Rs:9594759 
T-Allele 
Spine BMD 2 x10
-17* 
 
.12 (.09-.15)  
(Styrkarsdottir, 
Halldorsson et 
al. 2008) 
Initial: 5,861 
European 
ancestry 
individuals 
Replication: 
7,925 European 
ancestry 
individuals 
Male & 
Female 
Rs:9594759 
T-Allele 
Spine BMD 2 x10
-21* 
 
.17 (0.14-
0.21)  
OPG 
Dastgheib et al 501 Male & 
Female 
Rs:2073618 
G Allele 
Spine BMD .022 
 
.023 
(.003_.042) 
(Mencej-
Bedrač, 
Preželj et al. 
2011) 
478 post-
menopausal 
women of 
Slovenia 
Female Rs:2073618 
C:G vs C:C 
Spine BMD .006 
 
NA 
(Shang, Lin et 
al. 2013) 
108 pre-
menopausal 
and 127 post-
menopausal 
women 
Female Rs:2073618 
C:G/G:G vs C:C 
Total hip <0.05 
 
NA 
Dastgheib et al 501 Male & 
Female 
Rs:11995824 
G Allele 
Spine BMD 0.044 
 
-.021 (-.042_-
.001) 
(Rivadeneira, 
Styrkarsdottir 
et al. 2009) 
19,195 
European 
ancestry 
individuals 
Male & 
Female 
Rs:11995824 
G Allele 
Hip BMD 7 x10
-9* 
 
.07 (0.05-
0.09)  
Dastgheib et al 501 Male & 
Female 
Rs:4355801 
A Allele 
Spine BMD 0.029 
 
-.023 (-.044_-
.002) 
(Richards, 
Rivadeneira et 
al. 2008) 
Initial:2,094 
European 
ancestry 
women 
Replication: 
6,463 
European 
ancestry 
individuals 
Female Rs:4355801 
A Allele 
Femoral 
neck and 
spine BMD 
8x10
-10* 
 
.09 (NA)  
ESR1 
Dastgheib et al 501 Male & 
Female 
Rs:2077647 
C Allele 
Spine BMD 0.036 
 
.020 
(.001_.039) 
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(Sonoda, 
Takada et al. 
2012) 
Cases were 
114 Japanese 
women with a 
confirmed 
diagnosis of 
postmenopau
sal 
osteoporosis 
and 
controls were 
171 general 
Japanese 
women 
Female Rs:2077647 
C:T vs T:T 
Osteoporosis <0.0001 
 
3.27 (1.83–
5.85) 
Rs:2077647 
C:C vs T:T 
0.015 
 
2.48 (1.20–
5.16) 
LRP5 
Dastgheib et al 501 Male & 
Female 
RS:2306862 
T Allele 
Spine BMD 0.042 
 
-.031(-
.060_-.001) 
(Kiel, Ferrari et 
al. 2007) 
subset of 
1797 
unrelated 
individuals 
Men RS:2306862 
C:T/T:T vs C:C 
Neck BMD 0.01 
 
NA 
P2RX7 
Dastgheib et al 501 Male & 
Female 
Rs:3751143 
T Allele 
Neck BMD 0.024 
 
-.020 (-
.037_-.003) 
Total hip 
BMD 
0.045 
 
-.018 (-
.035_.000) 
(Wesselius, 
Bours et al. 
2013) 
Six hundred 
ninety women 
and 231 men 
aged 
≥50 years 
Male & 
Female 
Rs:3751143 
T:T vs G:G 
Hip BMD 0.018 
 
Table  3-11 : Summary of genetic BMD associations worldwide compared to the 
present Iranian study 
 Significant associations determined between BMD and selected SNPs in this study were 
compared with other populations. *P-value for genome wide association studies 
 
In addition to age and BMI, the sample size and ethnicity issue are possible causes of 
inconsistent findings between one study and another (Johnson et al. 2009; Shen et al. 2005). 
Although many association studies, including the present study, have used sample sizes 
ranging between 500-600 samples (Wesselius, Bours et al. 2013), there are obvious benefits 
to using a larger sample size group. For example, GWAS use large sample size groups in 
their studies, with replications in a range of ethnic groups (Estrada, Styrkarsdottir et al. 2012). 
Some of the genetic associations that were observed between BMD and specific SNPs in our 
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Iranian sample differed from the associations observed in other populations. This could be 
due to a number of underlying reasons, including variations in population parameters such as 
age, weight and height, and lack of power.  
Taking into account the extensive set of possible genetic associations investigated worldwide, 
the most important findings represent an extreme sample (Hong and Park 2012). Usually in 
any disease genetic associations are modest and single studies do not have the power to detect 
these associations effectively (Ioannidis, Ntzani et al. 2001).  
 
Finally the main findings from this chapter are as follows: 
Analysis of the Iranian sample population showed that the male subjects had significantly 
higher BMD means associated with L2-L4_BMD, neck_BMD, troch_BMD and total_BMD 
compared to that of the female population. 
There were statistically significantly negative correlations between age with L2-L4_BMD, 
age with neck BMD, and age with total hip BMD. In addition analysis to determine the 
existence of any correlation between BMD and BMI constituents in our random selection of 
Iranian subjects showed that correlations of height and weight with L2-L4 BMD, neck BMD, 
and total hip BMD were significantly positive. 
Genotyping data analysis identified associations between BMD and risk SNPs: VDR-
rs731236, P2RX7-rs3751143, RANK-rs884205, RANKL-rs9594738, RANKL-rs9594759, 
LRP5-rs2306862, OPG-rs2073618, OPG-rs11995824, OPG-rs4355801, and ESR1-
rs2077647. From our data we infer that BMD is genetically dependent. Interestingly, these 
finding are similar to results from genome wide association studies in other population.  
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Chapter 4 – Role of genetic variants in osteoclast 
function  
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4.1 Hypothesis and Objectives 
 
 
There are genomic associations between BMD and osteoclast function and between specific 
SNPs and osteoclast function within the Iranian population.  
 
To test this hypothesis the following objectives were determined: 
 
 
 Determine the number of osteoclasts, the number of osteoclasts in an active resorption 
state, and the resorption area on the dentine disc. 
 
 Evaluate any genetic associations between BMD and osteoclast function  
 
 Evaluate any genetic associations between the specific SNPs and osteoclast function  
 
 
 
 
 
 
 
 
 
 
 
4.1.1 Hypothesis 
4.1.2 Specific objectives 
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4.2 Introduction  
In the previous chapter the data consistent with literature indicated that variations in BMD are 
genetically dependent (Arden, Baker et al. 1996). Polymorphisms which affect osteoclast 
function may also contribute to the heritability of bone mass and diseases such as 
osteoporosis (Boyle, Simonet et al. 2003). Meta-analysis studies have suggested that BMD is 
also linked to genetic markers within the RANK/RANKL/OPG system (Richards, 
Rivadeneira et al. 2008; Styrkarsdottir, Halldorsson et al. 2008; Styrkarsdottir, Halldorsson et 
al. 2009). The RANK, RANKL and OPG molecules are key regulators of osteoclastogenesis 
(Boyle, Simonet et al. 2003). In addition, a further GWA meta-analysis study has since 
identified several important BMD-related pathways, including the RANK/RANKL/OPG 
signalling pathway (Rivadeneira, Styrkarsdottir et al. 2009). The expression of RANK and 
RANKL was shown in osteoclast cultures (CD14+ monocyte cells) (www.biogps.org). OPG, 
which encodes the OPG protein, is mainly expressed by osteoblast cells rather than osteoclast 
cells (www.biogps.org), so association with osteoclast function in osteoclast culture is not 
expected. 
There are limited data on the association between osteoclast activity and gene 
polymorphisms. The majority of studies examining genetic influences on bone have mainly 
focused on BMD due to availability of DXA scanners. However, BMD is effected by skeletal 
parameters including periosteal expansion, cortical density/thickness, and trabecular 
number/thickness, which may be biologically and genetically influenced (Bachrach 2001). 
Therefore assessing genetic associations in osteoclast function in correlation with BMD 
values could provide new insight into the genetics of osteoporosis. In the present study it was 
determined whether osteoclast number and resorption function were associated with 
variations in BMD and whether there were any genetic associations with osteoclast activity in 
a selection of an Iranian population sample.  
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4.3 Results 
 
 
Osteoclast cultures were isolated from peripheral blood samples obtained from the selected 
Iranian population samples needed for allelic imbalance experiments later in the thesis as 
described in the method section 2.7. Osteoclast number was determined per culture using 
TRAP staining and osteoclast point counting, as outlined in the method section 2.7. The 
osteoclast differentiation process was monitored for approximately three weeks. In the first 
day of culture cells were small, spherical, and mononuclear (Figure 4.1 A). Within seven 
days of culture cells grew with spread cytoplasm but were still mononuclear. Around the 
second week cells were larger and began to display an osteoclast-like appearance, some 
possibly being multinucleated. They became typically huge and round with extended 
cytoplasm. It seems from these experiments that multinucleated cells first appear in the 
second week, but larger multinucleated osteoclasts are seen from the fourteenth day onward 
(Figure 4.1 B). Counts showed that there was variation in the number of osteoclasts 
between individual biological samples with an average osteoclast number of 218 in the 
sample population (Figure 4.2).  
 
 
 
 
  
4.3.1 Determining osteoclast number in cultures obtained from a selected 
Iranian population  
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Figure  4-1: Osteoclast formation in culture medium supplemented with 
recombinant RANKL and MCSF 
Images are representative of cell appearance using phase-contrast microscopy. (A) D 0: cells 
are small, spherical and mononuclear, distributed in the culture medium. (B) D 21: cells are 
larger, multinucleated, with osteoclast shape (black arrows). Scale bar = 100 µm. 
A 
Day 0: small osteoclast progenitors 
B 
Day 21: Mature osteoclasts 
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Figure  4-2: The average number of osteoclasts obtained from primary human 
samples was determined using Trap staining 
Osteoclast cultures were isolated from human peripheral blood samples. Osteoclast numbers 
were determined per culture using Trap staining and osteoclast point counting. (A) Data 
showed variations in the number of osteoclasts across individual biological samples. (B) The 
average osteoclast number was 218 per culture. N=16 individual biological cases with 6 
replicates in each. The marked line shows the mean, and the bottom and top line show SD. 
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Osteoclasts that demonstrated resorption activity were used as a marker of osteoclast 
function. Osteoclasts were isolated from the Iranian population samples as outlined in the 
section 4.3.1. Trap staining of osteoclasts on dentine disks was performed, and non-active 
and active osteoclasts (Figure 4.3 A) were counted as outlined in the method sections 2.7.4 
and 2.7.5. Each osteoclast culture was maintained on 6 dentine disks, to give 6 replicates of 
the same biological sample. The percentage of resorbing osteoclasts was calculated based on 
the total number of osteoclasts. Osteoclast data from all donor samples within the selected 
Iranian population demonstrated that 19 – 83% of osteoclast cells were actively resorbing 
(Figure 4.3 B).  
 
 
 
 
 
 
 
 
 
 
  
4.3.2 Determining the number of active resorption osteoclast cells  
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Figure  4-4: The % of actively resorbing osteoclasts from the total osteoclast 
population was determined using Trap staining 
(A) Osteoclasts cultured on dentine disks were either in an activated or non-activated 
resorption state. (B) The proportion (%) of actively resorbing osteoclasts in cultures. N=16 
individual biological cases with 6 replicates in each. The marked line shows the mean, and 
the bottom and top line show SD. 
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Isolated monocytes seeded on dentine discs were cultured in the presence of M-CSF and 
RANKL for 21 days. After two weeks resorption pits appeared on the dentine discs. After 21 
days dentine discs were fixed and stained with toluidine blue staining to validate the Trap 
staining showing resorption. Resorption pits were visualised under the light microscope in 
fewer than 21 days. More defined pits were visible following three weeks in culture. The 
patterns of resorption pits produced by human osteoclast cells were often observed to be 
“snake like” (Figure 4.4 A). Osteoclasts formed authentic resorption lacunae on the dentine 
discs, determined by adjusting the focus of the light microscope (Figure 4.4 B and C). 
Commonly osteoclast cells could be seen located at the end of the resorption pit. The 
percentage of resorption area on dentine discs with osteoclast cells was determined in 16 
Iranian population samples. Data showed that percentage (%) resorption area of the 
osteoclast cultures varied across biological samples, ranging between approximately 1-33 % 
resorption per disc (Figure 4.4 D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.3 Determining the osteoclast resorption area  
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Figure  4-6: Determining osteoclast resorption activity using toluidine blue 
staining 
(A) snake-like resorption lacunae on dentine discs produced by osteoclast cells resorption 
lacunae on dentine disc after 3 weeks (B) Surface of dentine and resorption area. (C) Bottom 
of pit showing the depth of lacunae. (D) The proportion of the disc with resorption varied 
across biological samples. N=16 individual biological cases with 6 replicates in each. The marked 
line shows the mean, and the bottom and top line show SD. 
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The objective of this part of the study was to assess any links between osteoclast 
number/activity and BMD in the Iranian population sample. First the BMD value of each of 
the donor samples was determined. BMD values were determined according to the protocol 
outlined in the method section 2.1.2. Subjects were placed into normal, osteopenia and 
osteoporosis subtypes, based on the L2-L4 and total hip BMD (total hip BMD) values. 
Subjects that had a BMD within 1 SD of the adult reference mean (T-score=> -1 SD) were 
classified as ‘normal’ in relation to bone disease. Any subjects with a BMD within 1 to 2.5 
SD below the adult reference mean (-2.5<T-score< -1) were placed into the ‘osteopenia’ 
category and all subjects with BMD of <-2.5 SD below the adult reference mean (T-score=<-
2.5) were classed as diagnosed with osteoporosis (Kanis 1994). The osteoclast resorption area 
was determined for each of the normal, osteopenic and osteoporotic samples.  
Data showed that there were no differences in the osteoclast number within osteoporotic 
samples with low L2-L4 BMD compared to normal samples (Figure 4.5 A) and also was not 
observed in relation to total hip BMD-associated bone disease (Figure 4.5 B). The osteoclast 
numbers increased in osteopenic or osteoporotic donor samples with a L2-L4 BMD of >1 SD 
below the adult reference mean (Figure 4.5 C, *P<0.05).  
Next, the proportions of resorbing osteoclasts calculated as a percentage of the total osteoclast 
population were compared between normal, osteopenic and osteoporotic sample groups. Data 
showed that there was no difference in the % of resorbing osteoclasts within osteoporotic 
samples with low L2-L4 BMD compared to that of normal samples (Figure 4.6 A). Data 
analysis also determined no difference in the % of resorbing osteoclasts within osteopenic 
patient samples with low total hip BMD compared to that of normal samples (Figure 4.6 B).  
There were no difference in the % resorption area in osteoclast culture isolated from 
osteopenic and osteoporotic samples compared to normal samples. (Figure 4.7 A, B). Data 
showed that the % of osteoclast resorption area increased in sample donors with a L2-L4 
BMD of >1 SD below the adult reference mean, i.e. those classified as osteopenic or 
osteoporotic (Figure 4.7 C, *P<0.05).  
 
4.3.4 Osteoclast number and function were increased in osteopenia and 
osteoporotic patients  
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Figure  4-7: Osteoclast number was increased in patients with low L2-L4 BMD 
corresponding to osteopenia and osteoporosis 
The osteoclast number determined from osteopenic and osteoporotic samples was compared 
to normal samples. (A, B) There were no statistically significant differences in the osteoclast 
number between normal and osteopenic or osteoporotic samples. (C, D) The osteoclast 
number increased in osteopenic or osteoporotic sample donors with a L2-L4 BMD of >1 SD 
below the adult reference mean. N=16 biological cases. The marked line shows the mean, 
and the bottom and top line show SD. Students t-test and Man-Whitney test, *P<0.05.  
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Figure  4-8: The proportion of resorbing osteoclasts increased in patients with 
low BMD corresponding to osteopenia and osteoporosis 
The percentage of resorbing osteoclasts taken from whole osteoclast cultures was compared 
between normal, osteopenic and osteoporotic sample groups. (A, B,C,D) There were no 
statistically significant differences in the % of resorbing osteoclast numbers between normal 
and osteopenic or osteoporotic samples. N=16 biological cases. The marked line shows the 
mean, and the bottom and top line show SD. 
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Figure  4-9: Osteoclast function was increased in patients with low L2-L4 BMD 
corresponding to osteopenia and osteoporosis 
The % osteoclast resorbing area in osteoclast culture isolated from osteopenic and 
osteoporotic samples was compared to normal samples. (A, B) There were no statistically 
significant differences in the % of osteoclast resorption between normal and osteopenic or 
osteoporotic samples.  (C, D) The % of osteoclast resorption area increased in osteopenic 
or osteoporotic sample donors with a L2-L4 BMD of >1 SD below the adult reference mean. 
N=16 biological cases. The marked line shows the mean, and the bottom and top line show 
SD. Students t-test and Man-Whitney test, *P<0.0.  
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Specific genes including RANK, RANKL and OPG have been reported in the literature as 
genes which regulate osteoclastogenesis (Kikuchi, Matsuguchi et al. 2001). In the method 
section 2.2.1, the systemic review was identified risk SNPs associated with RANK, RANKL 
and OPG genes. In this study, we use the term ‘risk’ refer to SNPs which were associated 
with BMD. The following risk SNPs were identified for each of the genes: 
 RANK - rs884205 and rs30183625 
 RANKL -  rs9594738, rs9594759 and rs1021188 
 OPG - rs6469804, rs2062375, rs11995824, 4355801, and rs2062377 
In this part of the study any association between the risk SNPs associated with RANK, 
RANKL and OPG genes and osteoclast number/function in the 16 samples (selected in the 
section 2.5) were determined. To perform DNA genotyping, DNA was isolated from the 
peripheral blood of the corresponding osteoclast study volunteers and extraction was 
performed as described in section 2.3. DNA samples were sent to K-Bioscience for 
genotyping as outlined in section 2.4. The osteoclast number, the % of resorbing osteoclast 
numbers and % resorbing area were determined as outlined in section 2.7.5. Any statistical 
genetic associations between the RANK, RANKL and OPG genes, risk SNPs, and osteoclast 
number/resorption were assessed. Genetic association between the RANK, RANKL and OPG 
genotypes and osteoclast number/resorption were analysed, specifically looking at whether 
increasing copies of the risk allele (either homozygous or heterozygous, depending on the 
SNP) is associated with decreasing BMD. According to the genotyping that was performed, 
Due to the small number of osteoclast samples, subjects were classified determined into have 
either two genotypes (homozygous wild type or risk and heterozygous risk) or three 
genotypes (homozygous wild type, heterozygous risk and homozygous risk). 
Analysis of the genetic associations between the RANK gene SNPs rs884205 and 
rs30183625 and osteoclast number/ resorption activity showed that there was an increase in 
the osteoclast number (Figure 4.8 A, *P<0.05)  in those with risk heterozygous genotype (A: 
C) compared to wild homozygous genotypes (C: C) of the rs884205 SNP. There were no 
differences observed in the % resorption area and % of resorbing osteoclasts between the 
4.3.5 Osteoclast number were genetically associated by SNPs in a selected 
Iranian sample 
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heterozygous and homozygous genotypes (Figure 4.8 B, C). Data also showed an increase in 
the osteoclast in those with risk heterozygous genotype (A: C) compared to wild homozygous 
genotypes (C: C) of the rs30183625 SNP (Figure 4.9A *P<0.05). No differences were 
determined in the % resorption area and % of resorbing osteoclasts between heterozygous 
and homozygous genotypes of the rs30183625 SNP (Figure 4.9 B, C). 
The analysis for the genetic associations between the RANKL-associated risk SNPs 
rs9594759, rs9594738, and rs1021188 and osteoclast number/ resorption activity showed that 
there were no differences in the osteoclast number or % of resorbing osteoclasts between 
heterozygous and homozygous genotypes of rs9594738 (Figure 4.10). Statistical analysis 
showed that there were no differences in the osteoclast number or % of resorbing osteoclasts 
between heterozygous and homozygous genotypes of rs9594759 (Figure 4.11). Statistical 
analysis also showed that there were no differences in the osteoclast number or % of resorbing 
osteoclasts between heterozygous and homozygous genotypes of the rs1021188 SNP (Figure 
4.12).  
Further analysis for the genetic associations between the OPG-associated risk SNPs 
rs6469804, rs2062375, rs11995824 and rs2062377 and osteoclast number/ resorption activity 
showed that there were no differences in the osteoclast number, % of resorbing osteoclasts, 
and % resorption area between wild type and risk alleles in any of the tested rs6469804, 
rs2062375, rs11995824, or rs2062377 SNPs (Figures 4.13 – 4.17 ).  
  
144 | Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4-10:  Osteoclast number and function were genetically associated by 
RANK SNP rs884205 genotype 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of RANK SNPs. (A) There was statistically 
significant differences in the osteoclast number in those homozygous for the C (wild) allele 
(C: C) compared to heterozygous for the A (risk) allele (A: C) in the rs884205 SNP. (B, C) 
There were no statistical significant difference in % resorption area and % of resorbing 
osteoclasts between heterozygous and homozygous genotypes allele of rs884205 SNP. The 
marked line shows the mean, and the bottom and top line show SD. Student's t-Test and 
Man-Whitney test, *P<0.05.  
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Figure  4-11:  Osteoclast number and function were genetically associated by 
RANK SNP rs3018362 genotype 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of RANK SNPs. (A) There was statistically 
significant differences in the osteoclast number in those homozygous for the G (wild) allele 
(G: G) compared to heterozygous for A (risk) allele (G: A) in the rs30183625 SNP. (B, C) 
There were no statistically significant difference in % resorption area and % of resorbing 
osteoclasts between heterozygous and homozygous genotypes of rs30183625 SNP. The 
marked line shows the mean, and the bottom and top line show SD. Student's t-Test and 
Man-Whitney test, *P<0.05.  
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Figure  4-12: Osteoclast number and function were genetically associated by 
RANKL SNP rs9594738 genotype 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of RANKL SNPs. (A, B, C) There were no 
statistically significant differences in the osteoclast number, % of resorbing osteoclasts, or 
% resorption area between heterozygous and homozygous genotypes of  rs9594738 SNP. 
The marked line shows the mean, and the bottom and top line show SD. Student's t-Test.  
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Figure  4-13: Osteoclast number and function were genetically associated by 
RANKL SNPs rs9594759 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of RANKL SNPs. (A, B, C) There were no 
statistically significant increases in the osteoclast number, % of resorbing osteoclasts and % 
resorption area in those homozygous for the T (risk) allele (T: T) compared to those 
heterozygous for T allele (T: C)or those homozygous for the C allele in the rs9594759 SNP. 
The marked line shows the mean, and the bottom and top line show SD. One-way ANOVA.  
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Figure  4-14: Osteoclast number and function were genetically associated by 
RANKL SNP rs1021188 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of RANKL SNPs. (A, B, C) There were no 
statistically significant increases in the osteoclast number, % of resorbing osteoclasts and % 
resorption area in those heterozygous for C (risk) allele compared to those homozygous for 
T (wild) allele in the rs1021188 SNP. The marked line shows the mean, and the bottom and 
top line show SD. Student's t-Test. 
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Figure  4-15: Osteoclast number and function were genetically associated by 
OPG SNP rs6469804 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of OPG SNPs. (A, B, C) There were no statistically 
significant differences in osteoclast number, % of resorbing osteoclasts or % resorption 
area between heterozygous and homozygous genotypes of the rs6469804 SNP. The marked 
line shows the mean, and the bottom and top line show SD. Student's t-Test.  
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Figure  4-16: Osteoclast number and function were genetically associated by 
OPG SNP rs4355801 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of OPG SNPs. (A, B, C) There were no statistically 
significant differences in osteoclast number, % of resorbing osteoclasts or % resorption 
area between heterozygous and homozygous genotypes of the rs6469804 SNP. The marked 
line shows the mean, and the bottom and top line show SD. One-way ANOVA.  
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Figure  4-17: Osteoclast number and function were genetically associated by 
OPG SNP rs2062375 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of OPG SNPs. (A, B, C) There were no statistically 
significant differences in osteoclast number, % of resorbing osteoclasts or % resorption 
area between heterozygous and homozygous genotypes of the rs2062375 SNP. The marked 
line shows the mean, and the bottom and top line show SD. Student's t-Test.  
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Figure  4-18: Osteoclast number and function were genetically associated by 
OPG SNP rs11995824 genotype 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of OPG SNPs. (A, B, C) There were no statistically 
significant differences in osteoclast number, % of resorbing osteoclasts or % resorption 
area between heterozygous and homozygous genotypes of the rs11995824 SNP. The marked 
line shows the mean, and the bottom and top line show SD. Student's t-Test.  
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Figure  4-19: Osteoclast number and function was genetically associated by 
OPG SNP rs2062377 genotype 
Osteoclast number, proportion of resorbing osteoclasts and the % resorption area were 
assessed in association with genotyping of OPG SNPs. (A, B, C) There were no statistically 
significant differences in osteoclast number, % of resorbing osteoclasts or % resorption area 
between heterozygous and homozygous genotypes of the rs2062377 SNP. The marked line 
shows the mean, and the bottom and top line show SD. Student's t-Test.  
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4.4 Discussion 
 
In the previous chapter data are consistent with the larger body of published evidence, 
suggested that variations in BMD are genetically dependent (Arden, Baker et al. 1996). 
Polymorphisms which effect osteoclast function may also contribute to the heritability 
variation of bone mass and diseases such as osteoporosis. The formation of osteoclasts is 
centred on the key osteoclastogenic cytokine RANKL. Although there are many 
inflammatory cytokines known to promote the formation and activity of osteoclasts, 
RANKL is considered to be the final downstream effector cytokine that drives 
osteoclastogenesis and regulates osteoclastic bone resorption (Weitzmann 2013). The 
RANKL/RANK/OPG axis is now recognised as the pivotal regulator of osteoclastogenesis 
and mutations in the RANK, OPG, and RANKL genes cause bone disease, including 
osteoporosis (Kobayashi, Udagawa et al. 2009). In this chapter, we wanted to test the 
hypothesis that there are genomic associations between specific RANK, RANKL and OPG 
risk polymorphisms and osteoclast function within the Iranian population. The aim of this 
study was to firstly determine the number of osteoclasts and their level of resorption activity 
within the sample group. Next, any associations between these risk SNPs and osteoclast 
number/activity was assessed.  
A role for increased osteoclastic bone resorption observed in osteoporotic bone disease has 
been suggested by studies which have shown an increase in biochemical markers of bone 
resorption in patients with low skeletal BMD (Gough, Sambrook et al. 1998).  However, 
there are limited data on the genetic associations of osteoclast number/activity and BMD or 
RANK, RANKL and OPG risk SNPs, particularly in the Iranian population. Therefore, to 
investigate osteoclast activity in relation to BMD and genetic associations, we first 
characterised our human osteoclast model in-vitro.  
The ability to study the human osteoclasts formation and function of in-vitro has been 
limited. Our group has provided a reliable guide to isolating and culturing primary 
osteoclasts from human peripheral blood, with effective methodology that enables us to 
characterise osteoclasts and quantify resorption activity (Agrawal, Gallagher et al. 2012). 
However, as with all methods and protocols, there are some limitations. The initial attempt 
to culture osteoclasts from our human samples resulted in cells in the culture media that did 
not differentiate into mature osteoclast lineage. One possible reason for this problem may 
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have been the technical limitation of using the opaque interface containing the monocytes 
and lymphocytes fraction of blood for osteoclast isolation. An alternate method of osteoclast 
extraction derived from CD14+ monocytes isolated from peripheral blood (Sorensen, 
Henriksen et al. 2007), proved to be far more reliable in osteoclast cell differentiation within 
this study. Cultured mature osteoclast cell morphology and the presence of resorption pits 
were in agreement with findings from our group and others (Schilling, Linhart et al. 2004; 
Kreja, Liedert et al. 2007; Agrawal, Gallagher et al. 2012).  
As it was indicated before a single osteoclast culture could be performed to fulfil a dual 
purpose of functionally characterising the osteoclast cells in vitro and determining allelic 
imbalance expression. The limitations for this part of the study were the high cost of 
material for culture in remote sites, and the need for the large blood volume sample required 
from each subject. Within our project budget, approximately 16 cultures were affordable in a 
twelve months period in Iran. These samples are selected according to high heterozygosity 
for transcribed SNPs and are not random sampling but because they are not selected 
according to risk SNPs so the results are affected less.   
Having successfully cultured mature osteoclasts, TRAP staining of osteoclast cultures 
showed that there were variations in osteoclast numbers across donor samples in our 
selected Iranian population. Osteoclasts that demonstrated resorption activity were used as a 
marker of osteoclast function. These data showed that the proportion of resorbing osteoclasts 
taken from a total osteoclast population also varied greatly between donors. This data 
showed that although there was variability in the number of actively resorbing osteoclasts 
across donors, at least 1/3 of all the osteoclasts obtained from our human donors were indeed 
actively functioning. Subsequently data showed that the percentage area of resorption of the 
osteoclast cultures obtained from each donor varied, in the approximate range 1-33 % 
resorption area. To assess possible associations between osteoclast number/activity and 
BMD in our Iranian population sample, the BMD values of each of our 16 donor samples 
was determined and the donors placed into normal, osteopenia and osteoporosis subtypes. 
Our data suggested that individuals classified as having osteopenia or osteoporosis in L2-L4 
also, were associated with increased osteoclast number and resorption activity compared to 
normal individuals. Interestingly, this effect was observed relative to L2-L4 BMD and not 
total hip BMD. One possible explanation for this may be that from the total number of 
patients from our 16 donors only 2 were osteoporotic compared with 5 that were osteopenic 
in total hip region. These ratios in fact mirror data from the entire population from other 
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larger Iranian studies (Omrani 2006). A focus of interest within this study is that most of the 
associations observed with osteoclastogenesis and BMD appear to be evident in osteopenic 
and osteoporotic patients with low L2-L4 BMD. This is consistent with other studies within 
the literature that also those genetic associations with BMD are dependent on the bone site 
(Tran, Nguyen et al. 2008). The majority of subjects used in GWA studies related to BMD 
consisted of postmenopausal women and elderly men (Paternoster, Ohlsson et al. 2010). 
Therefore, it is difficult to determine whether the genetic effects reported are actually related 
to the control of peak bone gain in early life or bone loss that is age-related.  
A further analysis of gene polymorphisms associated with osteoclastogenesis regulators 
RANK, RANKL and OPG (Kikuchi, Matsuguchi et al. 2001) allowed us to identify the risk 
SNPs associated with these genes. Our objective was to then determine any genetic links 
between the risk SNPs associated with RANK, RANKL and OPG genes and osteoclast number 
or function. Our data showed that out of the three genes investigated, RANK polymorphisms 
had the most genetic association with osteoclast number.  
Data show that there were statistically significant associations between increasing osteoclast 
number and risk allele of RANK rs884205/rs3018362 SNPs. These associations were in the 
direction that would be expected from risk alleles of BMD. Analysis of genetic associations 
between RANKL rs9594738/rs9594759/rs1021188 risk SNPs and osteoclast number and 
resorption activity showed that there were no statistically significant association between 
increasing in the osteoclast number and activity and risk alleles of rs9594759 
/rs1021188/rs9594738 SNPs. No genetic associations were determined between osteoclast 
number/function and OPG SNPs rs6469804, rs2062375, 2062377, 4355801 and rs11995824.  
We have shown that osteoclast number and activity appear to be reduced in individuals with 
low L2-L4 BMD. It was of particular interest to us that the 16 individuals selected on the 
basis of strongest genetic heterozygosity from our study cohort, >70% were either osteopenic 
or osteoporotic in L2-L4 BMD. Taken together, these findings suggest that there may be 
genetic associations between specific RANK/RANKL polymorphisms and osteoclast number 
and function. 
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Finally the main findings from this chapter are as follows: 
 
The osteoclast numbers increased in osteopenic or osteoporotic donor samples with a L2-L4 
BMD of >1 SD below the adult reference mean. 
The % of osteoclast resorption area increased in sample donors with a L2-L4 BMD of >1 SD 
below the adult reference mean. 
There were statistically significant associations between osteoclast number and risk allele of 
RANKL rs9594759 /rs1021188 SNPs according to genotyping and osteoclast function assay. 
These associations are in the direction that would be expected from risk alleles of BMD.
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Chapter 5 – Allelic Expression Imbalance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
159 | Chapter 5 
 
5.1 Hypothesis and Objectives 
 
That association between candidate risk SNPs and variation in BMD may be mediated 
through allelic specific imbalance expression in different cell types. 
To test this hypothesis and to determine whether cis-acting effects of the risk SNPs in the 
selected candidate genes lead to allelic imbalance in different cellular populations, namely 
whole blood and differentiated osteoclasts the following objective was determined: 
 
 
 Determine level of allelic expression in whole blood and differentiated osteoclasts by using 
transcribed SNPs with Sequenom technology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.1  Hypothesis 
5.1.2 Specific objective 
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5.2 Introduction 
 
Gene expression is the process in which functional gene products are synthesised by using the 
information of genes. These products are proteins or non-protein coding genes such as 
transfer RNA (tRNA) genes or ribosomal RNA (rRNA) genes. Gene expression modulates a 
whole host of functions ranging from DNA-RNA transcription to post-translational 
modification of proteins. Recently, several studies have shown that genetic variation at a 
sequence level can result in the modulation of gene expression in a cell (Tung, Fedrigo et al. 
2009). The variations associated with disease susceptibility, particularly in complex diseases, 
frequently alter expression rather than function of proteins (Freedman, Monteiro et al. 2011). 
Such changes in gene expression may occur in two ways: by acting on genes at a distance 
through an expressed transcription factor (or non-coding RNA) on both the maternal and 
paternal chromosome (trans-acting factor), or by acting to regulate a gene on the same short 
range haplotype (allele) which resides on the same chromosome (cis-acting factor) (Monks, 
Leonardson et al. 2004; Cheung, Spielman et al. 2005). Cis-acting variants induce allelic 
expression imbalance (AEI). Trans-acting factors and environmental backgrounds influence 
expression of both alleles and are therefore not responsible for AEI (Tung, Fedrigo et al. 
2009). Cis-acting mutations may alter the regulation of a single allele through a change to the 
promoter regions, intron regions or enhancer elements that affect transcription factor-binding 
sites.  
The allele-specific expression is investigated by evaluation of cDNA from tissues expressing 
the genes of interest in the heterozygous (for the putative cis-acting variant) individual as it is 
not technically possible to measure the relative allele expression in a homozygous individual 
for the cis-acting variant. A major advantage of this approach is that the two SNP alleles are 
measured in the context of the same trans-acting and environmental factors with likely cis-
acting regulatory variants or parent of origin (imprinting) effects (Farh, Grimson et al. 2005). 
GWAS show AEI in approximately 20% of expressed genes (Milani, Gupta et al. 2007; Serre, 
Gurd et al. 2008). Consequently genetic variation has a significant role in the variation on 
gene expression between individuals. These differences can correlate with phenotypic 
differences or even with risk of diseases (Teare, Heighway et al. 2006).   
The most comprehensible way of observing allelic expression is by determining whether the 
imbalance observed from a set of transcribed SNPs across different heterozygous individuals 
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is consistent with a risk-acting effect. In the simplest scenario we consider that only one 
candidate polymorphism is tested and one transcribed polymorphism is used to measure 
technically the expression of the two alleles to find the ratio of one allele to the other. For an 
individual that is heterozygous at the transcribed and the risk-acting sites, the overexpressed 
transcribed allele is on the same chromosome (haplotype) as the risk-acting allele causing 
overexpression. A haplotype is a collection of DNA variation or polymorphisms that are 
likely to be inherited together. The phase between alleles at the two sites may vary between 
individuals. Determining the effect of the risk-acting polymorphism requires identifying the 
linkage disequilibrium (dissociation/association) between the transcribed and risk-acting sites. 
When there is complete linkage disequilibrium between both polymorphisms, only two 
distinct haplotype exists so those that are heterozygous should show systematic 
overexpression of the same transcribed allele. 
Within the current study, I aimed to investigate evidence of cis acting effects which may 
account for some of the association between BMD variation and genetic variations. Allele 
specific expression can only be detected technically where the transcribed alleles can be 
distinguished in some way (such as heterozygous for the transcribed regions) (Figure 5.1). I 
am interested in studying allelic expression imbalance (AEI) in cDNA obtained from 
osteoclast cultures and peripheral blood tissue samples. These data support the ideology that 
there may be a potential genetic association between non-transcribed SNPs and allelic 
imbalances in relation to BMD. This potential concept is further described in Figure 5.2, in 
which, using the TNSFR11B gene encoding OPG as an example, we propose that allelic 
imbalances in risk SNPs on non-transcribed loci have an effect on the regulation of 
transcribed SNPs.  
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Figure  5-1: Effect of a cis acting polymorphism on allelic expression 
The situation of a cis acting SNP with allele A and G, transcribed SNP with allele T and C, 
and affected transcript in an individual who is heterozygous for cis acting and transcribed 
SNPs. As it is shown A as a cis acting SNP have effected on one of the haplotype and 
induced more transcript which these affected transcribed are identified by allele T of 
transcribed SNP. Correlations between cis acting SNPs and AEI of transcribed SNPs in the 
samples which were heterozygous for transcribed SNPs were then determined. One of the 
most important goals of genetics is to identify (cis-) regulatory elements for gene expression 
and heritable variation of them, especially those that impact clinical phenotypes and common 
diseases (Teare, Pinyakorn et al. 2011). 
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Figure  5-2: Risk SNPs on non-transcribed loci may have an effect on BMD by 
allelic imbalance expression 
Rs4355801 as a risk SNP is associated with BMD according to GWAS. Rs2073618 as a transcribed 
SNP is as a label to investigate allelic imbalance expression 
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5.3 Results 
 
 
In the first part of this study, blood sampling and BMD were done for 501 randomly selected 
individuals as described in the method section 2.1.1. Genotyping of the peripheral blood 
samples donated from these 501 volunteers was performed as described in the method 
section 2.4. The method section 2.5 demonstrates what size of an effect would be detected 
(with 80% power) with sample sizes of 16 osteoclast cultures and 52 peripheral blood 
samples. Out of the 501 available volunteer samples, a total number of 52 subjects for blood 
sampling and 16 subjects for osteoclast culture were selected based on having the highest 
level of heterozygosity at each of the specified transcribed SNPs. This was performed by 
sorting the samples according to the number of heterozygous SNPs of the six transcribed 
SNPs in each sample. Six transcribed SNPs are: rs2077647, rs2073618, rs556442, rs1805034, 
rs208294 and rs731236, as described in the method section 2.5 (Table 2.4). Analysis of the 
genotyping data showed that 8% of the total selected 52 subjects were heterozygous for all 6 
transcribed SNPs. A larger proportion 79% of the total sample population was heterozygous 
for a minimum of 5 transcribed SNPs and all 52 subjects were heterozygous for a minimum 
of 4 transcribed SNPs (Figure 5.3). Data showed that out of our selected 52 subjects, 36 
subjects were heterozygous for ESR1 rs2077647 SNP, 42 were heterozygous for TNFRSF11 
rs2073618 SNP, 40 were heterozygous for LRP5 rs556442 SNP, 46 were heterozygous for 
P2RX7 rs208294 and 41 heterozygous for the RANK rs1805034 SNP (Figure 5.3). 
Transcribed SNP heterozygosity is important in AEI as it allows the expression of each allele 
to be quantified separately.  
  
 
 
 
5.3.1 Fifty-two candidate samples were selected to be used in the allelic 
imbalance expression study based on highest heterozygosity  
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Figure  5-3: All the sample candidates selected were heterozygous for at least 4 
transcribed SNPs 
 (A) Genotyping analysis showed that out of the 52 selected candidate samples, all were 
heterozygous for a minimum of 4 transcribed SNPs. A smaller population were heterozygous 
for all 6 SNPs. (B) The number of heterozygotes in the sample for selected transcribed SNPs 
of ESR1, OPG, LRP5, RANK, P2RX7 and VDR.  
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The 52 samples were selected for efficiency. With more resources the total sample would 
have been extended to ensure there was sufficient power (80%) to detect cis-acting effects on 
AEI at all the candidate loci of interest. With these limited resources the samples were 
selected to maximise the number of loci that could be examined. Hence subjects who were 
heterozygous at more of the transcribed SNPs were more desirable. However the test for cis-
acting effects relies on there being homozygous and heterozygous at the putative cis-acting 
loci, so before the allelic expression imbalance measurements were taken the breakdown of 
the genotype counts for each risk SNP in each candidate gene was examined to ensure there 
were sizeable numbers of homozygotes and heterozygotes for each risk SNP in those 
heterozygous for the transcribed SNPS. The next section shows this breakdown by candidate 
gene.  
 
 
AEI is only measurable in subjects that are heterozygous for the transcribed SNP. The power 
of the test to look for evidence for the cis-acting effects comes from comparing the 
distributions of the AEI by risk SNP genotype. An excel pivot table was used to cross 
tabulate the genotyping data of selected transcribed and risk SNPs within the 52 selected 
subject samples, as outlined in the method section 2.6. This shows how many of those who 
are heterozygous for the transcribed SNP belong to each risk SNP genotype group. For each 
of the ESR1, OPG, LRP5, RANK, P2RX7 and VDR candidate genes, all genotyping data of 
transcribed and risk SNPs were transferred into excel worksheets to form the pivot table. The 
numbers of those with specific risk SNP genotypes between each of the transcribed SNPs and 
risk SNPs genotype were then assessed.  
The genotype count breakdown of the 52 samples was used to ensure there were sufficient 
numbers of subjects who were heterozygous for both transcribed and risk SNPs. Here we 
firstly identified, out of our 52 candidate samples, how many were heterozygous for the 
transcribed SNP of our candidate gene. Next we constructed a contingency table to illustrate 
how many samples were risk allele homozygous, heterozygous or wild-type homozygous. 
Where genotyping was unsuccessful due to methodological issues, the risk SNP was 
5.3.2 The joint distribution between the transcribed SNP and risk SNP 
heterozygosity  
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categorised as having an ‘undetermined’ genotype. The number (count) of samples that was 
either risk homozygous, heterozygous or wild homozygous within our sample population was 
summarised. A profile was then created for each of the candidate transcribed SNPs in relation 
to the genotype of the associated risk SNPs. 
The genotype profile for the candidate samples heterozygous for transcribed ESR rs2077347 
SNP and risk SNPs rs2504063, rs1999805, rs4870044, rs1038304, rs2941740 and rs6929137 
is presented. Data showed that for the transcribed SNP rs2077647 the candidate sample 
population were heterozygous, risk homozygous and wild homozygous for all risk SNPs 
within this gene (Figure 5.4). The genotype profile for the candidate samples heterozygous 
for transcribed OPG rs2073618 SNP and risk SNPs rs6469804 rs4355801, rs2062375, 
rs2062377 and 11995824 is presented in (Figure 5.5). The majority of samples that were 
heterozygous for transcribed SNP rs2073618 were also heterozygous for rs6469804, 
rs4355801, rs2062375, rs2062377 and rs11995824. Figure 5.6 shows the candidate samples 
heterozygous for transcribed LRP5 rs556442 SNP and risk SNPs rs599083 and rs3736228; 
no samples were risk homozygous and the majority of samples were heterozygous. 
The genotype profile for the candidate samples heterozygous for transcribed RANK 
rs1805034 SNP and risk SNPs rs884205 and rs3018362 was presented (Figure 5.7). For the 
transcribed SNP rs1805034, the majority of samples were wild homozygous for risk SNPs 
rs884205 and rs3018362. For P2RX7, genotyping analysis showed that for the transcribed 
SNPs rs7958311 and rs1718119, the candidate sample population were either heterozygous 
or wild homozygous for the risk SNP rs3751143 (Figure 5.8). The genotype profile for the 
candidate samples heterozygous for transcribed VDR rs731236 SNP and risk SNP rs2228570 
showed that for the transcribed SNP rs731236, the candidate sample population were either 
heterozygous or risk homozygous for risk SNP 2228570 (Figure 5.9).   
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Figure  5-4:The genotype profile for the candidate samples heterozygous for 
transcribed ESR rs2077347 SNP and risk SNPs rs2504063, rs1999805, 
rs4870044, rs1038304, rs2941740 and rs6929137 
Genotyping analysis showed that for the transcribed SNP rs2077647, the candidate sample 
population were subdivided into heterozygous, risk homozygous and wild homozygous.  
 
ESR1 
 
   
Number of 
Heterozygous 
samples for 
transcribed 
Rs2077647 SNP 
Risk SNP Risk 
homozygous 
Heterozygous Wild 
homozygous 
Undetermined 
 
42 2504063 10 19 11 2 
 1999805 8 23 9 2 
 4870044 5 18 18 1 
 1038304 19 12 9 2 
 2941740 4 13 22 3 
 6929137 10 14 15 3 
Heterozygous 
Risk Homozygous 
Wild Homozygous 
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Figure  5-5: The genotype profile for the candidate samples heterozygous for 
transcribed OPG rs2073618 SNP and risk SNPs rs6469804 rs4355801, 
rs2062375, rs2062377 and 11995824 
Genotyping analysis showed that for the transcribed SNP rs2073618, the candidate sample 
population were subdivided into heterozygous, risk homozygous and wild homozygous. The 
majority of samples were heterozygous for transcribed SNP rs2073618 were also 
heterozygous for rs6469804, rs4355801, rs2062375, rs2062377, and 11995824. 
OPG 
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40 6469804 9 30 0 1 
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Figure  5-6: The genotype profile for the candidate samples heterozygous for 
transcribed LRP5 rs556442 SNP and risk SNPs sn599083 and 3736228 
Genotyping analysis showed that for the transcribed SNP rs556442, no samples were risk 
homozygous and the majority of samples were heterozygous. 
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Risk SNP Risk 
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Heterozygous Wild 
homozygous 
Undetermined 
      
37 599083  0 35 1 1 
 3736228  0 26 10 1 
R s 5 9 9 0 8 3 R s 3 7 3 6 2 2 8
0
1 0
2 0
3 0
4 0
R is k  S N P S  a s s o c ia te d  w ith
3 7  s a m p le s  h e te ro z y g o te  fo r
T ra n s c r ib e d  L R P 5  S N P : R s 5 5 6 4 4 2
S
a
m
p
le
 C
o
u
n
t
R is k  S N P
Heterozygous 
Wild Homozygous 
171 | Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-7: The genotype profile for the candidate samples heterozygous for 
transcribed RANK rs1805034 SNP and risk SNPs rs884205 and rs3018362 
Genotyping analysis showed that for the transcribed SNP rs1805034, the candidate sample 
population could be subdivided into heterozygous, risk homozygous and wild homozygous. 
The majority of samples were wild homozygous for risk SNPs rs884205 and rs3018362. 
 
RANK 
 
   
Number of 
Heterozygous 
samples for 
transcribed  
Rs1805034 
SNP 
Risk SNP Risk 
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 3018362 3 18 23 0 
      
      
R s 8 8 4 2 0 5 R s 3 0 1 8 3 6 2
0
1 0
2 0
3 0
4 0
R is k  S N P S  a s s o c ia te d  w ith
4 4  s a m p le s  h e te ro z y g o te  fo r
T ra n s c r ib e d  R A N K
S N P : R s 1 8 0 5 0 3 4
S
a
m
p
le
 C
o
u
n
t
R is k  S N P
Heterozygous 
Risk Homozygous 
Wild Homozygous 
172 | Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-8 : The genotype profile for the candidate samples heterozygous for 
transcribed P2RX7 rs208294 and risk SNP rs3751143 
Genotyping analysis showed that for the transcribed SNPs rs298294, the candidate sample 
population were either heterozygous or wild homozygous the risk SNP rs3751143. 
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Figure  5-9: The genotype profile for the candidate samples heterozygous for 
transcribed VDR rs731236 SNP and risk SNP rs2228570 
Genotyping analysis showed that for the transcribed SNP rs731236, the candidate sample 
population were either heterozygous or risk homozygous for risk SNP 2228570 
VDR 
 
    
Number of 
Heterozygou
s samples 
for 
transcribed  
Rs731236 
SNP 
Risk SNP Risk 
homozygous 
Heterozygous Wild 
homozygous 
     
38 2228570 17 21 0 
Heterozygous 
Risk Homozygous 
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The data presented in the above tables shows the number of subjects in each genotype for risk 
SNPs (homozygous, heterozygous) for individuals who are heterozygous for transcribed 
SNPs, which is essential to detect cis-acting effect. Knowledge of the presence of linkage 
disequilibrium between risk SNP and transcribed SNPs is also important and influences the  
method of  analysis to detect cis-acting effects (Teare, Pinyakorn et al. 2011). 
 
Linkage disequilibrium (LD) occurs when there is  non-random association of alleles at two 
or more loci (Slatkin 2008). In populations where the occurrence of some combinations of 
alleles is more frequent than would be expected from a random formation of haplotypes from 
alleles based on their frequencies were said to be in linkage disequilibrium.  
For example, let us assume there are two loci: locus 1 has alleles G and C, locus 2 has alleles 
A and T. It is considered that p1 and p2 are frequency of the alleles at locus 1 and q1 and q2 
are frequency of alleles at locus 2. 
SNP1 SNP2 
Allele Frequency Allele Frequency 
G p1 A q1 
C P2 T q2 
 
 It is supposed that haplotype frequencies are as follows:  
Haplotype Frequency Haplotype Frequency 
GA p11 GT p12 
CA p21 CT q22 
 
 
 
 
5.3.3 Linkage disequilibrium between selected ESR1, RANK, VDR, LRP5, 
OPG and P2RX7 SNPs 
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When haplotype frequencies are equal to their corresponding allele frequencies, it shows the 
loci are in the linkage equilibrium situation. 
 
Haplotype frequency  Product of allele frequency 
p11 = p1q1 
p12 = p1q2 
p21 = p2q1 
p22 = p2q2 
 
We now illustrate this phenomenon with a hypothetical example. It is assumed that samples 
of 100 subjects were taken and the following haplotype counts have been found: 
GA: 25; GT: 50; CA: 60; CT: 65. Total=200 
Haplotype frequency and allele frequency are as below: 
Haplotype frequencies                        Allele frequencies 
GA= 25/200= .125                                  p1= .375 
GT=50/200= .25                                     p2= .625 
CA=60/200= .3                                       q1= .325 
CT=65/200= .325                                   q2= .575 
After inputting values in the equation for D to calculate linkage disequilibrium we will have 
the result below: 
D = (P11* P22) – (P12* P21) 
D= (.25*.325) - (.125*.3) = .04375 
Depending on allele frequency of two loci sometimes the value of D can be negative but in 
reality frequencies cannot be negative so standardization methods have been proposed to 
overcome this issue. A relative measure of disequilibrium (D) compared to its maximum is 
used as a standardization method. The first of these measures is D’ where D is divided by the 
maximum value it could take (Dmax). 
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To estimate Dmax allele frequencies and value for D were inputted in the following equation: 
Dmax = min [(p1q2) or (p2q1) ] 
Dmax = (.375*.575) = .215 
D’= D/Dmax 
D’ =.04375/.215= .2 
Pearson coefficient of correction (r) is another commonly used measured to calculate LD 
between loci. However squared coefficient of correlation (R
2
) is used to remove arbitrary 
sign. 
R= D/ (p1p2q1q2)
1/2 
R= .043/ (.375*.625*.325*.575)
 ½ 
R= .043/.2= .215 
D' and R
2 
values describe the extent of the correlation between a pair of loci, and range from 
0 to 1.00, where for D', 0 means that there is complete linkage equilibrium and 1.00 means 
complete LD. The R
2
 values are also ranged from 0 to 1.00, where 0 means that there is 
complete linkage equilibrium and 1.00 means perfect LD. In this study we were not able to 
count haplotypes exactly so we used the software Haploview software version 4.0 (Barrett, 
Fry et al. 2005) to calculate D' and  R
2
 for this study by using genotyping data. Haploview 
software reports D' and R
2
 values as percentage. When D'= 1 is referred to as Complete LD, 
there are at most 3 of the 4 possible haplotypes present in the populations. It means in 
complete LD, two loci are not being separated by a recombination in population since at least 
one of the haplotypes does not occur in the population. When R
2
= 1 is referred to as Perfect 
LD, there are exactly 2 of the 4 possible haplotypes present in the population, and as a result, 
the two loci also have the same allele frequencies. Loci which are in perfect LD are also in 
complete LD (VanLiere and Rosenberg 2008).  
If two loci are independent (not co-inherent) then both the D´ and R
2
 values will be 0.0 
regardless of either allele frequency. If two polymorphisms are in total disequilibrium both 
with a 50% allele frequency then both the D´ and R
2
 values would be 1.0 but when the allele 
frequencies are not the same the result is different. For example, if there are two 
polymorphisms in total disequilibrium, one with a 50% allele frequency and the other with a 
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1% allele frequency the D´ value would be 1.0 but the R
2
 value would only be 0.01. So 
ranges of R
2
 value can depend on the frequencies of alleles at the loci under consideration. 
The range of D’ is frequency-independent (Hedrick 1987). 
The data in the previous section was shown to ensure that there were sufficient heterozygotes 
in the sample which was analysed for allelic expression imbalance. This was a small subset of 
the full population studied and the extent of linkage disequilibrium between the pairs of SNP 
in each candidate region can be examined in the full set of 501 samples.   
The form the statistical test takes depends upon the extent of LD between the transcribed and 
the risk SNP. Four scenarios are shown in Figure 5.5. As AEI cannot be measured in 
homozygous transcribed SNPs these figures include only individuals who are heterozygous. 
Figure 5.10.A shows what we might see if two loci were only in weak or no LD so that all 
four haplotypes exist and are directly measureable. In this scenario there is a cis-acting effect. 
When ‘c’ is in phase with ‘m’ the ratio tends to be below µ0 and when ‘c’ is in phase with 
‘M’ the ratio tends to be above µ0.  In fact we cannot distinguish between the two phases so 
when a cis-acting effect exists there tends to be a wider spread of values in the heterozygous 
group. The program implemented by MSK jointly estimates the haplotype phase and the 
parameter µ when phase is not known.  
Fig 5.10.B depicts a scenario where there is perfect disequilibrium between both 
polymorphisms or the cis-acting and the transcribed polymorphisms are one and the same 
(such as rs731236 in this study) when there is perfect LD and a cis-acting effect then one 
specific allele is overexpressed consistently. Investigating the effect shows a systematic 
deviation in one direction from balanced expression. In figure 5.10 C a complete 
disequilibrium situation is shown. As explained above, in complete disequilibrium there are 
at most 3 of the 4 possible haplotypes present in the populations. In this figure a functional 
polymorphism is expected to make a systematic overexpression of one and the same 
transcribed allele among heterozygotes. This overexpression is not seen in homozygotes.    
If phase is known the genotype groups can be rearranged to place the two types of 
heterozygotes in groups either side of the homozygotes as in Figure 5.10.D. When rearranged 
to this scheme the parameter µcis can be estimated by simple linear regression. So, µcis is the 
average increase in allelic expression when the cis-acting element is in phase with the 
transcribed allele. When there is only partial LD then it is not generally possible to classify 
the phase of double heterozygotes, so a simple group comparison or linear regression cannot 
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be done.  Hence when the phase of compound heterozygotes cannot be determined a 
specialist program is required which can estimate the phase of the haplotypes and estimate 
the µcis at the same time. In this study we had measured genotypes only, so we conducted an 
analysis of linkage disequilibrium to see what methods would be necessary in the following 
the AEI measurements. 
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Figure  5-10: Different scenario for testing an association between two allelic 
polymorphisms and allelic expression  
The distribution of allelic expression ratios across a population is shown. Two 
polymorphisms are considered here: 1) Cis-acting SNP with alleles: C and c.  2) Transcribed 
SNP with two alleles: M and m, used as a marker to determine allelic expression. Each 
diamond represents the spread and the mean of the AEI measurements by specific genotypes. 
A) All possible conditions. B) Perfect disequilibrium (R
2
 = 1, D
’
=1) between the transcribed 
and the cis-acting polymorphism, in this situation only two distinct haplotypes happen. C) 
Complete disequilibrium (R
2
< 1, D
’
=1), in this situation three distinct haplotypes happen. D) 
Situation when there is no phase between cis and transcribed alleles or it is unknown (Teare, 
Pinyakorn et al. 2011).  This figure is explanatory without data. 
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The allelic expression imbalance was only assessed on a maximum of 51 samples. These 
were a selected sample group from the larger population so the linkage disequilibrium 
analysis was performed on the full set of 501 genotyped samples obtained from volunteers as 
described in section 2.4. In this part of the population genetics study, the extent of LD 
between selected SNPs within our candidate genes: ESR1, OPG, LRP5, RANK, P2RX7 and 
VDR was summarised. For each candidate gene region, pairwise LD was summarised with D' 
and R
2
 statistic. Though D' and R
2
 are constrained to take values between 0 and 1, the 
Haploview software reports them as a percentage. 
The pairwise LD was calculated for the ESR risk SNPs rs4870044, rs1038304, rs6929137, 
rs2941740, rs1999805, rs2504063 and transcribed SNP rs2077647 (Figure 5.11 A). The D' 
values are less than 29 between the risk SNPs and transcribed SNPs. The R
2
 values are less 
than 4 between the risk SNPs and transcribed SNPs. So there is no complete or perfect LD 
between the transcribed SNP and risk SNPs. The risk SNPs rs1999805 and rs2504063 had the 
highest R
2
 value of 50 and therefore were associated with an increased level of LD. The R
2
 
value calculated for the RANK between the transcribed SNP rs1805034 and the risk SNPs 
were less than 16 and the D' values between the transcribed SNP rs1805034 and the risk 
SNPs were less than 91 which show there is no complete or perfect LD between transcribed 
and risk SNPs (Figure 5.11 B). The D' and R
2
 calculated for VDR SNPs rs731236 and 
rs228570 were 1 and 27 and these were associated with low LD between VDR SNPs (Figure 
5.11 C). 
The LD was also calculated for the OPG risk SNPs: rs4355801, rs2062375, rs2062377, 
rs11995824, rs6469804 and transcribed SNP rs4355801 (Figure 5.11 D). Interestingly, the D' 
and R
2
 values calculated showed high LD between the transcribed SNP rs4355801 and risk 
SNPs. The highest D' value was observed between transcribed SNP rs4355801 and risk 
SNPs: rs2062375 and rs2062375 with a calculated D' value of 95.The highest R
2
 value was 
observed between transcribed SNP rs4355801 and risk SNP rs2062375 with a calculated r
2
 
value of 83. Because both D' and R
2
 values are below 100 again there is no perfect or 
complete LD between transcribed and risks SNPs.  
For the P2RX7 gene, the LD was determined for risk SNPs rs795811, rs1718119, rs2230911, 
rs22309912, rs3751143 and rs1621388 and transcribed SNP rs208294 (Figure 5.11 E). The 
D' and R
2
 values calculated showed D' ≤ 76 and R2 ≤13 between the transcribed SNP 
rs208294 and any of the risk SNPs. However, a perfect LD represented by a D' and R
2
 value 
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of =100, was observed between risk SNPs rs1718119 and rs1621388. Also risk SNPs: 
rs1718119, rs2230911, 2230912, 3751143, and 1621388 are in complete LD with D' =100. 
Finally the LD associations were determined for LRP5 risk SNPs rs599083, rs3736228, and 
transcribed SNP rs545382 (Figure 5.11 F). Here D' calculations determined a complete LD 
between transcribed SNPs rs545382 and risk SNPs599083 (D'=100). However, R
2
 value 
between the transcribed SNP rs545382 and either risk SNP were low (R
2
 of ≤24).  
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Figure  5-11: Linkage disequilibrium associations between transcribed and risk 
SNPs with D' and R2 values. 
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A number of gene markers including ESR1, OPG, LRP5, RANK, P2RX7, and VDR have been 
reported in the literature as genes which are expressed by white blood cells and ESR1, LRP5, 
RANK, P2RX7, and VDR by osteoclast cells. In this study I wanted to determine the 
expression of these genes in the white blood cell and osteoclast cultures collected from the 
volunteer samples by RT-PCR, prior to performing the AEI analysis. Positive expression of 
these genes in our candidate samples was an essential prerequisite for AEI.  
RNA was extracted from the peripheral blood and osteoclast culture of a healthy human 
volunteer. RNA extraction and cDNA synthesis were performed as described in the method 
sections 2.8 and 2.9.1. End point PCR was performed to determine the expression of ESR1, 
OPG, LRP5, RANK, P2RX7 and VDR in cDNA isolated from white blood cell and osteoclast 
cell cultures using Promega GoTaq® DNA polymerase as described in the method section 
2.9.2. Amplified PCR products were detected on an agarose gel using electrophoresis as 
described in the method section. Detection of End-point PCR products showed the presence 
of ESR1, OPG, LRP5, RANK, P2RX7 and VDR (Figure 5.12). 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.4 White blood cells and osteoclasts express ESR1, OPG, LRP5, RANK, 
P2RX7 and VDR  
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Figure  5-12:ESR1, OPG, LRP5, RANK, P2RX7, and VDR were detected in 
osteoclast and white blood cell cultures by end-point PCR 
PCR products were visualised alongside a 100bp ladder. Gel images are representative of 
three independent experimental repeats. (A1) Osteoclast cells were positive for Rank 
expression in comparison to the RT –ve control (A2). (A3) The cDNA isolated from white 
blood cell cultures was also positive for Rank expression compared to its corresponding RT-
ve control (A4). (A5) No band was detected in no-template control. Data showed that 
osteoclast cells and white blood cell cDNA were positive P2RX2 (B1, B2), LRP5 (C1, C2), 
VDR (D1, D2) and ESR (E1, E2). No bands were detected for the corresponding negative 
cDNA controls for P2RX2 (B3), LRP5 (C3), VDR (D3) and ESR (E3). (F1) Osteoclast cells 
were negative for OPG expression and white blood cell cultures were positive for OPG 
expression compared to its corresponding negative cDNA control (F3). 
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In this study we wanted to use Sequenom technology to determine AEI in the white blood 
cell and osteoclast culture samples obtained from our candidates selected from the 
genotyping study outlined in the method section 2.5. The RNA was extracted from the 52 
individual white blood cell samples and 16 individual osteoclast culture samples, according 
to the method outlined in the main method section 2.8. Then cDNA was synthesised from 
500ng of RNA, as described in the method section 2.9.1 and stored at -20°C until required. 
The quality of the cDNA was checked by real time PCR and using GAPDH according to 
method section 2.9.3. The cycle threshold (Ct) values of 52 cDNA of blood samples and 16 
cDNA from osteoclast culture were determined. Ct value less than 29 is indicative of 
abundant target nucleic acid in the sample (Mylvaganam, Zhang et al. 2010). The qRT-PCR 
analysis showed that that GAPDH expression levels within the blood and osteoclast cells 
were between 17-25 Ct (Figures 5.13), indicating that the level of cDNA was viable for 
further gene expression analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.5 Validation of all blood and osteoclast cDNA samples using qRT-PCR 
and GAPDH  
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Figure  5-13: The Ct values of 52 cDNA of blood samples and 16 cDNA from 
osteoclast cultures. ( box-and-whisker plot: the marked line shows the median, and the 
bottom and top of the box show the lower and upper quartiles.) 
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The MassArray system from Sequenom (Sequenom, California, USA) was used for 
genotyping and determination of allelic expression by Wellcome Trust Centre for Human 
Genetics service of Oxford University as outlined in the method section 2.10.  Originally, 
AEI analysis was to be performed at the University of Sheffield and primers were extensively 
designed and optimised (Appendix 1). However, it was concluded that the Sequenom 
technology due to its higher sensitivity and efficiency would be a better choice of method. 
Genotyping was performed on the 53 cDNA samples derived from blood and 16 cDNA 
samples obtained from osteoclast cultures as described in the method section 2.8 and 2.9.1. 
Allelic expression imbalance was assessed using Sequenom assays for seven transcript SNPs; 
rs2228570, Rs731236, Rs208294, Rs1805034, Rs2073618, Rs2077647, and Rs556442. All 
53 cDNA samples were heterozygous for four or more of the seven SNPs. Allelic expression 
ratios were estimated as the ratios of the area under the G, A, C and T peaks. All analyses 
used the logarithm of the ratios. The error bars represent the standard error (of the mean of 
the log ratios) as estimated from up to four replicates.  
Two systematic quality control criteria for the allelic expression measurement at the 
transcribed SNPs were used. First all four replicates for each sample were checked with 
Grubb’s test for finding outliers (http://graphpad.com/quickcalcs/Grubbs1.cfm). Simply all 
four replicates were copied to this website: it was calculated that any replicated which is a 
significant outlier would be deleted. Once all single samples had been checked with Grubb’s 
test and any outliers removed then the mean and standard error of the mean (SEM) was 
calculated for each sample. Any samples with an SEM more than 0.15 were deleted 
(http://hdl.handle.net/10443/1083) 
Results from the amplification of genomic DNA (25 samples) were used as a reference to 
normalise the blood cDNA and osteoclast cDNA values. Allelic expression ratios of the 
blood and osteoclast samples were normalised by subtracting the mean ratio of the 25 DNA 
samples after the removal of outliers.  
To illustrate the quality control and data processing steps we show the data for the ESR 
transcribed SNP rs2077647. The plot (Figure 5.14) shows the mean log ratio and SE for each 
sample. The data (x-axis) are sorted by size of the mean and this type of graph is referred to 
as a caterpillar plot.  Figure 5.14A shows two very clear outliers in the raw data of blood 
5.3.6 Allelic expression ratio within ESR1, RANK, VDR, LRP5 and OPG 
SNPs 
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samples. Using Grubb’s test and the SE check, two outlier samples were detected, and 
removed. Once the outliers were removed the range of ratios was smaller in genomic DNA 
than in the cDNAs (Figure 5.14B). 
Figure 5.15A shows the raw data: clear outliers can be seen in the blood and osteoclast 
samples for the OPG transcribed SNP rs2073618. First Grubb’s test was applied to each 
sample and seventeen outlier samples (twelve in genomic and five in blood samples) were 
detected within these results, which were removed and accounted for as a result of technical 
error. The range of individual allelic expression ratios was greater in the blood samples 
compared to osteoclast culture (Figure 5.1B).  
Figure 5.16A shows the raw data: clear outliers can be seen in the blood and genomic 
samples for the RANK transcribed SNP rs1805034. First Grubb’s test was applied to each 
sample: five outlier samples (three in genomic and two in blood samples) were detected 
within these results, which were removed and accounted for as a result of technical error. The 
range of individual allelic expression ratios was greater in the blood samples compared to 
osteoclast cultures (Figure 5.16B).  
Figure 5.17A shows the raw data: clear outliers can be seen in the blood and osteoclast 
samples for the VDR transcribed SNP rs731236. First Grubb’s test was applied to each 
sample and twelve outlier samples (ten in blood and two in osteoclast samples) were detected 
within these results, which were removed and accounted for as a result of technical error. The 
range of individual allelic expression ratios was greater in the osteoclast samples compared to 
genomic DNA (Figure 5.17B).  
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Figure  5-14: Allelic expression ratio for ESR transcribed SNP rs2077647 
(A) Raw allelic ratio data shown (B) Outliers were removed before Allelic expression ratios 
of the blood and osteoclast samples were normalized by subtracting the mean ratio of the 
DNA samples. This figure shows that only 1/16 of the osteoclast samples have a ratio above 
0, and 11/41 of the bloods show a ratio above 0. So this is consistent with the transcribed 
SNP itself having a cis-acting effect or this transcribed SNP is in LD with a cis-acting 
variant. (C)Mean of allelic imbalance expression ratio from up to four replicates shown.  
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Figure  5-15: Allelic expression ratio for OPG transcribed SNP rs2073618 
(A) Raw allelic ratio data shown (B) Outliers were removed before Allelic expression ratios 
of the blood and osteoclast samples were normalized by subtracting the mean ratio of the 
DNA samples. (C)Mean and SD of allelic imbalance expression ratio from up to four 
replicates shown. 
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Figure  5-16: Allelic expression ratio for RANK transcribed SNP rs1805034 
(A) Raw allelic ratio data shown (B) Outliers were removed before Allelic expression ratios 
of the blood and osteoclast samples were normalized by subtracting the mean ratio of the 
DNA samples. (C) Mean and SD of allelic imbalance expression ratio from up to four 
replicates shown. 
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Figure  5-17: Allelic expression ratio for VDR SNP rs731236 
 (A) Raw allelic ratio data shown (B) Outliers were removed before Allelic expression ratios 
of the blood and osteoclast samples were normalized by subtracting the mean ratio of the 
DNA samples. This figure shows that only 2/29 of the osteoclast samples have a ratio above 
0, and 2/11 of the bloods show a ratio above 0. So this is consistent with the transcribed SNP 
itself having a cis-acting effect or this transcribed SNP is in LD with a cis-acting variant. (C) 
Mean and SD of allelic imbalance expression ratio from up to four replicates shown. 
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To assess the association between transcribed SNPs and allelic expression ratio, we used an 
extension of the method published previously by Teare et al., 2006. Allelic expression ratio 
across the blood and osteoclast was used to evaluate associations between selected risk and 
transcribed SNPs for osteoporosis ESR1, OPG, RANK and VDR candidate genes. In these 
experiments the expression ratios of the transcribed SNPs were then grouped by specific risk 
SNP genotype for each subject within our Iranian population. The allelic expression ratio of 
the transcribed SNPs was determined for genomic DNA samples (gDNA) and used as an 
assay control. All allelic expression data are presented as the log ratios and are a mean of four 
replicates. All tests for cis-acting effect on allelic imbalance expression were done using Dr 
Santibanez-Koref method (MSK test). 
There is evidence of a cis-acting effect associated with the transcribed SNP rs2077647 of the 
ESR candidate gene, as after normalisation by the genomic sample mean both the blood and 
osteoclast cDNA ratios show a tendency for over expression of one of the alleles (Figure 
5.14) (one-sample t-test, blood cDNA µcis =-0.07 p=0.0004; osteoclast µcis = -0.14 p=0.0003).  
The cis-acting effect could be due to the transcribed variant or one in LD with the transcribed 
SNP. A total of six risk SNPs were tested for evidence of cis-acting effects on the blood and 
osteoclast samples. A significant result was observed for the two SNPs rs2941740 and 
rs2504063. For the SNP rs294170 (Figure 5.22A) the distribution of the AE ratio looks to be 
centred lower for the AG group compared to the AA group, the cis-acting effect reducing the 
ratio by -0.12 (p=0.02). This effect cannot be seen on the osteoclast analysis (p=0.69), but 
this may be due to lack of power, only two heterozygotes were available in the osteoclast 
sample.  
A more consistent result is observed with the SNP rs2504063. The anticipated pattern 
associated with a cis-acting effect is observed in the osteoclast with the heterozygous group 
showing a wider range of values than the two homozygotes. The anticipated pattern is not so 
obvious in the blood sample, with the GG genotype group having a wider range of values 
than the AG group. However, as the MSK test relies on a test of the means there is sufficient 
statistical evidence that the estimated known-phase haplotype groups do differ from the 
homozygous means (µcis =-0.1, p=0.007) (Figure 5.18). So overall, within ESR, evidences of 
5.3.7 Effect of risk SNP genotype on allelic expression ratio of transcribed 
SNPs 
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a cis-acting effect with the transcribed SNP 2077647 were seen. One statistically strong cis-
acting effect was seen for rs2504063 in both blood and osteoclast cDNA. A weaker but still 
statistically significant association was seen for SNP rs2941740 in the blood sample only.  
 A total of five risk SNPs was tested for evidence of cis-acting effects on the blood and 
osteoclast samples for the rs2073618 transcribed SNP of the OPG candidate gene. A 
significant result was observed in osteoclast cells for two SNPs rs4355801 and rs2062375. 
For the SNP rs4355801 (Figure 5.25B) there is just one homozygous sample and others are 
heterozygous for rs4355801. The heterozygous group shows a wider value than the G DNA 
samples, the cis-acting effect increasing the ratio by 0.07 (p=0.02). For the SNP rs2062375 
(Figure 5.26B) all osteoclast samples are heterozygous. The heterozygous group shows a 
wider value than the G DNA samples, the cis-acting effect increasing the ratio by 0.06 
(p=0.05). 
Two risk SNPs were tested for evidence of cis-acting effects on the blood and osteoclast 
samples for the rs1805034 transcribed SNP of the RANK candidate gene. A significant result 
was observed in osteoclast cells for the risk SNPs rs3018362, the cis-acting effect increasing 
the ratio by 0.06 (p=0.02) (Figure 5.30B).  
There is evidence of a cis-acting effect associated with the transcribed SNP rs731236 of the 
VDR, as after normalisation by the genomic sample mean both the blood and osteoclast 
cDNA ratios show a tendency for over-expression of one of the alleles   (Figure 5.17) (one-
sample t-test, blood cDNA µcis = 0.116 p=< 0.0001; osteoclast µcis = 0.183 p=0.005).  The 
cis-acting effect could be due to the transcribed variant or one in LD with the transcribed 
SNP. Two risk SNPs in total were tested for evidence of cis-acting effects on the blood and 
osteoclast samples. A significant result was observed for the SNPs rs731236 which is also 
transcribed SNPs so it is in perfect disequilibrium (Figure 5.10.B). In the blood samples 
(Figure 5.32A) the distribution of the AE ratio looks to be centred upper for the CT group 
compared to the GDNA group,  the cis-acting effect increasing the ratio by 0.12 (p=1.8e
-08
).  
In the osteoclast samples (Figure 5.32B) the distribution of the AE ratio looks to be centred 
upper for the CT group compared to the G DNA group, the cis-acting effect increasing the 
ratio by 0.18 (p=0.002).  So overall within VDR evidences of a cis-acting effect with the 
transcribed SNP 731236 were seen.  
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Figure  5-18: Effect of genotype at rs2504063 on allelic expression ratio of 
transcribed ESR SNP rs2077647 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2077647 for each individual: the data are grouped into homozygous risk (A:A), 
heterozygous  (A:G) or homozygous wild type (G:G) of the risk SNP rs2504063. The genomic 
DNA sample mean was used as a normalization control. (A) The blood sample genotype of 
SNP rs2504063 for the transcribed SNP rs2077647 (µcis=-0.10, P-value=0.007 for the 
comparison with genomic DNA between different genotypes of rs2504063). (B) The 
osteoclast sample genotype of SNP rs2504063 for the transcribed SNP rs2077647 (µcis=-
0.15, P-value=0.02 MSK test for checking the evidence of a cis-acting effect with the 
transcribed SNP rs2077647). 
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Figure  5-19: Effect of genotype at rs1999805 on allelic expression ratio of 
transcribed ESR SNP rs2077647 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2077647 for each individual: the data are grouped into homozygous risk (A:A), 
heterozygous  (A:G) or homozygous wild type (G:G) of the risk SNP 1999805. The genomic 
DNA sample mean was used as a normalization control. (A) The blood sample genotype of 
SNP rs1999805 for the transcribed SNP rs2077647 (µcis=0.13, P-value=0.13 for the 
comparison with genomic DNA between different genotypes of rs1999805). (B) The 
osteoclast sample genotype of SNP rs1999805 for the transcribed SNP rs2077647 (µcis=0.1, 
P-value=0.18 MSK test for checking the evidence of a cis-acting effect with the transcribed 
SNP rs2077647). 
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Figure  5-20: Effect of genotype at rs4870044 on allelic expression ratio of 
transcribed ESR SNP rs2077647 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2077647 for each individual: the data are grouped into homozygous risk (T: T), 
heterozygous  (C:T) or homozygous wild type (C:C) of the risk SNP 4870044. The genomic 
DNA sample mean was used as a normalization control. (A) The blood sample genotype of 
SNP rs4870044 for the transcribed SNP rs2077647 (µcis=0.053, P-value=0.15 for the 
comparison with genomic DNA between different genotypes of rs4870044). (B) The 
osteoclast sample genotype of SNP rs4870044 for the transcribed SNP rs2077647 (µcis=-
0.01, P-value=0.90 MSK test for checking the evidence of a cis-acting effect with the 
transcribed SNP rs2077647). 
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Figure  5-21: Effect of genotype at rs1038304 on allelic expression ratio of 
transcribed ESR SNP rs2077647 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2077647 for each individual: the data are grouped into homozygous risk (G:G), 
heterozygous  (A:G) or homozygous wild type (A:A) of the risk SNP rs1038304. The genomic 
DNA sample mean was used as a normalization control. (A) The blood sample genotype of 
SNP rs1038304 for the transcribed SNP rs2077647 (µcis=0.045, P-value=0.45 for the 
comparison with genomic DNA between different genotypes of rs1038304). (B) The 
osteoclast sample genotype of SNP rs1038304 for the transcribed SNP rs2077647 (µcis=0.15, 
P-value=0.53 MSK test for checking the evidence of a cis-acting effect with the transcribed 
SNP rs2077647). 
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Figure  5-22: Effect of genotype at rs2941740 on allelic expression ratio of 
transcribed ESR SNP rs2077647 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2077647 for each individual: the data are grouped into homozygous risk (G:G), 
heterozygous  (A:G) or homozygous wild type (A:A) of the risk SNP rs2941740. The genomic 
DNA sample mean was used as a normalization control. (A) The blood sample genotype of 
SNP rs2941740 for the transcribed SNP rs2077647 (µcis=-0.12, P-value=0.02 for the 
comparison with genomic DNA between different genotypes of rs2941740). (B) The 
osteoclast sample genotype of SNP rs2941740 for the transcribed SNP rs2077647 (µcis=-
0.05, P-value=0.69 MSK test for checking the evidence of a cis-acting effect with the 
transcribed SNP rs2077647). 
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Figure  5-23: Effect of genotype at rs6929137 on allelic expression ratio of 
transcribed ESR SNP rs2077647 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2077647 for each individual: the data are grouped into homozygous risk (A:A), 
heterozygous  (A:G) or homozygous wild type (G:G) of the risk SNP rs6929137. The genomic 
DNA sample mean was used as a normalization control. (A) The blood sample genotype of 
SNP rs6929137 for the transcribed SNP rs2077647 (µcis=-0.07, P-value=0.18 for the 
comparison with genomic DNA between different genotypes of rs6929137). (B) The 
osteoclast sample genotype of SNP rs6929137 for the transcribed SNP rs2077647 (µcis=0.06, 
P-value=0.60 MSK test for checking the evidence of a cis-acting effect with the transcribed 
SNP rs2077647). 
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Figure  5-24: Effect of genotype at rs6469804 on allelic expression ratio of 
transcribed OPG SNP rs2073618 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2073618 for each individual: the data are grouped into homozygous risk (A:A) and 
heterozygous  (G:A) of the risk SNP rs6469804. The genomic DNA sample mean was used as 
a normalization control. (A) The blood sample genotype of SNP rs6469804 for the 
transcribed SNP rs2073618 (µcis =0.01, P-value=0.61 for the comparison with genomic DNA 
between different genotypes of rs6469804). (B) The osteoclast sample genotype of SNP 
rs6469804 for the transcribed SNP rs2073618 (µcis =0.03, P-value=0.54 MSK test for 
checking the evidence of a cis-acting effect with the transcribed SNP rs2073618). 
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Figure  5-25: Effect of genotype at rs4355801 on allelic expression ratio of 
transcribed OPG SNP rs2073618 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2073618 for each individual: the data are grouped into homozygous risk (AA), 
heterozygous (G:A) and homozygous wild type (G:G) of the risk SNP rs4355801for blood 
samples and all except homozygous risk (AA) for osteoclast cells. The genomic DNA sample 
mean was used as a normalization control. (A) The blood sample genotype of SNP rs4355801 
for the transcribed SNP rs2073618 (µcis =0.00, P-value=0.98 for the comparison with 
genomic DNA between different genotypes of rs4355801). (B) The osteoclast sample 
genotype of SNP rs4355801 for the transcribed SNP rs2073618 (µcis =0.07, P-value=0.02 
MSK test for checking the evidence of a cis-acting effect with the transcribed SNP 
rs2073618). 
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Figure  5-26: Effect of genotype at rs2062375 on allelic expression ratio of 
transcribed OPG SNP rs2073618 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2073618 for each individual: the data are grouped into homozygous risk (G:G) and 
heterozygous (G:C) of the risk SNP 2062375 for blood samples and just heterozygous (GC) 
for osteoclast cells. The genomic DNA sample mean was used as a normalization control. (A) 
The blood sample genotype of SNP rs2062375 for the transcribed SNP rs2073618 (µcis=0.00, 
P-value=0.96 for the comparison with genomic DNA between different genotypes of 
rs2062375). (B) The osteoclast sample genotype of SNP rs2062375 for the transcribed SNP 
rs2073618 (µcis=0.06, P-value=0.05 MSK test for checking the evidence of a cis-acting effect 
with the transcribed SNP rs2073618). 
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Figure  5-27:Effect of genotype at rs2062377 on allelic expression ratio of 
transcribed OPG SNP rs2073618 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2073618 for each individual: the data are grouped into heterozygous (A: T) and 
homozygous wild type (A:A) of the risk SNP rs2062377. The genomic DNA sample mean was 
used as a normalization control. (A) The blood sample genotype of SNP rs2062377 for the 
transcribed SNP rs2073618 (µcis=0.01, P-value=0.60 for the comparison with genomic DNA 
between different genotypes of rs2062377). (B) The osteoclast sample genotype of SNP 
rs2062377 for the transcribed SNP rs2073618 (µcis=0.02, P-value=0.61 MSK test for 
checking the evidence of a cis-acting effect with the transcribed SNP rs2073618). 
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Figure  5-28:Effect of genotype at rs11995824 on allelic expression ratio of 
transcribed OPG SNP rs2073618 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs2073618 for each individual: the data are grouped into homozygous risk (G: G) and 
heterozygous (G: C) of the risk SNP rs11995824. The genomic DNA sample mean was used 
as a normalization control. (A) The blood sample genotype of SNP rs11995824 for the 
transcribed SNP rs2073618 (µcis=0.01, P-value=0.60 for the comparison with genomic DNA 
between different genotypes of rs11995824). (B) The osteoclast sample genotype of SNP 
rs11995824 for the transcribed SNP rs2073618 (µcis=0.02, P-value=0.61 MSK test for 
checking the evidence of a cis-acting effect with the transcribed SNP rs2073618). 
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Figure  5-29: Effect of genotype at rs884205 on allelic expression ratio of 
transcribed RANK SNP rs1805034 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs1805034 for each individual: the data are grouped into homozygous risk (A:A) and 
heterozygous (A:C) and homozygous wild type (C:C) of the risk SNP rs884205for blood 
samples and all except homozygous risk (A:A) for osteoclast cells. Genomic DNA was used 
as a normalization control. (A) The blood sample genotype of SNP rs884205 for the 
transcribed SNP rs1805034 (µcis =0.00, P-value=0.95 for the comparison with genomic DNA 
between different genotypes of rs884205). (B) The osteoclast sample genotype of SNP 
rs884205 for the transcribed SNP rs1805034 (µcis =0.06, P-value=0.1495 MSK test for 
checking the evidence of a cis-acting effect with the transcribed SNP rs1805034).  
A 
 
 
A
: A
 (
1
)
A
: C
 (
1
3
)
C
: C
( 3
1
)
G
 D
N
A
( 2
1
)
- 0 . 4
- 0 . 2
0 . 0
0 . 2
0 . 4
B l o o d  t r a n s c r i b e d  s n p  1 8 0 5 0 3 4
R s 8 8 4 2 0 5
E
x
p
r
e
s
s
io
n
 r
a
t
io
A
: C
 (
5
)
C
: C
 (
1
1
)
G
 D
N
A
 (
2
1
)
- 0 . 2
- 0 . 1
0 . 0
0 . 1
0 . 2
O s t e o c l a s t  S N P  1 8 0 5 0 3 4
R s 8 8 4 2 0 5
E
x
p
r
e
s
s
io
n
 r
a
t
io
B 
 
 
208 | Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-30: Effect of genotype at rs3018362 on allelic expression ratio of 
transcribed RANK SNP rs1805034 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs1805034 for each individual: the data are grouped into homozygous risk (A:A), 
heterozygous  (G:A) or homozygous wild type (G:G) of the risk SNP rs3018362. The genomic 
DNA sample mean was used as a normalization control. (A) The blood sample genotype of 
SNP rs3018362 for the transcribed SNP rs1805034 (µcis ==0.001, P-value=0.94 for the 
comparison with genomic DNA between different genotypes of rs3018362). (B) The 
osteoclast sample genotype of SNP rs3018362 for the transcribed SNP rs1805034 (µcis 
=0.06, P-value=0.02 MSK test for checking the evidence of a cis-acting effect with the 
transcribed SNP rs1805034). 
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Figure  5-31: Effect of genotype at rs228570 on allelic expression ratio of 
transcribed VDR SNP rs731236 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs731236 for each individual: the data are grouped into homozygous risk (C:C) and 
heterozygous  (A:C) of the risk SNP rs228570. The genomic DNA sample mean was used as a 
normalization control. (A) The blood sample genotype of SNP rs228570 for the transcribed 
SNP rs731236 (µcis=0.06, P-value=0.28 for the comparison with genomic DNA between 
different genotypes of rs228570). (B) The osteoclast sample genotype of SNP rs228570 for 
the transcribed SNP rs731236 (µcis=.01, P-value=0.37 MSK test for checking the evidence of 
a cis-acting effect with the transcribed SNP rs731236). 
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Figure  5-32: Effect of genotype at rs731236 on allelic expression ratio of 
transcribed VDR SNP rs731236 
Each point of the graph is representative of the allelic expression ratio for the transcribed 
SNP rs731236 for each individual. Transcribed and risk SNPs are same and data of 
heterozygous (C: T) samples have been shown. The genomic DNA sample mean was used as 
a normalization control. (A) the blood sample genotype of SNP rs731236 for the transcribed 
SNP rs731236 (µcis=0.12, P-value=1.8e
-08
) for the comparison with genomic DNA between 
different genotypes of rs731236). (B) The osteoclast sample genotype of SNP rs731236 for 
the transcribed SNP rs731236 (µcis=0.18, P-value=0.002 MSK test for checking the evidence 
of a cis-acting effect with the transcribed SNP rs731236). 
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5.4 Discussion  
 
In the previous chapter our data suggested that polymorphisms which have an effect on the 
variation of bone mass and diseases such as osteoporosis may also contribute to osteoclast 
function. GWA studies now commonly use SNP maps and this method has revolutionised the 
mapping of common genetic loci. As a result of these mapping methods, the susceptibility to 
a wide range of common, multifactorial disorders can now be determined (Wellcome Trust 
Case Control 2007). Current evidence suggests that few of the causal loci within the genome 
consist of variants which directly affect the protein amino-acid sequence. Whereas coding 
variants are rare, regulatory SNPs appear to be common (Heap, Yang et al. 2010). 
Variation in gene expression can result from alterations in the sequence of regulatory 
elements including SNPs, and recent reports indicate that this phenomenon is widespread 
throughout the genome and tissues (Cheung, Conlin et al. 2003) (Morley, Molony et al. 
2004). These alterations could explain up to 25-35% of the inter-individual variations 
between allelic gene expression (Pastinen and Hudson 2004). Hence identification and 
characterisation of AEI can aid in understanding the level of regulatory variation that is 
functionally important. Identifying candidate SNPs with variations in allelic expression may 
provide a means to determine significant links between genetic variation and complex traits, 
including osteoporosis (Palacios, Gazave et al. 2009).  
This chapter looked at initially selecting candidate samples to be used in the AEI study based 
on highest heterozygosity. Time and cost limitations are always a major limitation in 
independent genetic correlation studies outside of the GWAS and these problems were 
applicable within the present study. Careful selection of samples which had a high 
heterozygous genotype was essential for the present study, as expression imbalances of each 
allele could only be defined in individuals heterozygous for that allele. Correlations between 
risk SNPs and AEI of transcribed SNPs in the samples which were heterozygous for 
transcribed SNPs were then determined.  
The transcribed SNPs which had the highest heterozygosity were initially identified from the 
literature from previously studied populations for selected candidate genes. The transcribed 
SNPs associated with ESR1, OPG, LRP5, RANK, RANKL, P2RX7 and VDR candidate 
genes were identified as having the highest heterozygosity according to NCBI search 
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(Section 2.1). The selected transcribed SNPs for each candidate gene were determined as: 
ESR1-rs2077647, OPG-rs2073618, LRP5-556442, RANK-rs1805034, RANKL-rs9562415, 
P2RX7-rs208294, and VDR-rs731236. Genotyping of the 501 samples within the present 
study showed that our population was not highly heterozygous for RANKL-rs9562415. Out 
of the 501 samples, only 1% was heterozygous for RANKL-rs9562415 and therefore this 
SNP was unsuitable for the AEI study and was omitted. Genotyping for ESR1-rs2077647, 
OPG-rs556442, RANK-rs2073618, P2RX7-rs208294, LRP5-rs1805034 and VDR-rs731236 
showed that approximately 20% of our 501 sample population were heterozygous for at least 
four of these transcribed SNPs. 
Out of the 501 available volunteer samples that we had access to, a total number of 52 
subjects were selected, based on having the highest level of heterozygosity at each of the 
specified transcribed SNPs. We determined that the genotyping data obtained from 52 
candidates would be preliminarily sufficient to produce statistically viable results within the 
AEI study. These statistics were based on computing the effective sample size and statistical 
power using sample size tables for clinical studies software. 
We also showed the expression of ESR1, LRP5, OPG, RANK, P2RX7 and VDR in the 
candidate blood samples and this was in line with findings in the literature, which have 
shown white blood cells express the latter genes (www.biogps.org). The expression of ESR1, 
LRP5, RANK, P2RX7 and VDR genes was also determined in osteoclast cultures with the 
exception of OPG. This was an expected result as OPG, which encodes the OPG protein, is 
mainly expressed by osteoblast cells rather than osteoclast cells (www.biogps.org). The 
integrity of the cDNA samples determined using quantification of GAPDH expression 
showed that our cDNA isolated from candidate samples was viable to perform further gene 
expression analysis. These validator experiments of determining expression of the genes of 
interest and ensuring that the cDNA samples were viable in our candidate samples were 
essential for performing AEI analysis.  
Allele specific expression is used to compare the expression of the two alleles in the same 
individual as an alternative method to the mapping of regulatory variants. For this approach 
the gene under study should be polymorphisms in the transcript, such as SNPs. The relative 
expression of the two alleles is quantified by using these polymorphisms in heterozygous 
individuals. The expression of the gene is under cis-regulation when the expression of the 
alleles is not equal (allelic imbalance). As both allele expression are measured in the context 
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of the same genetic (e.g. trans-acting effects) technical, and environmental factors relative 
abundance of allele specific transcript will reflect cis-acting effects only (Campino, Forton et 
al. 2008) 
Following the selection of the 52 individuals with the heterozygosity, correlation analysis 
was performed between heterozygous transcribed SNPs and risk SNPs. Analysis for each 
heterozygous transcribed SNP determined the number of risk SNPs which were homozygous 
(risk or wild) and which were heterozygous. These results were particularly important as they 
could determine any associations between risk SNPs and transcribed SNPs following AEI 
analysis. Correlation between risk SNPs and transcribed SNPs in OPG, LRP5, and VDR 
showed the majority of samples heterozygous for selected risk SNPs were heterozygous for 
selected transcribed SNPs.  
In order to study AEI across our sample population we performed a study in which 
genotyping was coupled with an analysis of allele-specific gene expression by screening four 
transcribed SNPs to identify differential allelic expression using Sequenom technology. The 
cDNA isolated from osteoclast and blood tissue was synthesised one base pair at a time and 
Sequenom was used to determine which specific base had been added at each individual step 
of the sequencing procedure. Therefore we hypothesise that the association between 
candidate risk SNPs on non-coding DNA sequences and BMD is mediated through specific 
allelic imbalance expression of transcribed SNPs.  
As mentioned previously, sample size was the main limiting factor in this study. The sample 
size for detecting associations between disease and SNP markers is known to be highly 
affected by disease allele frequency, disease prevalence, effect size of the genetic variants 
(e.g., relative risk, odds ratio, etc.), and linkage disequilibrium (LD) (Pfeiffer and Gail 2003; 
Scherag, Muller et al. 2003). Previous studies have presented that a population-based design 
can be more powerful than a family-based study design in investigating genes influencing 
human complex traits (Risch and Teng 1998) as in our study, which was cohort study.  
In the next part of the population genetics study, LD was used to determine specific 
associations between SNPs associated with ESR1, OPG, LRP5, RANK, P2RX7 and VDR 
candidate genes. Of particular interest to this study were the LD values determined between 
risk and transcribed SNPs. A complete LD between risk and transcribed SNPs is indicative 
that there is a known phase between alleles of risk and transcribed SNPs. Here the parameter 
µcis can be estimated by a simple group comparison (simple t-test). However, when the phase 
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cannot be determined a specialist program is required which can estimate the phase of the 
haplotypes and estimate the µcis at the same time, as was the case in the present study, which 
used the MSK test. According to the LD results, a complete LD between transcribed SNPs 
rs545382 and risk SNPs599083 (D'=100) was present. In rs731236 of VDR gene, the risk and 
transcribed SNP are the same, resulting in perfect disequilibrium. For other risk and 
transcribed SNPs there were no phase between cis and transcribed alleles or it was unknown 
and MSK test was used for AEI analysis. 
Following on from the LD analysis, Sequenom technology was used to determine the allelic 
expression ratios for four transcript SNPs: rs2077647, rs2073618, rs1805034, and rs731236 
in 53 cDNA samples derived from blood and 16 cDNA obtained from osteoclast cultures. 
The allelic expression ratios for G, A, C and T were performed in quadruples. Here it was 
important to determine the SEM within the quadruple analysis data points for each individual 
so that the data obtained could be deemed reliable. Due to the sensitive nature of the 
Sequenom technology, small technical errors could potentially result in greater inter-
individual data variances. Sequenom analysis showed that for all OPG, ESR, RANK and 
VDR, the inter-individual variances represented by the SEM were within a statistically 
acceptable range of <0.15. In addition the outlier samples were removed from the set of data 
as these values often distort the distribution of allelic expression ratios.   
It is important to acknowledge that the LRP5 were excluded from the Sequenom analysis due 
to technical issues and the results of P2RX7 were not useable. The cDNA was extracted from 
subjects in Iran and, following transportation to the UK, quantified. Based on the Sequenom 
requirements, the cDNA concentration was sufficient for a total of quadruple replicates 
performed in the assay. After careful consideration it was decided that OPG, ESR, RANK, 
P2RX7 and VDR would be analysed for allelic imbalance expression and the LRP5 would be 
omitted from analysis. The reasoning for this omission was that the LRP5 required a new 
multiplexes assay. This was an added cost and it was decided to make the analyse in a 
separate study at a future date. The results from P2RX7 assay were not reliable, as data 
showed the primer was extending even when there was no DNA present (in the blanks and 
primer only samples). Therefore the results of P2RX7 were excluded from analysis: this gene 
was omitted from the current study, scheduled for re-analysed in a separate study at a future 
date with LRP5. 
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We would expect that allelic expression ratio between genomic DNA samples would be close 
to the log of 1 (expression ratio=0). Therefore any differences in expression ratio observed in 
blood or osteoclast samples compared to our genomic DNA control could potentially be an 
indication of allelic expression imbalances. To ensure that each expression ratio observed 
was a true value, expression ratios were matched and normalised to their corresponding 
genomic DNA controls. Our data showed that there were consistent inter-individual 
variations within the expression ratios of the four replications. There was also consistent 
variation between the allelic expression ratios for individuals within all three blood, 
osteoclast and genomic sample types. Interestingly, most of the expression ratios of ESR1-
rs2077647 in osteoclast culture and blood samples were below zero. In the VDR-rs731236 
the expression ratios were above zero. These data indicated that these two transcribed SNPs 
have a cis-acting effect. 
To assess further the cis-acting effect with the transcribed SNPs for ESR1, OPG, RANK and 
VDR genes, the expression ratios of the transcribed SNPs were determined for the various 
allelic genotypes for a specific risk SNP for each individual. The various genotypes included 
homozygous risk, heterozygous and homozygous wild type. The study examined the 
association of risk variants of low BMD with allelic expression of transcribed SNP 2077647 
of ESR gene. From the present study, there was evidence of a cis-acting effect with the 
transcribed SNP 2077647 of ESR. One statistically significant cis-acting effect was seen for 
risk SNP rs2504063 in both blood and osteoclast cDNA and statistically significant 
association was observed for risk SNP rs2941740 in the blood sample only. Cis-acting effects 
were also seen for both risk SNPs rs4355801 and rs2062375 in osteoclast cDNA with the 
transcribed SNP rs2073618 of OPG. There was evidence of a cis-acting effect for risk SNP 
rs3018362 in osteoclast cells with the transcribed SNP rs1805034 of RANK.   
There was evidence of a cis-acting effect associated with the transcribed SNP rs731236 of the 
VDR. Interestingly this cis-acting effect was observed for the risk SNPs rs731236, which is 
also a transcribed SNP. From this data there is compelling evidence for a correlation between 
the BMD-associated SNP rs731236 and AEI of VDR candidate gene in both blood and 
osteoclast samples. Allelic imbalance expression of rs731236 was also shown by Grundberg 
et al in 2007. They investigated the function of the VDR 3` haplotypes by studying allelic 
imbalance analysis of VDR transcripts in the normal chromosomal context of 70 unrelated 
human trabecular bone samples. This was performed by the quantitative genotyping of 
coding polymorphisms in RNA samples and in corresponding DNA samples. Both were 
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sequenced in parallel from the trabecular bone samples. Grundberg et al also showed that 
over-expression of VDR baT haplotype could be considered as a risk allele for osteoporosis. 
One of the SNPs in the 3` end of the VDR gene, which Grundberg et al defined as baT 
haplotype, is rs731236 (Grundberg, Lau et al. 2007). This is consistent with the present study 
which showed cis acting effect with rs731236. There is no other paper which investigates cis 
acting effect of osteoporotic risk SNPs. One of the most important goals of genetics is to 
identify (cis-) regulatory elements for gene expression and heritable variation of them, 
especially those that impact clinical phenotypes and common diseases (Sun, Southard et al. 
2010). In fact AEI, seems to be an important factor in the variation of human phenotypic and 
as a consequence, for the development of complex traits and common diseases (Palacios, 
Gazave et al. 2009). 
This study examined the association of risk variants with expression of ESR1, RANK, OPG 
and VDR genes in both blood samples and osteoclast culture. Allelic imbalance expression in 
osteoclast cells as an important cell in osteoporosis was not previously investigated, and this 
study showed cis-acting effect in osteoclast cells for the first time. Such in vitro studies have 
limitations, especially in osteoclast cultures, first results depend on the methods and material 
that are used. Second expression is investigated outside of the normal body context, which 
may not show the same expression as in complex tissues in vivo (Pastinen and Hudson 2004; 
Cirulli and Goldstein 2007). Allelic expression analysis in blood samples allows in vivo 
assessment of RNA transcripts in their regulatory context and native environment, which has 
higher sensitivity to detect cis-acting effects. Expression could be tested in other cells, which 
are potentially relevant to BMD regulation. However, many cis-acting effects on gene 
expression are predicted to be the same in various cell types (Mahr, Burmester et al. 2006). 
This study analysed the SNPs influencing expression in IMOS-D cohort of Iranian population 
for the first time. Although this cohort is of mixed ethnicity, the SNPs associated with 
expression may vary in other populations due to differing LD patterns and allele frequencies 
(Goddard, Hopkins et al. 2000). Further studies will be necessary to consider the association 
of other SNPs at present and other candidate genes associated with BMD in Iranian and other 
populations. 
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Chapter 6 – General discussion 
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Summary and Discussion  
 
Genetic variation plays an important role in osteoporosis by reducing bone mass and 
increasing the risk of fragility fractures. Many different genetic variants contribute to the 
regulation of BMD and other determinants of fracture risk, including ultrasound properties of 
bone, skeletal geometry, and bone turnover. It is becoming increasingly obvious that most 
common traits are influenced by large numbers of distinct loci that individually have small 
effects. It is now known that the majority of complex trait alleles regulate gene expression by 
modulating transcription or affecting the stability of the transcript (Ralston 2010; Li, Hou et 
al. 2010). 
 
Over the past ten years, there has been extensive progress in identifying links between 
genetics and osteoporosis on an international level, particularly following numerous GWAS. 
However, the Iranian population has been studied less than some other populations for 
effective genetic variants in osteoporosis. Due to population differences in allele frequency, 
the Iranian population may have different relative risk factors than other populations causing 
different results. There is little known in relation to the effect of genetic variants in the 
function of osteoclast cells and especially the effect of risk-acting factors on the transcribed 
SNPs in osteoclast cells. The present study investigated the effect of specific genetic variants 
in the BMD and functions of osteoclast cells of the Iranian population. This study went on to 
investigate the effect of risk-acting factors on the transcribed SNPs in osteoclast cultures and 
peripheral blood within our population.  
 
To develop pharmaceutical agents that arrest the progression of osteoporosis, it is essential to 
determine the mechanism by which osteoclasts are formed and how they destroy bone. In the 
past years there has been great progress in understanding the molecular mechanisms involved 
in osteoclastogenesis. Interestingly this understanding has come mainly from results of 
genetic studies of abnormal bone phenotypes in animal models and humans. From these 
genetic observations there is an array of new osteoporosis therapies for both prevention and 
treatment of osteoporosis (Teitelbaum and Ross 2003). One way to study the function of 
genes in osteoporosis is to focus on the osteoclast cell itself with regard to its central role in 
the pathogenesis of osteoporosis (Teitelbaum and Ross 2003). 
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GWASs have successfully detected associations between hundreds of common SNPs and 
complex traits in humans (Altshuler, Daly et al. 2008; Stranger, Stahl et al. 2011). While this 
gene catalogue has uncovered important biological insights, the discovered associations are 
known to be dependent on variations in sex, age and BMI (Johnson et al. 2009; Shen et al. 
2005). This corresponds to the differences seen between findings in genetic association 
studies. In the present study the descriptive analysis, which included age, sex, and BMI, of 
the subjects from our Iranian population cohort, was comparable to those observed in other 
similar studies using Iranian populations (Bahrami, Sadatsafavi et al. 2006). Similarly the 
BMD trends of our Iranian population samples showing a high male BMD compared to 
females was consistent with other BMD data obtained from other Iranian (Larijani, Moayyeri 
et al. 2006; Omrani et al 2006), European (Styrkarsdottir, Halldorsson et al. 2010) and 
American groups (Mazess and Barden 1999). Taken together, our randomly selected subjects 
showed similarities to other populations in their descriptive factors data, thus increasing the 
viability of future genetic association studies.  
 
In the first part of the study, using a random selection of subjects from an Iranian population, 
we looked at whether the BMD used here as the most common predictor of osteoporosis bone 
disease was associated with a selection of candidate genes previously associated with BMD. 
A thorough review of osteoporosis susceptibility loci via large-scale association studies, 
meta-analyses and GWAS of SNPs revealed 15 BMD genes linked to osteoporosis (Li, Hou 
et al. 2010). In the present study, LRP5, RANK, RANKL, P2RX7, ESR1, OPG and VDR 
genes were selected due to their important roles in oestrogen endocrine signalling, Wnt/β-
catenin signalling, RANKL/RANK/OPG pathway, and the vitamin D synthesis pathway (Li, 
Hou et al. 2010).  
There is a lack of data demonstrating the effect of genetic variants in osteoporosis-associated 
LRP5, RANK, RANKL, P2RX7, ESR1, OPG and VDR genes in the Iranian population. We 
sought to identify the most highly associated SNPs for the osteoporosis-associated LRP5, 
RANK, RANKL, P2RX7, ESR1, OPG and VDR genes to perform genotyping and 
hypothesised that there are genomic associations between specific SNPs and BMD within the 
Iranian population. Using genotyping specific and allele specific analysis in the present study, 
genetic associations were determined between BMD and 37 selected candidate SNPs.  From 
these associations 10 SNPs were significantly associated with BMD (P<0.05), thus 
suggesting there is evidence of links with this set of genetic loci in the Iranian sample.  
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For the RANK gene the present study showed that SNP rs884205 was associated with total 
hip BMD: the same association was observed in studies by Styrkarsdottir et al within a 
European and East Asian population (Estrada, Styrkarsdottir et al 2012; Rivadenier, 
Styrkarsdottir et al 2009). The present study further showed that RANK SNPs rs9594738 and 
rs9594759 were also linked closely to spine BMD, similar to studies by Duncan et al and 
Styrkarsdottir et al in the European population (Duncan, Danoy et al 2001; Styrkarsdottir, 
Halldorsson et al 2008). The OPG SNP rs2073618, rs1995824 and rs4355801 associations 
with spine BMD determined in the present study were also observed in other studies specific 
to spine and hip BMD in post/pre-menopausal women and the European population 
respectively (Mencej-Bedrač, Preželj et al. 2011; (Shang, Lin et al. 2013).  
The ESR1 SNP 2077647 associated with spine BMD in the present study was also associated 
with post-menopausal osteoporosis in Japanese women in a recent study (Sonoda, Takada et 
al 2012). LRP5 SNP rs2306862 was associated with BMD in men and women in the present 
study as well as in a larger study carried out by Kiel et al. Interestingly, where we observed 
an association with spine BMD, and the Kiel study showed an association of rs2306862 with 
femoral neck BMD in men only. Although there are few data on P2RX7, one study did 
correlate with ours in that SNP rs3751143 was associated with BMD in a similar number of 
subjects (Wesselius, Bours et al. 2013). From our data we infer that BMD is genetically 
dependent, and these findings correlated with the literature (Arden, Baker et al. 1996). 
In the second part of the study we predicted that there are genomic associations between 
specific SNPs and osteoclast function within our Iranian population sample. Polymorphisms 
affecting osteoclast activity could potentially be linked to osteoporosis. The 
RANKL/RANK/OPG axis is now recognised as the pivotal regulator of osteoclastogenesis, 
and mutations in the RANK, OPG, and RANKL genes cause osteoporosis (Kobayashi, 
Udagawa et al. 2009). Increased osteoclastic bone resorption and increased bone resorption 
markers have been linked to osteoporosis characterised by low skeletal BMD (Gough, 
Sambrook et al. 1998).  However, there are limited data on the genetic associations of 
osteoclast function and BMD or RANK, RANKL and OPG associated SNPs, particularly in 
the Iranian population.  
The in vitro assessment of osteoclast number, resorption activity and apoptosis rates allowed 
investigation of the relationship between genetic variants and osteoclast function (Gartland, 
Buckley et al. 2003; Chan, Gartland et al. 2007). The effective culturing of human osteoclasts 
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in vitro is technically demanding: our group has invested in optimising the method for 
primary osteoclast isolation and culture from human peripheral blood (Agrawal, Gallagher et 
al. 2012). In the present study we were able to characterise osteoclasts and quantify the 
resorption activity of osteoclasts in agreement with the literature (Schilling, Linhart et al. 
2004, Kreja, Liedert et al. 2007).  
Based on this optimised osteoclast model we were able to determine the osteoclast number 
and active resorption state of the cultures isolated from the sample group, and assess genetic 
associations between osteoclast function and the specific SNPs. Finally we sought to 
determine potential genetic links between the osteoclast genes, associated polymorphisms, 
and BMD. A single osteoclast culture could be performed to fulfil a dual purpose of 
functionally characterising the osteoclast cells in vitro and determining allelic imbalance 
expression. The limitations for this part of the study were the high cost of material for culture 
in remote sites, and the need for the large blood volume sample required from each subject. 
Within our project budget, approximately 16 cultures were affordable in a twelve months 
period in Iran.  
Osteoclast functional studies showed that at least 30% of all the osteoclasts obtained from our 
human donors were actively resorbing. The individuals classified as having osteoporosis in 
L2-L4 also had increased osteoclast number and resorption activity compared to normal 
individuals. Of particular interest is that our findings suggest that the associations observed 
with osteoclastogenesis and BMD appear to be specific to low L2-L4 BMD. These findings 
are consistent with other studies that demonstrate that genetic associations with BMD are 
bone site dependent (Tran, Nguyen et al. 2008). One limitation of most BMD GWASs is that 
subjects are usually postmenopausal women and elderly men (Paternoster, Ohlsson et al. 
2010), meaning that the genetic effects reported could actually be related to age-related bone 
loss or to the control of peak bone gain in early life. It could be reasoned that genetic 
variation in the regulatory RANK/RANKL/OPG mechanisms involved in osteoclastogenesis 
may influence the rate of bone loss in older subjects.  
Identifying the risk SNPs associated with osteoclastogenesis regulators RANK, RANKL and 
OPG enabled the identification of related gene polymorphisms (Kikuchi, Matsuguchi et al. 
2001). Genotyping and osteoclast function assays showed that RANK polymorphisms had a 
significant genetic association with osteoclast number. An increase in the number of 
osteoclast number was linked to heterozygous alleles of RANK rs884205 and rs30183625 
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SNPs compared to homozygous wild type allele. There were no genetic associations between 
osteoclast number/function and OPG or RANKL SNPs.  
The osteoclast number and activity was lower in individuals with low L2-L4 BMD but not 
total hip BMD. Again, it is particularly interesting that out of the 16 individuals selected on 
the basis of strongest genetic heterozygosity from our study cohort, >70% were either 
osteopenic or osteoporotic. Taken together, these findings suggest that there may be genetic 
associations between specific RANK/RANKL polymorphisms and osteoclast number and 
function. 
In the final part of the present study, transcribed SNPs and risk-acting SNPs associated with 
the LRP5, RANK, P2RX7, ESR1, OPG and VDR candidate genes were identified. Samples 
from each subject were genotyped according to the percentage of heterozygosity of the 
defined transcribed SNPs within our population. This study facilitated the investigation of the 
risk-variant in the transcribed SNP and was important as most of the variations contributing 
to disease susceptibility, especially in complex disease, may alter the expression rather than 
the function of proteins (Leonardson et al. 2004). Identifying candidate SNPs with variations 
in allelic expression may provide a means to determine an important link between individual 
genetic variation and complex traits including osteoporosis (Palacios, Gazave et al. 2009). 
Allele-specific expression was investigated by evaluation of cDNA from tissues expressing 
the genes of interest in the heterozygous individual (Marsh 2007), in both osteoclast culture 
and peripheral blood. The relative amount of transcript arising from each allele in 
heterozygous individuals was measured in this technique. Risk-acting effects on gene 
expression are shown by unequal amounts of transcript from each allele (Cunnington, Kay et 
al. 2009).  
The data from chapter 3 showed that both ESR1-rs2077647 and VDR-rs731236 were 
associated with BMD. Interestingly, AEI analysis of these genes also indicated that most of 
the expression ratios of transcribed SNPs ESR1-rs2077647 and VDR-rs731236 in osteoclast 
culture and blood samples had a cis-acting effect. The expression ratios of the transcribed 
SNPs were determined for the various allelic genotypes for a specific risk SNP for each 
individual. Statistically cis-acting effect was evident for risk SNPs rs2504063 and rs2941740 
on ESR1 and for risk SNP rs731236 on VDR. Cis-acting effects were also seen only in 
osteoclast cells for both risk SNPs rs4355801 and rs2062375 with OPG and for risk SNP 
rs3018362 with RANK.   
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Although several AEI studies have been conducted to date, according to our knowledge only 
one study has investigated AEI in osteoporosis. This AEI study has focused on one haplotype 
in the 3` end of the VDR gene (Grundberg, Lau et al. 2007). Grundberg et al showed over-
expression of VDR baT haplotype compared with other haplotypes in 70 unrelated human 
trabecular bone samples, and also showed that over-expression of VDR baT haplotype could 
be considered a risk allele for osteoporosis. One of the SNPs in the 3` end of the VDR gene, 
which Grundberg et al defined as baT haplotype, is rs731236 (Grundberg, Lau et al. 2007). 
Interestingly these findings are consistent with the present study, in which we showed cis 
acting effect with rs731236.  
The present study extends our understanding of the AEI in some important candidate genes in 
BMD. It was shown that there was a relationship between some risk variants and expression 
of ESR1, RANK, OPG and VDR genes. Identifying (cis-) regulatory elements for gene 
expression, especially those that impact clinical phenotypes and common diseases is one of 
the most important goals of genetics (Sun, Southard et al. 2010). In fact, one of the important 
factors in the variation of human phenotypes and, as a consequence, for the development of 
complex traits and common diseases is AEI (Palacios, Gazave et al. 2009).   
In the present study osteoclast cells were used for AEI for the first time. The AEI in 
osteoclasts, cells known for their functional importance in osteoporosis, has not been 
previously investigated. For the first time the findings from the present data provided 
evidence to suggest a cis-acting effect in osteoclast cells. Although such in vitro studies have 
limitations, the results and their interpretation primarily depend on the methods and material 
that are used, and also have to take into consideration that the expression outside of the 
normal body context may not necessarily reflect the same expression as in complex tissues in 
vivo (Pastinen and Hudson 2004; Cirulli and Goldstein 2007).  
An interesting approach employed in the current studies was the use of Iranian ancestry for 
association analyses. The Caucasian populations have primarily been studied for 
characterisation of genetic variation, such as SNPs and genomic sequence, and populations of 
European ancestry have been studied for most association studies performed to date 
(Manolio, Brooks et al. 2008). Investigation of diverse populations has the significant ability 
to develop the mapping of the genetic determinants of complex diseases for the whole human 
population. By investigating less studied populations it is possible to consider new findings 
that are perhaps of a higher prevalence in non-European populations, or establish the 
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generality of findings obtained initially in the European ancestry (Rosenberg, Huang et al. 
2010). 
Suggestions for Future Study: 
The key issue for determining statistically significant outcomes from any meta-analysis or 
genetic-association study is heavy reliance on the total number of subjects participating. In 
the present study there were issues in recruiting and obtaining enough samples from the 
donors. Resolving restricted factors, including the recruitment of human donors, would allow 
further for the selection of more subjects for osteoclast cultures. As a result it would be 
possible to increase the power of statistical tests to detect a theoretical difference less than 
0.8. This would mean that, based on more reliable results, a clinical outcome would be more 
likely. To build on the data for the present study, recruiting strategies would have to be 
improved, and the study extended nationally within Iran for both higher subject numbers and 
to obtain a better clinical reflection of the whole population.  
Bone is a dynamic tissue with interactions between osteoblasts, osteoclasts and osteocytes 
vital for its maintenance, and for responses to strain and stress. This study explores the effects 
of genetic variation on osteoclast bone cells in isolation, ignoring the regulatory effects that 
bone cells have on each other. This could be overcome to a certain extent by evaluating the 
changes in gene expression of several regulatory molecules in these cells (according to 
genetic variations) in the context of bone tissue (Raggatt and Partridge 2010). As discussed 
previously, osteoblast cells have a critical role in bone maintenance and remodelling 
(Crockett, Rogers et al. 2011). Consequently dysfunction of osteoblast cell activity can result 
in development and progression of osteoporosis. The present study has focused on building 
upon the knowledge we have of the genetic association between osteoporosis and osteoclast 
function, in particular with regard to the Iranian population. However, due to the coupling 
relationship between osteoclast and osteoblast cells, it is of equal importance to study also 
BMI-osteoporosis genetic associations in osteoblast cells, with a particular interest in 
exploring the AEI of candidate genes in osteoblast cells. 
As previously mentioned, the results from the P2RX7 assay were not reliable, as data showed 
the primers were extending even in the absence of DNA. As part of future study plans, these 
primers must be to re-designed and optimised prior to performing Seqeunom assay. Also 
LRP5, which was omitted from the Sequenom assay due to added cost, would be scheduled 
for re-analysis in a separate study at a future date alongside P2RX7.  
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This study analysed for the first time the SNPs influencing expression in an IMOS-D cohort 
of Iranian population. The SNPs associated with expression may vary in other populations 
due to differing allele frequencies and LD patterns (Goddard, Hopkins et al. 2000). Future 
studies will be necessary to investigate the SNPs influencing expression of selected candidate 
genes in other populations. This project provides an insight into the role of genetic variation 
in BMD and also analyses the SNPs influencing expression in the Iranian population. This 
study and other similar studies help to improve our knowledge about the role of genetic 
variation in osteoporosis, with the goal of providing a genetic profile that can be used for 
genetic screening tests for the identification of individuals at risk of osteoporosis (Wu, Guo et 
al. 2013). At the present time performance of genetic profiling tests is weak in complex 
diseases because associations between component SNPs and diseases are weak. Genetic 
profiling tests could be useful in screening. This would be after extending our knowledge in 
different populations to find either an extremely large panel of SNPs, each with a modest 
association with disease, or a few SNPs with very strong associations with disease 
(Simmonds 2011). A suitable genetic profiling test helps to find useful treatment. Novel 
pathways that contribute to control of BMD could be identified, improving our knowledge 
about the effect of genetic variation with the possibility of producing new therapeutic agents 
(Duncan and Brown 2008). 
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Appendix 
Primers of the selected SNPs to be used in pyrosequencing were optimised in different 
concentration of MgCl2 
To perform pyrosequencing, Dr Reynard kindly designed the primers specific to the 
candidate SNPs to be used subsequently in the AEI study (Table A.1). End-point PCR was 
performed to optimise these primers using Promega GoTaq® DNA polymerase, as outlined 
in the method section 2.9.2. Product with no cDNA templates were also used for detection of 
contamination in samples. The baseline PCR amplification reactions were pre-incubated at 
94°C for 2 minutes, followed by 34 cycles of denaturation at 94°C for 60 seconds, anneal at 
55°C for 30 seconds and extension at 72°C for 30 seconds. The PCR amplified products were 
visualised on an electrophoretic 2% agarose gel stained with ethidium bromide and product 
bands detected using the Gel Doc XR System and Quantity One Software as described in the 
method section 2.9.2.   
The optimized conditions for each primer were determined by visualising the amplified 
product under varying annealing temperatures and MgCl2 concentrations. As it is shown in 
the table A.1, different melting temperature (TM) and MgCl2 concentrations were checked 
for primers A to E to find the optimised state for performing end-point PCR. 
The optimised states for performing end-point PCR for primers of OPG and LRP5 were 
1.5Mm MgCl2 and 55°C TM. The optimised states for performing end-point PCR for primers 
VDR and ESR-Rs2077647 (F4, R4) of ESR1 were 2Mm MgCl2 and 58°C TM. The PCR 
amplified product of the Rs2077647 (F1, R1) primer of ESR1 optimised by using 2Mm 
MgCl2 and 55°C TM. Finally the optimised states for performing end-point PCR for 
P2RX7/SNP primers were 2.0mM MgCl2 and 55°C TM (Figure A.1-3 and Table A.1).  
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Figure A.1:  End-point PCR optimisation using 1.5Mm MgCl2 and 55°C TM 
 A1, B1, C1, and D1 were –ve control by water indicating no contamination in samples. Two 
bright bands were detected between 100 and 200 base pairs for primers C and D. The bands 
for primers A and B were not visible under the same PCR conditions. Both A and B are 
different primer for rs2077647.  
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Figure A.2: End point PCR optimisation using 2Mm MgCl2 and 58°C TM 
 Two bright bands were visible between 100 and 200 base pairs for primers B and E. The 
band using primer was not visible. A1, B1, and E1 were –ve control by water for DNA 
contamination. Both A and B are different primer for rs2077647. 
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Figure A.3:  End point PCR optimisation using 1.5Mm or 2.0mM MgCl2 and 55°C TM 
for P2RX7/SNP primers 
 F, G, H, and I represent bands optimised using 1.5mM MgCl2 and F2, G2, H2, and I2 using 
2mM MgCl2. Band representing PCR products appeared brighter using 2mM MgCl2. F1, 
G1, H1, and I1 were –ve control by water for DNA contamination. Both F and G are different 
primer for rs7958311.  
 
  
Candidate 
gene/SNP 
 
ID 
P2RX7  
Rs7958311  F 
Rs7958311  G 
Rs1718119  H 
Rs1718119  I 
230 | Appendix 
 
SNP ID Primer Tm 
(°C)  
𝐌𝐠𝟐+ 
(mM) 
Rs2077647 F1 A 5’-ACCATGACCCTCCACACCA-3’ 55 2.0mM 
Rs2077647 R1 A 5’-CTCCAG GGGGATCTTGAGCT-3’ 55 2.0mM 
Rs2077647 F4 B 5’-GGGGACACG GTCTGCACC-3’ 58 2.0mM 
Rs2077647 R4 B 5’-TTGAGCTGCGGACGGTTC-3’ 58 2.0mM 
Rs2073618 F1 C 5’-GAGCGCGCAGCACAG CAA-3’ 55 1.5mM 
Rs2073618 R1 C 5’-CTGTTG CCGGGACGCTAT-3’ 55 1.5mM 
Rs556442 F1 D 5’-CGAGCGCGAGGTCCTCTT-3’ 55 1.5mM 
Rs556442 R1 D 5’-CAATGCGCTTCAGGTCCG-3’ 55 1.5mM 
Rs731236 F1 E 5’-GGAAGGAGAGGCAGCGGT ACT-3’ 58 2.0mM 
Rs731236 r1 E 5’-TCCTGG GGTGCAGGACGC-3’ 58 2.0mM 
Rs7958311 F1 F 5’-ACTGGGACTGCAACCTAGACCG-3’ 55 2.0mM 
Rs7958311 R1 F 5’-TAGCCAGGGTACAAGGACACGT-3’ 55 2.0mM 
Rs7958311 F14 G 5’-ATCTACTGGGACTGCAACCTAGAC-3’ 55 2.0mM 
Rs1718119 F1 H 5’-TTTGGAGAAGGAAGTGACTAACG-3’ 55 2.0mM 
Rs1718119 R1 H 5’-ATGGGAGCGACAGCAGTTACT-3’ 55 2.0mM 
Rs1718119 F2 I 5’-GTTTGGAGAAGGAAGTGACTAACG-3’ 55 2.0mM 
Rs1718119 R2 I 5’-ATATGGGAGCGACAGCAGTTAC-3’ 55 2.0mM 
 
 
Table A.1:  Optimization states for primers A-I 
The optimized conditions for each primer including annealing temperature (TM) and MgCl2 
concentration (mM) are summarized.  
 
 
 
 
231 | Bibliography 
 
 
Bibliography 
 
Agrawal, A., K. A. Buckley, et al. (2010). "The effects of P2X7 receptor antagonists 
on the formation and function of human osteoclasts in vitro." Purinergic Signal 
6(3): 307-315. 
Agrawal, A., J. A. Gallagher, et al. (2012). "Human osteoclast culture and phenotypic 
characterization." Methods Mol Biol 806: 357-375. 
Altshuler, D., M. J. Daly, et al. (2008). "Genetic mapping in human disease." Science 
322(5903): 881-888. 
Arai, H., K. I. Miyamoto, et al. (2001). "The polymorphism in the caudal-related 
homeodomain protein Cdx-2 binding element in the human vitamin D receptor 
gene." J Bone Miner Res 16(7): 1256-1264. 
Arden, N. K., J. Baker, et al. (1996). "The heritability of bone mineral density, 
ultrasound of the calcaneus and hip axis length: a study of postmenopausal 
twins." J Bone Miner Res 11(4): 530-534. 
Arko, B., J. Prezelj, et al. (2005). "Association of the osteoprotegerin gene 
polymorphisms with bone mineral density in postmenopausal women." 
Maturitas 51(3): 270-279. 
Bachrach, L. K. (2001). "Acquisition of optimal bone mass in childhood and 
adolescence." Trends Endocrinol Metab 12(1): 22-28. 
Bahrami, H., M. Sadatsafavi, et al. (2006). "Obesity and hypertension in an Iranian 
cohort study; Iranian women experience higher rates of obesity and 
hypertension than American women." BMC Public Health 6: 158. 
Barrett, J. C., B. Fry, et al. (2005). "Haploview: analysis and visualization of LD and 
haplotype maps." Bioinformatics 21(2): 263-265. 
Boyle, W. J., W. S. Simonet, et al. (2003). "Osteoclast differentiation and activation." 
Nature 423(6937): 337-342. 
Bush, W. S. and J. H. Moore (2012). "Chapter 11: Genome-wide association 
studies." PLoS Comput Biol 8(12): e1002822. 
Campino, S., J. Forton, et al. (2008). "Validating discovered Cis-acting regulatory 
genetic variants: application of an allele specific expression approach to 
HapMap populations." PLoS One 3(12): e4105. 
Canalis, E. (2013). "Wnt signalling in osteoporosis: mechanisms and novel 
therapeutic approaches." Nat Rev Endocrinol 9(10): 575-583. 
Chan, B. Y., A. Gartland, et al. (2007). "PPAR agonists modulate human osteoclast 
formation and activity in vitro." Bone 40(1): 149-159. 
Cheung, C. L., S. M. Xiao, et al. (2010). "Genetic epidemiology of age-related 
osteoporosis and its clinical applications." Nat Rev Rheumatol 6(9): 507-517. 
Cheung, V. G., L. K. Conlin, et al. (2003). "Natural variation in human gene 
expression assessed in lymphoblastoid cells." Nat Genet 33(3): 422-425. 
Cheung, V. G., R. S. Spielman, et al. (2005). "Mapping determinants of human gene 
expression by regional and genome-wide association." Nature 437(7063): 
1365-1369. 
Choi, J. Y., C. S. Shin, et al. (2006). "Single-nucleotide polymorphisms and 
haplotypes of bone morphogenetic protein genes and peripheral bone mineral 
density in young Korean men and women." Calcif Tissue Int 78(4): 203-211. 
232 | Bibliography 
 
Christakos, S., M. Hewison, et al. (2013). "Vitamin D: beyond bone." Ann N Y Acad 
Sci 1287: 45-58. 
Cirulli, E. T. and D. B. Goldstein (2007). "In vitro assays fail to predict in vivo effects 
of regulatory polymorphisms." Hum Mol Genet 16(16): 1931-1939. 
Clark, S. (2002). "Osteoporosis--the disease of the 21st century?" Lancet 359(9319): 
1714. 
Cole, Z. A., E. M. Dennison, et al. (2008). "Osteoporosis epidemiology update." Curr 
Rheumatol Rep 10(2): 92-96. 
Constancia, M., B. Pickard, et al. (1998). "Imprinting mechanisms." Genome Res 
8(9): 881-900. 
Cowles, C. R., J. N. Hirschhorn, et al. (2002). "Detection of regulatory variation in 
mouse genes." Nat Genet 32(3): 432-437. 
Crockett, J. C., M. J. Rogers, et al. (2011). "Bone remodelling at a glance." J Cell Sci 
124(Pt 7): 991-998. 
Cummings, S. R., M. C. Nevitt, et al. (1995). "Risk factors for hip fracture in white 
women. Study of Osteoporotic Fractures Research Group." N Engl J Med 
332(12): 767-773. 
Delaisse, J. M. (2014). "The reversal phase of the bone-remodeling cycle: cellular 
prerequisites for coupling resorption and formation." Bonekey Rep 3: 561. 
Dewan, A., M. Liu, et al. (2006). "HTRA1 promoter polymorphism in wet age-related 
macular degeneration." Science 314(5801): 989-992. 
Dhanwal, D. K., E. M. Dennison, et al. (2011). "Epidemiology of hip fracture: 
Worldwide geographic variation." Indian J Orthop 45(1): 15-22. 
Dixon, A. L., L. Liang, et al. (2007). "A genome-wide association study of global gene 
expression." Nat Genet 39(10): 1202-1207. 
Ducy, P., T. Schinke, et al. (2000). "The osteoblast: a sophisticated fibroblast under 
central surveillance." Science 289(5484): 1501-1504. 
Duncan, E. L. and M. A. Brown (2008). "Genetic studies in osteoporosis--the end of 
the beginning." Arthritis Res Ther 10(5): 214. 
Duncan, E. L., P. Danoy, et al. (2011). "Genome-wide association study using 
extreme truncate selection identifies novel genes affecting bone mineral 
density and fracture risk." PLoS Genet 7(4): e1001372. 
Enard, W., P. Khaitovich, et al. (2002). "Intra- and interspecific variation in primate 
gene expression patterns." Science 296(5566): 340-343. 
Estrada, K., U. Styrkarsdottir, et al. (2012). "Genome-wide meta-analysis identifies 
56 bone mineral density loci and reveals 14 loci associated with risk of 
fracture." Nat Genet 44(5): 491-501. 
Everts, V., J. M. Delaissé, et al. (2002). "The bone lining cell: its role in cleaning 
Howship's lacunae and initiating bone formation." J Bone Miner Res 17(1): 
77-90. 
Fang, Y., F. Rivadeneira, et al. (2006). "Vitamin D receptor gene BsmI and TaqI 
polymorphisms and fracture risk: A meta-analysis." Bone 39(4): 938-945. 
Fang, Y., J. B. van Meurs, et al. (2003). "Cdx-2 polymorphism in the promoter region 
of the human vitamin D receptor gene determines susceptibility to fracture in 
the elderly." J Bone Miner Res 18(9): 1632-1641. 
Fang, Y., J. B. van Meurs, et al. (2005). "Promoter and 3'-untranslated-region 
haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: 
the rotterdam study." Am J Hum Genet 77(5): 807-823. 
233 | Bibliography 
 
Farh, K. K., A. Grimson, et al. (2005). "The widespread impact of mammalian 
MicroRNAs on mRNA repression and evolution." Science 310(5755): 1817-
1821. 
Fauci, A. S., E. Braunwald, et al (2008). Harrison's principles of internal medicine, 
17th edition. 
Favus, M. J. (2008). Primer on the metabolic bone diseases and disorders of mineral 
metabolism. Chicago, American society for bone and mineral research. 
Felson, D. T., Y. Zhang, et al. (1993). "Effects of weight and body mass index on 
bone mineral density in men and women: the Framingham study." J Bone 
Miner Res 8(5): 567-573. 
Feng, X. and J. M. McDonald (2011). "Disorders of bone remodeling." Annu Rev 
Pathol 6: 121-145. 
Freedman, M. L., A. N. Monteiro, et al. (2011). "Principles for the post-GWAS 
functional characterization of cancer risk loci." Nat Genet 43(6): 513-518. 
Galena, H. J. (1992). "Complications occurring from diagnostic venipuncture." J Fam 
Pract 34(5): 582-584. 
Gartland, A. (2012) "P2X receptors in bone 
Wiley Interdisciplinary Reviews: Membrane Transport and Signaling Volume 1, Issue 
2." Wiley Interdisciplinary Reviews: Membrane Transport and Signaling 1, 
221-227. 
Gartland, A., K. A. Buckley, et al. (2003). "Blockade of the pore-forming P2X7 
receptor inhibits formation of multinucleated human osteoclasts in vitro." Calcif 
Tissue Int 73(4): 361-369. 
Gartland, A., R. A. Hipskind, et al. (2001). "Expression of a P2X7 receptor by a 
subpopulation of human osteoblasts." J Bone Miner Res 16(5): 846-856. 
Gartland, A., K. K. Skarratt, et al. (2012). "Polymorphisms in the P2X7 receptor gene 
are associated with low lumbar spine bone mineral density and accelerated 
bone loss in post-menopausal women." Eur J Hum Genet 20(5): 559-564. 
Gaur, U., K. Li, et al. (2013). "Research progress in allele-specific expression and its 
regulatory mechanisms." J Appl Genet 54(3): 271-283. 
Gennari, L., D. Merlotti, et al. (2005). "Estrogen receptor gene polymorphisms and 
the genetics of osteoporosis: a HuGE review." Am J Epidemiol 161(4): 307-
320. 
Goddard, K. A., P. J. Hopkins, et al. (2000). "Linkage disequilibrium and allele-
frequency distributions for 114 single-nucleotide polymorphisms in five 
populations." Am J Hum Genet 66(1): 216-234. 
Golbahar, J., A. Hamidi, et al. (2004). "Association of plasma folate, plasma total 
homocysteine, but not methylenetetrahydrofolate reductase C667T 
polymorphism, with bone mineral density in postmenopausal Iranian women: 
a cross-sectional study." Bone 35(3): 760-765. 
Gong, Y., R. B. Slee, et al. (2001). "LDL receptor-related protein 5 (LRP5) affects 
bone accrual and eye development." Cell 107(4): 513-523. 
Gough, A., P. Sambrook, et al. (1998). "Osteoclastic activation is the principal 
mechanism leading to secondary osteoporosis in rheumatoid arthritis." J 
Rheumatol 25(7): 1282-1289. 
Grundberg, E., E. M. Lau, et al. (2007). "Vitamin D receptor 3' haplotypes are 
unequally expressed in primary human bone cells and associated with 
increased fracture risk: the MrOS Study in Sweden and Hong Kong." J Bone 
Miner Res 22(6): 832-840. 
234 | Bibliography 
 
Gueguen, R., P. Jouanny, et al. (1995). "Segregation analysis and variance 
components analysis of bone mineral density in healthy families." J Bone 
Miner Res 10(12): 2017-2022. 
Guntur, A. R. and C. J. Rosen (2012). "Bone as an endocrine organ." Endocr Pract 
18(5): 758-762. 
Harada, S. and G. A. Rodan (2003). "Control of osteoblast function and regulation of 
bone mass." Nature 423(6937): 349-355. 
Heap, G. A., J. H. Yang, et al. (2010). "Genome-wide analysis of allelic expression 
imbalance in human primary cells by high-throughput transcriptome 
resequencing." Hum Mol Genet 19(1): 122-134. 
Hedrick, P. W. (1987). "Gametic disequilibrium measures: proceed with caution." 
Genetics 117(2): 331-341. 
Herbon, N., M. Werner, et al. (2003). "High-resolution SNP scan of chromosome 
6p21 in pooled samples from patients with complex diseases." Genomics 
81(5): 510-518. 
Hindorff LA, J. H., Hall PN, Mehta JP, and Manolio TA. A Catalog of Published 
Genome-Wide Association Studies. Available at: 
www.genome.gov/gwastudies. 
Hindorff, L. A., P. Sethupathy, et al. (2009). "Potential etiologic and functional 
implications of genome-wide association loci for human diseases and traits." 
Proc Natl Acad Sci U S A 106(23): 9362-9367. 
Hofbauer, L. C. and M. Schoppet (2002). "Osteoprotegerin gene polymorphism and 
the risk of osteoporosis and vascular disease." J Clin Endocrinol Metab 87(9): 
4078-4079. 
Holliday, K. L., S. R. Pye, et al. (2011). "The ESR1 (6q25) locus is associated with 
calcaneal ultrasound parameters and radial volumetric bone mineral density in 
European men." PLoS One 6(7): e22037. 
Hong, E. P. and J. W. Park (2012). "Sample size and statistical power calculation in 
genetic association studies." Genomics Inform 10(2): 117-122. 
Hossein-nezhad, A., F. N. Varzaneh, et al. (2011). "Association of the FokI 
polymorphism in the vitamin D receptor gene with vertebral fracture in Iranian 
postmenopausal women." Endocr Pract 17(5): 826-827. 
Hsu, Y. H., S. Demissie-Banjaw, et al. (2008). "Genome-wide association study of 
BMD and hip geometry indices. The Framingham Osteoporosis Study." Bone 
43: S34-S34. 
Hsu, Y. H., T. Niu, et al. (2006). "Variation in genes involved in the 
RANKL/RANK/OPG bone remodeling pathway are associated with bone 
mineral density at different skeletal sites in men." Hum Genet 118(5): 568-
577. 
Hsu, Y. H., M. C. Zillikens, et al. (2010). "An integration of genome-wide association 
study and gene expression profiling to prioritize the discovery of novel 
susceptibility Loci for osteoporosis-related traits." PLoS Genet 6(6): 
e1000977. 
Hunter, D., M. De Lange, et al. (2001). "Genetic contribution to bone metabolism, 
calcium excretion, and vitamin D and parathyroid hormone regulation." J Bone 
Miner Res 16(2): 371-378. 
Ioannidis, J. P., E. E. Ntzani, et al. (2001). "Replication validity of genetic association 
studies." Nat Genet 29(3): 306-309. 
Ioannidis, J. P., S. H. Ralston, et al. (2004). "Differential genetic effects of ESR1 
gene polymorphisms on osteoporosis outcomes." JAMA 292(17): 2105-2114. 
235 | Bibliography 
 
Ioannidis, J. P., I. Stavrou, et al. (2002). "Association of polymorphisms of the 
estrogen receptor alpha gene with bone mineral density and fracture risk in 
women: a meta-analysis." J Bone Miner Res 17(11): 2048-2060. 
Jia, F., R. F. Sun, et al. (2013). "Vitamin D receptor BsmI polymorphism and 
osteoporosis risk: a meta-analysis from 26 studies." Genet Test Mol 
Biomarkers 17(1): 30-34. 
Johnell, O., J. A. Kanis, et al. (2005). "Predictive value of BMD for hip and other 
fractures." J Bone Miner Res 20(7): 1185-1194. 
Kanis, J. A. (1994). "Assessment of fracture risk and its application to screening for 
postmenopausal osteoporosis: synopsis of a WHO report. WHO Study 
Group." Osteoporos Int 4(6): 368-381. 
Kanis, J. A. (2002). "Diagnosis of osteoporosis and assessment of fracture risk." 
Lancet 359(9321): 1929-1936. 
Kanis, J. A., G. Bianchi, et al. (2011). "Towards a diagnostic and therapeutic 
consensus in male osteoporosis." Osteoporos Int 22(11): 2789-2798. 
Kanis, J. A., N. Burlet, et al. (2008). "European guidance for the diagnosis and 
management of osteoporosis in postmenopausal women." Osteoporos Int 
19(4): 399-428. 
Kanis, J. A. and O. Johnell (2005). "Requirements for DXA for the management of 
osteoporosis in Europe." Osteoporos Int 16(3): 229-238. 
Kanis, J. A., E. V. McCloskey, et al. (2008). "A reference standard for the description 
of osteoporosis." Bone 42(3): 467-475. 
Kaprio, J., A. Rimpela, et al. (1995). "Common genetic influences on BMI and age at 
menarche." Hum Biol 67(5): 739-753. 
Karasik, D. and S. L. Ferrari (2008). "Contribution of gender-specific genetic factors 
to osteoporosis risk." Ann Hum Genet 72(Pt 5): 696-714. 
Kassim Javaid, M., J. Chana, et al. (2013). "Hip fracture as the tracer condition." 
Best Pract Res Clin Rheumatol 27(6): 711-715. 
Kiel, D. P., S. L. Ferrari, et al. (2007). "Genetic variation at the low-density lipoprotein 
receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the 
relationship of physical activity with bone mineral density in men." Bone 40(3): 
587-596. 
Kim, H. S. and S. O. Yang (2014). "Quality Control of DXA System and Precision 
Test of Radio-technologists." J Bone Metab 21(1): 2-7. 
Kobayashi, Y., N. Udagawa, et al. (2009). "Action of RANKL and OPG for 
osteoclastogenesis." Crit Rev Eukaryot Gene Expr 19(1): 61-72. 
Koh, L. K. H. (2004). "Osteoporosis: assessment for diagnosis, evaluation and 
treatment." jmhg, 1. 
Korcok, J., L. N. Raimundo, et al. (2004). "Extracellular nucleotides act through P2X7 
receptors to activate NF-kappa B in osteoclasts." Journal of Bone and Mineral 
Research 19(4): 642-651. 
Krakauer, T. (2008). "Nuclear factor-kappaB: fine-tuning a central integrator of 
diverse biologic stimuli." Int Rev Immunol 27(5): 286-292. 
Krall, E. A. and B. Dawson-Hughes (1993). "Heritable and life-style determinants of 
bone mineral density." J Bone Miner Res 8(1): 1-9. 
Kreja, L., A. Liedert, et al. (2007). "Influence of receptor activator of nuclear factor 
(NF)-kappaB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) 
and fetal calf serum on human osteoclast formation and activity." J Mol Histol 
38(4): 341-345. 
236 | Bibliography 
 
Krishnan, V., H. U. Bryant, et al. (2006). "Regulation of bone mass by Wnt signaling." 
J Clin Invest 116(5): 1202-1209. 
Langdahl, B. L., M. Carstens, et al. (2002). "Polymorphisms in the osteoprotegerin 
gene are associated with osteoporotic fractures." J Bone Miner Res 17(7): 
1245-1255. 
Larijani, B., A. Moayyeri, et al. (2006). "Peak bone mass of Iranian population: The 
Iranian Multicenter Osteoporosis Study." Journal of Clinical Densitometry 9(3): 
367-374. 
Lau, R. Y. and X. Guo (2011). "A review on current osteoporosis research: with 
special focus on disuse bone loss." J Osteoporos 2011: 293808. 
Lee, Y. H., J. H. Woo, et al. (2010). "Associations between osteoprotegerin 
polymorphisms and bone mineral density: a meta-analysis." Mol Biol Rep 
37(1): 227-234. 
Lei, S. F., F. Y. Deng, et al. (2004). "Bone mineral density in elderly Chinese: effects 
of age, sex, weight, height, and body mass index." Journal of Bone and 
Mineral Metabolism 22(1): 71-78. 
Lewis, C. M. and J. Knight (2012). "Introduction to genetic association studies." Cold 
Spring Harb Protoc 2012(3): 297-306. 
Li, W. F., S. X. Hou, et al. (2010). "Genetics of osteoporosis: accelerating pace in 
gene identification and validation." Hum Genet 127(3): 249-285. 
Luo, Y., Z. Hu, et al. (2014). "Significant associations between the A163G and 
G1181C polymorphisms of the osteoprotegerin gene and risk of osteoporosis, 
especially in postmenopausal women: a meta-analysis." Genet Test Mol 
Biomarkers 18(3): 211-219. 
Ma, C., Q. L. Zhou, et al. (2014). "Association of vitamin D receptor BsmI gene 
polymorphism with risk of low bone mineral density in post-menopausal 
women: a meta-analysis." Genet Mol Res 13(3): 7791-7799. 
Mahr, S., G. R. Burmester, et al. (2006). "Cis- and trans-acting gene regulation is 
associated with osteoarthritis." Am J Hum Genet 78(5): 793-803. 
Manolagas, S. C. (2000). "Birth and death of bone cells: basic regulatory 
mechanisms and implications for the pathogenesis and treatment of 
osteoporosis." Endocr Rev 21(2): 115-137. 
Manolagas, S. C. J., Robert L. (1995). "Mechanisms of Diseases: Bone Marrow, 
Cytokines, and Bone Remodeling -- Emergency Insights into the 
Pathophysiology of Osteoporosis." The New England Journal Of Medicin. 
Manolio, T. A., L. D. Brooks, et al. (2008). "A HapMap harvest of insights into the 
genetics of common disease." J Clin Invest 118(5): 1590-1605. 
Marini, F. and M. L. Brandi (2010). "Genetic determinants of osteoporosis: common 
bases to cardiovascular diseases?" Int J Hypertens 2010. 
Mascarenhas, M. R., F. Negreiro, et al. (2003). "Age, weight and height: How to 
predict the low bone mineral density risk in males?" Osteoporosis 
International 14: P6. 
Massey, H. M. and A. M. Flanagan (1999). "Human osteoclasts derive from CD14-
positive monocytes." Br J Haematol 106(1): 167-170. 
Mazess, R. B. and H. Barden (1999). "Bone density of the spine and femur in adult 
white females." Calcif Tissue Int 65(2): 91-99. 
Mencej-Bedrač, S., J. Preželj, et al. (2011). "TNFRSF11B gene polymorphisms 
1181G > C and 245T > G as well as haplotype CT influence bone mineral 
density in postmenopausal women." Maturitas 69(3): 263-267. 
237 | Bibliography 
 
Milani, L., M. Gupta, et al. (2007). "Allelic imbalance in gene expression as a guide to 
cis-acting regulatory single nucleotide polymorphisms in cancer cells." Nucleic 
Acids Research 35(5): e34. 
Monks, S. A., A. Leonardson, et al. (2004). "Genetic inheritance of gene expression 
in human cell lines." American Journal of Human Genetics 75(6): 1094-1105. 
Morley, M., C. M. Molony, et al. (2004). "Genetic analysis of genome-wide variation 
in human gene expression." Nature 430(7001): 743-747. 
Morrison, N. A., J. C. Qi, et al. (1994). "Prediction of bone density from vitamin D 
receptor alleles." Nature 367(6460): 284-287. 
Morrison, S. J. and D. T. Scadden (2014). "The bone marrow niche for 
haematopoietic stem cells." Nature 505(7483): 327-334. 
Munafo, M. R. and J. Flint (2004). "Meta-analysis of genetic association studies." 
Trends Genet 20(9): 439-444. 
Munasinghe, R., V. Botea, et al. (2002). "Association between age, height, weight 
and bone mass index with discordant changes in bone mineral density 
detected on sequential bone densitometry scans." Journal of Bone and 
Mineral Research 17: WG8. 
Mylvaganam, S., L. Zhang, et al. (2010). "Hippocampal seizures alter the expression 
of the pannexin and connexin transcriptome." J Neurochem 112(1): 92-102. 
Nagy, T. R. and A. L. Clair (2000). "Precision and accuracy of dual-energy X-ray 
absorptiometry for determining in vivo body composition of mice." Obes Res 
8(5): 392-398. 
Nguyen, T. V., J. R. Center, et al. (2000). "Osteoporosis in elderly men and women: 
effects of dietary calcium, physical activity, and body mass index." J Bone 
Miner Res 15(2): 322-331. 
Nicholson, G. C., M. Malakellis, et al. (2000). "Induction of osteoclasts from CD14-
positive human peripheral blood mononuclear cells by receptor activator of 
nuclear factor kappaB ligand (RANKL)." Clin Sci (Lond) 99(2): 133-140. 
Ohlendorff, S. D., C. L. Tofteng, et al. (2007). "Single nucleotide polymorphisms in 
the P2X7 gene are associated to fracture risk and to effect estrogen 
treatment." Pharmacogenet Genomics 17(7): 555-567. 
Ohta, H. (2014). "[Updates on Lifestyle-Related Diseases and Bone Metabolism. 
Efficacy of selective estrogen receptor modulators (SERMs) in lifestyle-related 
osteoporosis]." Clin Calcium 24(11): 1679-1687. 
Okeson, G. C. and P. H. Wulbrecht (1998). "The safety of brachial artery puncture 
for arterial blood sampling." Chest 114(3): 748-751. 
Omrani, G. R. (2006). Bone mineral density in the normal Iranian population: a 
comparison with American reference data. 
Palacios, R., E. Gazave, et al. (2009). "Allele-specific gene expression is widespread 
across the genome and biological processes." PLoS One 4(1): e4150. 
Panupinthu, N., J. T. Rogers, et al. (2008). "P2X7 receptors on osteoblasts couple to 
production of lysophosphatidic acid: a signaling axis promoting osteogenesis." 
J Cell Biol 181(5): 859-871. 
Pastinen, T. and T. J. Hudson (2004). "Cis-acting regulatory variation in the human 
genome." Science 306(5696): 647-650. 
Paternoster, L., M. Lorentzon, et al. (2013). "Genetic determinants of trabecular and 
cortical volumetric bone mineral densities and bone microstructure." PLoS 
Genet 9(2): e1003247. 
Paternoster, L., M. Lorentzon, et al. (2010). "Genome-wide association meta-
analysis of cortical bone mineral density unravels allelic heterogeneity at the 
238 | Bibliography 
 
RANKL locus and potential pleiotropic effects on bone." Plos Genetics 6(11): 
e1001217. 
Paternoster, L., C. Ohlsson, et al. (2010). "OPG and RANK polymorphisms are both 
associated with cortical bone mineral density: findings from a metaanalysis of 
the Avon longitudinal study of parents and children and gothenburg 
osteoporosis and obesity determinants cohorts." J Clin Endocrinol Metab 
95(8): 3940-3948. 
Pearson, T. A. (2008). "How to interpret a genomewide association study (vol 299, 
pg 1335, 2008)." Jama-Journal of the American Medical Association 299(18): 
2150-2150. 
Pfeiffer, R. M. and M. H. Gail (2003). "Sample size calculations for population- and 
family-based case-control association studies on marker genotypes." Genet 
Epidemiol 25(2): 136-148. 
Pocock, N. A., J. A. Eisman, et al. (1987). "Genetic determinants of bone mass in 
adults. A twin study." J Clin Invest 80(3): 706-710. 
Pouresmaeili, F., J. Jamshidi, et al. (2013). "Association between Vitamin D 
Receptor Gene BsmI Polymorphism and Bone Mineral Density in A 
Population of 146 Iranian Women." Cell J 15(1): 75-82. 
Qin, G., Z. Dong, et al. (2013). "Association of vitamin D receptor BsmI gene 
polymorphism with risk of osteoporosis: a meta-analysis of 41 studies." Mol 
Biol Rep 40(1): 497-506. 
Raggatt, L. J. and N. C. Partridge (2010). "Cellular and molecular mechanisms of 
bone remodeling." J Biol Chem 285(33): 25103-25108. 
Raisz, L. G. (2005). "Pathogenesis of osteoporosis: concepts, conflicts, and 
prospects." J Clin Invest 115(12): 3318-3325. 
Ralston, S. H. (2007). "Genetics of osteoporosis." Proceedings of the Nutrition 
Society 66: 158-165. 
Ralston, S. H. (2010). "Genetics of osteoporosis." Skeletal Biology and Medicine 
1192: 181-189. 
Ralston, S. H. (2010). "Genetics of osteoporosis." Ann N Y Acad Sci 1192: 181-189. 
Ravn, P., G. Cizza, et al. (1999). "Low body mass index is an important risk factor for 
low bone mass and increased bone loss in early postmenopausal women. 
Early Postmenopausal Intervention Cohort (EPIC) study group." J Bone Miner 
Res 14(9): 1622-1627. 
Richards, J. B., F. K. Kavvoura, et al. (2009). "Collaborative Meta-analysis: 
Associations of 150 Candidate Genes With Osteoporosis and Osteoporotic 
Fracture." Annals of Internal Medicine 151(8): 528-U532. 
Richards, J. B., F. Rivadeneira, et al. (2008). "Bone mineral density, osteoporosis, 
and osteoporotic fractures: a genome-wide association study." Lancet 
371(9623): 1505-1512. 
Richards, J. B., H. F. Zheng, et al. (2012). "Genetics of osteoporosis from genome-
wide association studies: advances and challenges." Nat Rev Genet 13(8): 
576-588. 
Risch, N. and J. Teng (1998). "The relative power of family-based and case-control 
designs for linkage disequilibrium studies of complex human diseases I. DNA 
pooling." Genome Res 8(12): 1273-1288. 
Rivadeneira, F., F. Kavvoura, et al. (2008). "Large-scale Meta-analysis of Genome-
wide Association (GWA) Scans for Osteoporosis Traits: the GEFOS 
Consortium." Journal of Bone and Mineral Research 23: S27-S27. 
239 | Bibliography 
 
Rivadeneira, F., U. Styrkársdottir, et al. (2009). "Twenty bone-mineral-density loci 
identified by large-scale meta-analysis of genome-wide association studies." 
Nat Genet 41(11): 1199-1206. 
Rosenberg, N. A., L. Huang, et al. (2010). "Genome-wide association studies in 
diverse populations." Nat Rev Genet 11(5): 356-366. 
Ross, F. P. (2003). "Interleukin 7 and estrogen-induced bone loss." Trends 
Endocrinol Metab 14(4): 147-149. 
Rumney, R. M., N. Wang, et al. (2012). "Purinergic signalling in bone." Front 
Endocrinol (Lausanne) 3: 116. 
Salamat, M. R., A. H. Salamat, et al. (2013). "Relationship between Weight, Body 
Mass Index, and Bone Mineral Density in Men Referred for Dual-Energy X-
Ray Absorptiometry Scan in Isfahan, Iran." J Osteoporos 2013: 205963. 
Sambrook, P. and C. Cooper (2006). "Osteoporosis." Lancet 367(9527): 2010-2018. 
Sassi, R., H. Sahli, et al. (2014). "Association of LRP5 genotypes with osteoporosis 
in Tunisian post-menopausal women." BMC Musculoskelet Disord 15: 144. 
Sattui, S. E. and K. G. Saag (2014). "Fracture mortality: associations with 
epidemiology and osteoporosis treatment." Nat Rev Endocrinol 10(10): 592-
602. 
Schadt, E. E., S. A. Monks, et al. (2003). "Genetics of gene expression surveyed in 
maize, mouse and man." Nature 422(6929): 297-302. 
Scherag, A., H. H. Muller, et al. (2003). "Data adaptive interim modification of sample 
sizes for candidate-gene association studies." Hum Hered 56(1-3): 56-62. 
Schilling, A. F., W. Linhart, et al. (2004). "Resorbability of bone substitute 
biomaterials by human osteoclasts." Biomaterials 25(18): 3963-3972. 
Serre, D., S. Gurd, et al. (2008). "Differential allelic expression in the human 
genome: a robust approach to identify genetic and epigenetic cis-acting 
mechanisms regulating gene expression." Plos Genetics 4(2): e1000006. 
Shang, M., L. Lin, et al. (2013). "Association of genetic polymorphisms of RANK, 
RANKL and OPG with bone mineral density in Chinese peri- and 
postmenopausal women." Clin Biochem 46(15): 1493-1501. 
Simmonds, M. (2011). "Genetic profiling tests in screening for cardiovascular 
disease." J Med Screen 18(2): 56-57. 
Singh, M., P. Singh, et al. (2013). "Vitamin D receptor (VDR) gene polymorphism 
influences the risk of osteoporosis in postmenopausal women of Northwest 
India." Arch Osteoporos 8(1-2): 147. 
Slatkin, M. (2008). "Linkage disequilibrium--understanding the evolutionary past and 
mapping the medical future." Nat Rev Genet 9(6): 477-485. 
Smith, E. P., J. Boyd, et al. (1994). "Estrogen resistance caused by a mutation in the 
estrogen-receptor gene in a man." N Engl J Med 331(16): 1056-1061. 
Sonoda, T., J. Takada, et al. (2012). "Interaction between ESRα polymorphisms and 
environmental factors in osteoporosis." J Orthop Res 30(10): 1529-1534. 
Sorensen, M. G., K. Henriksen, et al. (2007). "Characterization of osteoclasts derived 
from CD14+ monocytes isolated from peripheral blood." J Bone Miner Metab 
25(1): 36-45. 
Soveid, M., A. R. Serati, et al. (2005). "Incidence of hip fracture in Shiraz, Iran." 
Osteoporos Int 16(11): 1412-1416. 
Stewart, T. L. and S. H. Ralston (2000). "Role of genetic factors in the pathogenesis 
of osteoporosis." J Endocrinol 166(2): 235-245. 
Stranger, B. E., A. C. Nica, et al. (2007). "Population genomics of human gene 
expression." Nat Genet 39(10): 1217-1224. 
240 | Bibliography 
 
Stranger, B. E., E. A. Stahl, et al. (2011). "Progress and promise of genome-wide 
association studies for human complex trait genetics." Genetics 187(2): 367-
383. 
Styrkarsdottir, U., B. V. Halldorsson, et al. (2008). "Multiple genetic loci for bone 
mineral density and fractures." N Engl J Med 358(22): 2355-2365. 
Styrkarsdottir, U., B. V. Halldorsson, et al. (2009). "New sequence variants 
associated with bone mineral density." Nature Genetics 41(1): 15-17. 
Styrkarsdottir, U., B. V. Halldorsson, et al. (2010). "European bone mineral density 
loci are also associated with BMD in East-Asian populations." PLoS One 
5(10): e13217. 
Sun, C., C. Southard, et al. (2010). "Allelic imbalance (AI) identifies novel tissue-
specific cis-regulatory variation for human UGT2B15." Hum Mutat 31(1): 99-
107. 
Tang, K., P. Oeth, et al. (2004). "Mining disease susceptibility genes through SNP 
analyses and expression profiling using MALDI-TOF mass spectrometry." J 
Proteome Res 3(2): 218-227. 
Teare, M. D. (2011). "Candidate gene association studies." Methods Mol Biol 713: 
105-117. 
Teare, M. D., J. Heighway, et al. (2006). "An expectation-maximization algorithm for 
the analysis of allelic expression imbalance." American Journal of Human 
Genetics 79(3): 539-543. 
Teare, M. D., S. Pinyakorn, et al. (2011). "Comparing methods for mapping cis acting 
polymorphisms using allelic expression ratios." PLoS One 6(12): e28636. 
Teitelbaum, S. L. (2000). "Bone resorption by osteoclasts." Science 289(5484): 
1504-1508. 
Thakkinstian, A., C. D'Este, et al. (2004). "Meta-analysis of molecular association 
studies: Vitamin D receptor gene polymorphisms and BMD as a case study." 
Journal of Bone and Mineral Research 19(3): 419-428. 
Tran, B. N. H., D. Nguyen, et al. (2008). "Association between LRP5 polymorphism 
and bone mineral density: a Bayesian meta-analysis." Bmc Medical Genetics 
9. 
Tremollieres, F. A., J. M. Pouilles, et al. (2010). "Fracture risk prediction using BMD 
and clinical risk factors in early postmenopausal women: sensitivity of the 
WHO FRAX tool." J Bone Miner Res 25(5): 1002-1009. 
Tung, J., O. Fedrigo, et al. (2009). "Genomic features that predict allelic imbalance in 
humans suggest patterns of constraint on gene expression variation." 
Molecular Biology and Evolution 26(9): 2047-2059. 
Uitterlinden, A. G., S. H. Ralston, et al. (2006). "The association between common 
vitamin D receptor gene variations and osteoporosis: a participant-level meta-
analysis (vol 145, pg 255, 2006)." Annals of Internal Medicine 145(12): 936-
936. 
Uman, L. S. (2011). "Systematic reviews and meta-analyses." J Can Acad Child 
Adolesc Psychiatry 20(1): 57-59. 
Urano, T. and S. Inoue (2014). "Genetics of osteoporosis." Biochem Biophys Res 
Commun 452(2): 287-293. 
Vaananen, H. K. and T. Laitala-Leinonen (2008). "Osteoclast lineage and function." 
Arch Biochem Biophys 473(2): 132-138. 
Vaananen, H. K., H. Zhao, et al. (2000). "The cell biology of osteoclast function." 
Journal of Cell Science 113(3): 377-381. 
241 | Bibliography 
 
van Meurs, J. B., T. A. Trikalinos, et al. (2008). "Large-scale analysis of association 
between LRP5 and LRP6 variants and osteoporosis." JAMA 299(11): 1277-
1290. 
Van Wesenbeeck, L., E. Cleiren, et al. (2003). "Six novel missense mutations in the 
LDL receptor-related protein 5 (LRP5) gene in different conditions with an 
increased bone density." Am J Hum Genet 72(3): 763-771. 
VanLiere, J. M. and N. A. Rosenberg (2008). "Mathematical properties of the r2 
measure of linkage disequilibrium." Theor Popul Biol 74(1): 130-137. 
Vidal, C., R. Formosa, et al. (2011). "Functional polymorphisms within the 
TNFRSF11B (osteoprotegerin) gene increase the risk for low bone mineral 
density." J Mol Endocrinol 47(3): 327-333. 
Vidal, D. O., J. E. de Souza, et al. (2011). "Analysis of allelic differential expression 
in the human genome using allele-specific serial analysis of gene expression 
tags." Genome 54(2): 120-127. 
Wade, S. W., C. Strader, et al. (2014). "Estimating prevalence of osteoporosis: 
examples from industrialized countries." Arch Osteoporos 9: 182. 
Wang, C. L., X. Y. Tang, et al. (2007). "Association of estrogen receptor alpha gene 
polymorphisms with bone mineral density in Chinese women: a meta-
analysis." Osteoporos Int 18(3): 295-305. 
Wang, D., R. Liu, et al. (2013). "Vitamin D receptor Fok I polymorphism is associated 
with low bone mineral density in postmenopausal women: a meta-analysis 
focused on populations in Asian countries." Eur J Obstet Gynecol Reprod Biol 
169(2): 380-386. 
Weitzmann, M. N. (2013). "The Role of Inflammatory Cytokines, the RANKL/OPG 
Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and 
Osteoporosis." Scientifica (Cairo) 2013: 125705. 
Wellcome Trust Case Control, C. (2007). "Genome-wide association study of 14,000 
cases of seven common diseases and 3,000 shared controls." Nature 
447(7145): 661-678. 
Welter, D., J. MacArthur, et al. (2014). "The NHGRI GWAS Catalog, a curated 
resource of SNP-trait associations." Nucleic Acids Res 42(Database issue): 
D1001-1006. 
Wesselius, A., M. J. Bours, et al. (2011). "Role of purinergic receptor polymorphisms 
in human bone." Front Biosci (Landmark Ed) 16: 2572-2585. 
Wesselius, A., M. J. Bours, et al. (2013). "Association of P2X7 receptor 
polymorphisms with bone mineral density and osteoporosis risk in a cohort of 
Dutch fracture patients." Osteoporos Int 24(4): 1235-1246. 
Wilkening, S., B. W. Chen, et al. (2009). "Is there still a need for candidate gene 
approaches in the era of genome-wide association studies?" Genomics 93(5): 
415-419. 
Williams, R. B., E. K. Chan, et al. (2007). "The influence of genetic variation on gene 
expression." Genome Res 17(12): 1707-1716. 
Wu, X., S. Guo, et al. (2013). "Screening of osteoprotegerin-related feature genes in 
osteoporosis and functional analysis with DNA microarray." Eur J Med Res 
18: 15. 
Xiong, D. H., H. Shen, et al. (2006). "Robust and comprehensive analysis of 20 
osteoporosis candidate genes by very high-density single-nucleotide 
polymorphism screen among 405 white nuclear families identified significant 
association and gene-gene interaction." J Bone Miner Res 21(11): 1678-1695. 
242 | Bibliography 
 
Xu, X. H., S. S. Dong, et al. (2010). "Molecular genetic studies of gene identification 
for osteoporosis: the 2009 update." Endocr Rev 31(4): 447-505. 
Yamada, Y., F. Ando, et al. (2003). "Association of polymorphisms of the 
osteoprotegerin gene with bone mineral density in Japanese women but not 
men." Mol Genet Metab 80(3): 344-349. 
Yan, H., Z. Dobbie, et al. (2002). "Small changes in expression affect predisposition 
to tumorigenesis." Nat Genet 30(1): 25-26. 
Yan, H., W. Yuan, et al. (2002). "Allelic variation in human gene expression." 
Science 297(5584): 1143. 
Yeh, L.-R., C. K. H. Chen, et al. (2004). "Normal bone mineral density in 
anteroposterior, lateral spine and hip of Chinese men in Taiwan: effect of age 
change, body weight and height." J Chin Med Assoc 67(6): 287-295. 
Zappitelli, T. and J. E. Aubin (2014). "The "connexin" between bone cells and 
skeletal functions." J Cell Biochem 115(10): 1646-1658. 
Zhang, L., H. J. Choi, et al. (2014). "Multistage genome-wide association meta-
analyses identified two new loci for bone mineral density." Hum Mol Genet 
23(7): 1923-1933. 
Zhao, E., H. Xu, et al. (2012). "Bone marrow and the control of immunity." Cell Mol 
Immunol 9(1): 11-19. 
Zmuda, J. M., Y. T. Sheu, et al. (2005). "Genetic epidemiology of osteoporosis: past, 
present, and future." Curr Osteoporos Rep 3(3): 111-115. 
Zmuda, J. M., Y. T. Sheu, et al. (2006). "The search for human osteoporosis genes." 
J Musculoskelet Neuronal Interact 6(1): 3-15. 
 
 
